Rethinking schizophrenia

Nature

468, 187-193

DOI: 10.1038/nature09552

Citation Report

#	Article	IF	Citations
1	Abnormal Trajectories of Neurodevelopment and Behavior Following In Utero Insult in the Rat. Biological Psychiatry, 2011, 70, 842-851.	1.3	138
2	Linking neurodevelopmental and synaptic theories of mental illness through DISC1. Nature Reviews Neuroscience, 2011, 12, 707-722.	10.2	384
3	Schizophrenia, â€œJust the Factsâ€•6. Moving ahead with the schizophrenia concept: From the elephant to the mouse. Schizophrenia Research, 2011, 127, 3-13.	2.0	186
4	Moving on in Schizophrenia Research to the next decade. Schizophrenia Research, 2011, 127, 14-15.	2.0	9
6	Brain tissue changes and antipsychotic medication. Expert Review of Neurotherapeutics, 2011, 11, 943-946.	2.8	11
7	Nocturnal hyperactivity, increased social novelty preference and delayed extinction of fear responses in post-weaning socially isolated mice. Brain Research Bulletin, 2011, 85, 354-362.	3.0	49
8	Effects of antipsychotics on the behavioral deficits in human dominant-negative DISC1 transgenic mice with neonatal polyI:C treatment. Behavioural Brain Research, 2011, 225, 305-310.	2.2	42
9	Sex differences in prenatal epigenetic programing of stress pathways. Stress, 2011, 14, 348-356.	1.8	191
10	Is schizophrenia developmental adaptation to environmental menaces?. Medical Hypotheses, 2011, 77, 756-762.	1.5	0
11	DISC1 at 10: connecting psychiatric genetics and neuroscience. Trends in Molecular Medicine, 2011, 17, 699-706.	6.7	126
12	Altered MHC class I expression in dorsolateral prefrontal cortex of nonsmoker patients with schizophrenia. Neuroscience Research, 2011, 71, 289-293.	1.9	32
13	Evidence for the interaction of d-amino acid oxidase with pLG72 in a glial cell line. Molecular and Cellular Neurosciences, 2011, 48, 20-28.	2.2	52
14	An Epigenetic Mark that Protects the Epithelial Phenotype in Health and Disease. Cell Stem Cell, 2011, 8, 462-463.	11.1	4
15	Human Induced Pluripotent Stem Cells: A New Model for Schizophrenia?. Cell Stem Cell, 2011, 8, 461-462.	11.1	5
16	Synapsin III: Role in neuronal plasticity and disease. Seminars in Cell and Developmental Biology, 2011, 22, 416-424.	5.0	34
17	Young people at ultra high risk for psychosis: research from the PACE clinic. Revista Brasileira De Psiquiatria, 2011, 33, s143-s160.	1.7	15
18	Unipolar and bipolar depression: different or the same?. British Journal of Psychiatry, 2011, 199, 272-274.	2.8	32
19	Inflammatory processes in schizophrenia: A promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. , 2011, 132, 96-110.		217

#	Article	IF	Citations
20	Schizophrenia, Oxidative Stress and Selenium. , 2011, , 355-367.		3
21	Spatio-temporal transcriptome of the human brain. Nature, 2011, 478, 483-489.	27.8	1,753
22	Cognitive, Behavioural and Psychiatric Phenotype in 22q11.2 Deletion Syndrome. Behavior Genetics, 2011, 41, 403-412.	2.1	115
23	The Search for Modifiable Risk Factors for Schizophrenia. American Journal of Psychiatry, 2011, 168, 1235-1238.	7.2	15
24	Parental Origin, DNA Structure, and the Schizophrenia Spectrum. American Journal of Psychiatry, 2011, 168, 350-353.	7.2	12
26	Commentary on â€˜â€˜Should the diagnostic boundaries of schizophrenia be expanded?â€™â€™. Cognitive Neuropsychiatry, 2011, 16, 107-112.	1.3	0
27	The Adolescent Brain: Implications for the Understanding, Pathophysiology, and Treatment of Schizophrenia. Schizophrenia Bulletin, 2011, 37, 480-483.	4.3	32
28	Transition to Adulthood: The Critical Period for Pre-emptive, Disease-modifying Care for Schizophrenia and Related Disorders. Schizophrenia Bulletin, 2011, 37, 524-530.	4.3	90
29	Postnatal Developmental Trajectories of Neural Circuits in the Primate Prefrontal Cortex: Identifying Sensitive Periods for Vulnerability to Schizophrenia. Schizophrenia Bulletin, 2011, 37, 493-503.	4.3	109
30	GABA Neuron Alterations, Cortical Circuit Dysfunction and Cognitive Deficits in Schizophrenia. Neural Plasticity, 2011, 2011, 1-24.	2.2	193
31	Vision Science and Schizophrenia Research: Toward a Re-view of the Disorder Editors' Introduction to Special Section. Schizophrenia Bulletin, 2011, 37, 681-689.	4.3	76
32	Bleuler and the Neurobiology of Schizophrenia. Schizophrenia Bulletin, 2011, 37, 1131-1135.	4.3	42
33	Clinical utility of serum biomarkers for major psychiatric disorders. International Review of Neurobiology, 2011, 101, 351-374.	2.0	6
34	Increased Risk of Schizophrenia From Additive Interaction Between Infant Motor Developmental Delay and Obstetric Complications: Evidence From a Population-Based Longitudinal Study. American Journal of Psychiatry, 2011, 168, 1295-1302.	7.2	47
35	'Why, why did you have me treated?': the psychotic experience in a literary narrative. Medical Humanities, 2011, 37, 123-126.	1.2	4
37	Classification issues and challenges in child and adolescent psychopathology. International Review of Psychiatry, 2012, 24, 514-529.	2.8	27
38	Attenuated psychosis and the schizophrenia prodrome: current status of risk identification and psychosis prevention. Neuropsychiatry, 2012, 2, 345-353.	0.4	48
39	Next-Generation Treatments for Mental Disorders. Science Translational Medicine, 2012, 4, 155ps19.	12.4	136

#	Article	IF	Citations
40	Cxcr4 regulation of interneuron migration is disrupted in 22q11.2 deletion syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 18601-18606.	7.1	94
41	White Matter Development in Adolescence: Diffusion Tensor Imaging and Meta-Analytic Results. Schizophrenia Bulletin, 2012, 38, 1308-1317.	4.3	190
42	Brain SCALE: Brain Structure and Cognition: an Adolescent Longitudinal Twin Study into the Genetic Etiology of Individual Differences. Twin Research and Human Genetics, 2012, 15, 453-467.	0.6	48
43	Association of a functional variant of the nitric oxide synthase 1 gene with personality, anxiety, and depressiveness. Development and Psychopathology, 2012, 24, 1225-1235.	2.3	25
44	Crosstalk within GPCR Heteromers in Schizophrenia and Parkinsons Disease: Physical or Just Functional?. Current Medicinal Chemistry, 2012, 19, 1119-1134.	2.4	10
45	Overlapping and Segregating Structural Brain Abnormalities in Twins With Schizophrenia or Bipolar Disorder. Archives of General Psychiatry, 2012, 69, 349.	12.3	107
46	The Death of Specificity in Psychiatry: cheers or tears?. Perspectives in Biology and Medicine, 2012, 55, 443-460.	0.5	20
47	Puzzling over schizophrenia: Schizophrenia, social environment and the brain. Nature Medicine, 2012, 18, 211-213.	30.7	53
48	The Ultra High Risk Approach to Define Psychosis Risk. Current Pharmaceutical Design, 2012, 18, 346-350.	1.9	20
49	Altered Oxygen Metabolism Associated to Neurogenesis of Induced Pluripotent Stem Cells Derived from a Schizophrenic Patient. Cell Transplantation, 2012, 21, 1547-1559.	2.5	150
50	Can we prevent the onset of psychosis? Yes, we can. Neuropsychiatry, 2012, 2, 189-193.	0.4	1
51	Genetics of schizophrenia from a clinicial perspective. International Review of Psychiatry, 2012, 24, 393-404.	2.8	10
52	Genomic and proteomic advances in autism research. Electrophoresis, 2012, 33, 3653-3658.	2.4	8
53	Prenatal exposure to bacterial endotoxin reduces the number of GAD67- and reelin-immunoreactive neurons in the hippocampus of rat offspring. European Neuropsychopharmacology, 2012, 22, 300-307.	0.7	61
54	Impaired plasmalogens in patients with schizophrenia. Psychiatry Research, 2012, 198, 347-352.	3.3	63
55	DNA methylation in schizophrenia: progress and challenges of epigenetic studies. Genome Medicine, 2012, 4, 96.	8.2	78
56	A stereological comparison of GAD67 and reelin expression in the hippocampal stratum oriens of offspring from two mouse models of maternal inflammation during pregnancy. Neuropharmacology, 2012, 62, 1767-1776.	4.1	82
57	Expression in Escherichia coli of the catalytic domain of human proline oxidase. Protein Expression and Purification, 2012, 82, 345-351.	1.3	29

#	Article	IF	Citations
58	Association of the ZNF804A gene polymorphism rs1344706 with white matter density changes in Chinese schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 36, 122-127.	4.8	28
59	5-HT2A/C receptors mediate the antipsychotic-like effects of alstonine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 36, 29-33.	4.8	15
60	Neurodevelopmental model of schizophrenia: update 2012. Molecular Psychiatry, 2012, 17, 1228-1238.	7.9	652
61	Development of Disease-Modifying Treatment of Schizophrenia. Handbook of Experimental Pharmacology, 2012, , 419-442.	1.8	8
62	The effect of DISC1 on regional gray matter density of schizophrenia in Han Chinese population. Neuroscience Letters, 2012, 517, 21-24.	2.1	14
63	5â€HT ₆ receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia. EMBO Molecular Medicine, 2012, 4, 1043-1056.	6.9	152
64	Modeling resilience to schizophrenia in genetically modified mice: a novel approach to drug discovery. Expert Review of Neurotherapeutics, 2012, 12, 785-799.	2.8	23
65	The Nosology of Schizophrenia. Psychiatric Clinics of North America, 2012, 35, 557-569.	1.3	61
66	Medical Needs in the Treatment of Psychotic Disorders. Handbook of Experimental Pharmacology, 2012, , 165-185.	1.8	9
67	CHAPTER 2. The Pathophysiology of Schizophrenia. RSC Drug Discovery Series, 2012, , 13-34.	0.3	0
68	Early Cognitive Experience Prevents Adult Deficits in a Neurodevelopmental Schizophrenia Model. Neuron, 2012, 75, 714-724.	8.1	114
69	Trace Amine-Associated Receptor 1 Partial Agonism Reveals Novel Paradigm for Neuropsychiatric Therapeutics. Biological Psychiatry, 2012, 72, 934-942.	1.3	155
70	The future of fMRI and genetics research. NeuroImage, 2012, 62, 1286-1292.	4.2	59
71	Brain connectivity in psychiatric imaging genetics. NeuroImage, 2012, 62, 2250-2260.	4.2	62
72	Consistency and interpretation of changes in millimeter-scale cortical intrinsic curvature across three independent datasets in schizophrenia. NeuroImage, 2012, 63, 611-621.	4.2	46
73	Modelling the contribution of family history and variation in single nucleotide polymorphisms to risk of schizophrenia: A Danish national birth cohort-based study. Schizophrenia Research, 2012, 134, 246-252.	2.0	33
74	Adolescents at ultra-high risk for psychosis with and without 22q11 deletion syndrome: A comparison of prodromal psychotic symptoms and general functioning. Schizophrenia Research, 2012, 139, 151-156.	2.0	48
75	Mutant Mouse Models in Evaluating Novel Approaches to Antipsychotic Treatment. Handbook of Experimental Pharmacology, 2012, , 113-145.	1.8	8

#	Article	IF	Citations
76	Dynamics of Subcellular Proteomes During Brain Development. Journal of Proteome Research, 2012, 11, 2467-2479.	3.7	41
77	Current Antipsychotics. Handbook of Experimental Pharmacology, 2012, , .	1.8	6
78	Influence of contact with schizophrenia on implicit attitudes towards schizophrenia patients held by clinical residents. BMC Psychiatry, 2012, 12, 205.	2.6	33
79	Marked Reduction of AKT1 Expression and Deregulation of AKT1-Associated Pathways in Peripheral Blood Mononuclear Cells of Schizophrenia Patients. PLoS ONE, 2012, 7, e32618.	2.5	52
80	Prophylactic Valproic Acid Treatment Prevents Schizophrenia-Related Behaviour in Disc1-L100P Mutant Mice. PLoS ONE, 2012, 7, e51562.	2.5	25
81	Cognition-Emotion Dysinteraction in Schizophrenia. Frontiers in Psychology, 2012, 3, 392.	2.1	47
82	Connectomic Intermediate Phenotypes for Psychiatric Disorders. Frontiers in Psychiatry, 2012, 3, 32.	2.6	90
83	An fMRI Study of Neuronal Activation in Schizophrenia Patients with and without Previous Cannabis Use. Frontiers in Psychiatry, 2012, 3, 94.	2.6	20
84	A Structure-Function Mechanism for Schizophrenia. Frontiers in Psychiatry, 2012, 3, 108.	2.6	11
85	miRNA-mediated risk for schizophrenia in 22q11.2 deletion syndrome. Frontiers in Genetics, 2012, 3, 291.	2.3	34
86	Polyunsaturated Fatty Acids and their Metabolites in Neural Development and Implications for Psychiatric Disorders. Current Psychopharmacology, 2012, 2, 73-83.	0.3	11
87	Clinical applications of schizophrenia genetics: genetic diagnosis, risk, and counseling in the molecular era. The Application of Clinical Genetics, 2012, 5, 1.	3.0	35
88	The Unique Properties of the Prefrontal Cortex and Mental Illness. , 2012, , .		7
89	Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Molecular Psychiatry, 2012, 17, 1206-1227.	7.9	479
90	Astrocytes and disease: a neurodevelopmental perspective. Genes and Development, 2012, 26, 891-907.	5.9	578
91	Neuregulin and dopamine modulation of hippocampal gamma oscillations is dependent on dopamine D4 receptors. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 13118-13123.	7.1	82
92	Cortical basket cell dysfunction in schizophrenia. Journal of Physiology, 2012, 590, 715-724.	2.9	119
93	Neurodevelopmental and neuropsychiatric behaviour defects arise from 14-3-3Î¶ deficiency. Molecular Psychiatry, 2012, 17, 451-466.	7.9	95

#	Article	IF	Citations
94	Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap. Nature Reviews Drug Discovery, 2012, 11, 560-579.	46.4	154
95	Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacology Biochemistry and Behavior, 2012, 100, 665-677.	2.9	132
96	Mushroom body neuronal remodelling is necessary for shortâ€term but not for longâ€term courtship memory in Drosophila. European Journal of Neuroscience, 2012, 35, 1684-1691.	2.6	21
97	Cortical circuit dysfunction and cognitive deficits in schizophrenia â€“ implications for preemptive interventions. European Journal of Neuroscience, 2012, 35, 1871-1878.	2.6	130
98	Drug development in pediatric psychiatry: current status, future trends. Child and Adolescent Psychiatry and Mental Health, 2012, 6, 7.	2.5	7
99	Mouse models of geneâ€“environment interactions in schizophrenia. Neurobiology of Disease, 2013, 57, 5-11.	4.4	50
100	Clinical classification in mental health at the cross-roads: which direction next?. BMC Medicine, 2013, 11, 125.	5.5	68
101	Functional dysconnectivity in schizophrenia and its relationship to neural synchrony. Expert Review of Neurotherapeutics, 2013, 13, 755-765.	2.8	18
102	Impaired GABAergic Neurotransmission in Schizophrenia Underlies Impairments in Cortical Gamma Band Oscillations. Current Psychiatry Reports, 2013, 15, 346.	4.5	42
103	Defining new guidelines for screening the 22q11.2 deletion based on a clinical and dysmorphologic evaluation of 194 individuals and review of the literature. European Journal of Pediatrics, 2013, 172, 927-945.	2.7	53
104	Updating the mild encephalitis hypothesis of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 42, 71-91.	4.8	120
105	The mild encephalitis concept for psychiatric disorders revisited in the light of current psychoneuroimmunological findings. Neurology Psychiatry and Brain Research, 2013, 19, 87-101.	2.0	26
106	Premorbid adjustment and schizophrenia in individuals with 22q11.2 deletion syndrome. Schizophrenia Research, 2013, 151, 221-225.	2.0	21
107	Relationship between negative symptoms and plasma levels of insulin-like growth factor 1 in first-episode schizophrenia and bipolar disorder patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 44, 29-33.	4.8	45
108	Brain-wide functional inter-hemispheric disconnection is a potential biomarker for schizophrenia and distinguishes it from depression. NeuroImage: Clinical, 2013, 2, 818-826.	2.7	62
109	The Role of Consultation-Liaison Psychiatrists in Improving Health Care of Patients with Schizophrenia. Psychosomatics, 2013, 54, 22-27.	2.5	9
110	Harnessing cognitive neuroscience to develop new treatments for improving cognition in schizophrenia: CNTRICS selected cognitive paradigms for animal models. Neuroscience and Biobehavioral Reviews, 2013, 37, 2087-2091.	6.1	67
111	Urban social stress â€“ Risk factor for mental disorders. The case ofÂschizophrenia. Environmental Pollution, 2013, 183, 2-6.	7.5	87

#	Article	IF	Citations
112	Molecular genetic geneâ€“environment studies using candidate genes in schizophrenia: A systematic review. Schizophrenia Research, 2013, 150, 356-365.	2.0	80
113	Circular inferences in schizophrenia. Brain, 2013, 136, 3227-3241.	7.6	153
114	The emerging spectrum of allelic variation in schizophrenia: current evidence and strategies for the identification and functional characterization of common and rare variants. Molecular Psychiatry, 2013, 18, 38-52.	7.9	75
115	Brainnetome: A new -ome to understand the brain and its disorders. NeuroImage, 2013, 80, 263-272.	4.2	116
116	Pathogenic rare copy number variants in community-based schizophrenia suggest a potential role for clinical microarrays. Human Molecular Genetics, 2013, 22, 4485-4501.	2.9	120
117	Balancing Plasticity/Stability Across Brain Development. Progress in Brain Research, 2013, 207, 3-34.	1.4	515
118	Brainnetome-wide association studies in schizophrenia: The advances and future. Neuroscience and Biobehavioral Reviews, 2013, 37, 2818-2835.	6.1	25
119	Quantitative and qualitative symptomatic differences in individuals at Ultra-High Risk for psychosis and healthy controls. Psychiatry Research, 2013, 210, 432-437.	3.3	11
120	Erbb4 Deletion from Fast-Spiking Interneurons Causes Schizophrenia-like Phenotypes. Neuron, 2013, 79, 1152-1168.	8.1	254
121	Epidemiological and Clinical Characterization Following a First Psychotic Episode in Major Depressive Disorder: Comparisons With Schizophrenia and Bipolar I Disorder in the Cavan-Monaghan First Episode Psychosis Study (CAMFEPS). Schizophrenia Bulletin, 2013, 39, 756-765.	4.3	52
122	Genes and environments in schizophrenia: The different pieces of a manifold puzzle. Neuroscience and Biobehavioral Reviews, 2013, 37, 2424-2437.	6.1	44
123	Definition and description of schizophrenia in the DSM-5. Schizophrenia Research, 2013, 150, 3-10.	2.0	491
124	Nosology of psychoses in DSM-5: Inches ahead but miles to go. Schizophrenia Research, 2013, 150, 40-41.	2.0	11
125	Questions about DISC1 as a genetic risk factor for schizophrenia. Molecular Psychiatry, 2013, 18, 1050-1052.	7.9	86
126	Animal models of brain maldevelopment induced by cycad plant genotoxins. Birth Defects Research Part C: Embryo Today Reviews, 2013, 99, 247-255.	3.6	31
127	Endocannabinoid system: Potential novel targets for treatment of schizophrenia. Neurobiology of Disease, 2013, 53, 10-17.	4.4	43
128	Pluripotent stem cells as a model to study oxygen metabolism in neurogenesis and neurodevelopmental disorders. Archives of Biochemistry and Biophysics, 2013, 534, 3-10.	3.0	14
129	Dysconnectivity, large-scale networks and neuronal dynamics in schizophrenia. Current Opinion in Neurobiology, 2013, 23, 283-290.	4.2	149

#	Article	IF	Citations
130	Classification of psychotic disorders: Need to move toward a neuroscience-informed nosology. Asian Journal of Psychiatry, 2013, 6, 191-192.	2.0	6
131	Human brain imaging studies of DISC1 in schizophrenia, bipolar disorder and depression: A systematic review. Schizophrenia Research, 2013, 147, 1-13.	2.0	70
132	Expression and differential response to haloperidol treatment of Cyclon/CCDC86 mRNA in schizophrenia patients. Neurochemistry International, 2013, 62, 870-872.	3.8	3
133	A clinical and demographic comparison between a forensic and a general sample of female patients with schizophrenia. Psychiatry Research, 2013, 210, 1176-1183.	3.3	15
134	Quantification of endocannabinoids in postmortem brain of schizophrenic subjects. Schizophrenia Research, 2013, 148, 145-150.	2.0	65
135	A multimodal approach to investigate biomarkers for psychosis in a clinical setting: The integrative neuroimaging studies in schizophrenia targeting for early intervention and prevention (IN-STEP) project. Schizophrenia Research, 2013, 143, 116-124.	2.0	54
136	Psychosis-proneness and the rubber hand illusion of body ownership. Psychiatry Research, 2013, 207, 45-52.	3.3	77
137	Decreased left middle temporal gyrus volume in antipsychotic drug-naive, first-episode schizophrenia patients and their healthy unaffected siblings. Schizophrenia Research, 2013, 144, 37-42.	2.0	84
138	Using rodents to model schizophrenia and substance use comorbidity. Neuroscience and Biobehavioral Reviews, 2013, 37, 896-910.	6.1	18
139	Early and late stages of visual processing in individuals in prodromal state and first episode schizophrenia: An ERP study. Schizophrenia Research, 2013, 146, 95-102.	2.0	42
140	Schizophrenia research in 2013: Are we making progress?. Neurobiology of Disease, 2013, 53, 1-2.	4.4	1
141	Roles of glial cells in schizophrenia: Possible targets for therapeutic approaches. Neurobiology of Disease, 2013, 53, 49-60.	4.4	59
142	Directed Differentiation and Functional Maturation of Cortical Interneurons from Human Embryonic Stem Cells. Cell Stem Cell, 2013, 12, 559-572.	11.1	505
143	Decision Making: From Neuroscience to Psychiatry. Neuron, 2013, 78, 233-248.	8.1	129
144	Maternal Immune Activation during Gestation Interacts withDisc1Point Mutation to Exacerbate Schizophrenia-Related Behaviors in Mice. Journal of Neuroscience, 2013, 33, 7654-7666.	3.6	129
145	Structure of the psychotic disorders classification in DSMâ€5. Schizophrenia Research, 2013, 150, 11-14.	2.0	170
146	Genetic models of schizophrenia and related psychotic disorders: progress and pitfalls across the methodological â€œminefieldâ€• Cell and Tissue Research, 2013, 354, 247-257.	2.9	10
147	Developmental neuroinflammation and schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 42, 20-34.	4.8	258

#	Article	IF	Citations
148	Relation between variants in the neurotrophin receptor gene, NTRK3, and white matter integrity in healthy young adults. NeuroImage, 2013, 82, 146-153.	4.2	37
149	Neuropoietic cytokines in normal brain development and neurodevelopmental disorders. Molecular and Cellular Neurosciences, 2013, 53, 63-68.	2.2	57
150	Long-lasting changes in hippocampal synaptic plasticity and cognition in an animal model of NMDA receptor dysfunction in psychosis. Neuropharmacology, 2013, 74, 48-58.	4.1	43
151	Sex differences and the role of estrogen in animal models of schizophrenia: Interaction with BDNF. Neuroscience, 2013, 239, 67-83.	2.3	85
152	A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. Molecular Psychiatry, 2013, 18, 543-556.	7.9	226
153	A protective-compensatory model may reconcile the genetic and the developmental findings in schizophrenia. Schizophrenia Research, 2013, 144, 9-15.	2.0	21
154	White matter tract abnormalities between rostral middle frontal gyrus, inferior frontal gyrus and striatum in first-episode schizophrenia. Schizophrenia Research, 2013, 145, 1-10.	2.0	89
155	A hierarchical coherentâ€geneâ€group model for brain development. Genes, Brain and Behavior, 2013, 12, 147-165.	2.2	17
156	Reimagining psychoses: An agnostic approach to diagnosis. Schizophrenia Research, 2013, 146, 10-16.	2.0	77
157	Genetic variation in GAD1 is associated with cortical thickness in the parahippocampal gyrus. Journal of Psychiatric Research, 2013, 47, 872-879.	3.1	9
158	Characterization of geneâ€“environment interactions by behavioral profiling of selectively bred rats: The effect of NMDA receptor inhibition and social isolation. Behavioural Brain Research, 2013, 240, 134-145.	2.2	31
159	Characterization of human DAAO variants potentially related to an increased risk of schizophrenia. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 400-410.	3.8	26
160	Search for missing schizophrenia genes will require a new developmental neurogenomic perspective. Journal of Genetics, 2013, 92, 335-340.	0.7	1
162	Long-term Follow-up of a Group at Ultra High Risk (â€œProdromalâ€) for Psychosis. JAMA Psychiatry, 2013, 70, 793.	11.0	373
164	Microvascular Abnormality in Schizophrenia as Shown by Retinal Imaging. American Journal of Psychiatry, 2013, 170, 1451-1459.	7.2	95
165	Prevention, innovation and implementation science in mental health: the next wave of reform. British Journal of Psychiatry, 2013, 202, s3-s4.	2.8	47
166	Homeoprotein Signaling in Development, Health, and Disease: A Shaking of Dogmas Offers Challenges and Promises from Bench to Bed. Pharmacological Reviews, 2013, 65, 90-104.	16.0	45
167	Convergence of genetic and environmental factors on parvalbumin-positive interneurons in schizophrenia. Frontiers in Behavioral Neuroscience, 2013, 7, 116.	2.0	78

#	Article	IF	Citations
168	Rethinking schizophrenia in the context of normal neurodevelopment. Frontiers in Cellular Neuroscience, 2013, 7, 60.	3.7	157
169	Stereological assessment of the dorsal anterior cingulate cortex in schizophrenia: absence of changes in neuronal and glial densities. Neuropathology and Applied Neurobiology, 2013, 39, 348-361.	3.2	24
170	Operational Architectonics Methodology for EEG Analysis: Theory and Results. Neuromethods, 2013, , 1-59.	0.3	22
171	Insights into Rapid Modulation of Neuroplasticity by Brain Estrogens. Pharmacological Reviews, 2013, 65, 1318-1350.	16.0	110
172	Development of liability syndromes for schizophrenia: Where did they come from and where are they going?. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2013, 162, 687-697.	1.7	3
173	Disruption of Arp2/3 Results in Asymmetric Structural Plasticity of Dendritic Spines and Progressive Synaptic and Behavioral Abnormalities. Journal of Neuroscience, 2013, 33, 6081-6092.	3.6	157
174	Peripheral Endocannabinoid System Dysregulation in First-Episode Psychosis. Neuropsychopharmacology, 2013, 38, 2568-2577.	5.4	73
175	The worst disease. Australian and New Zealand Journal of Psychiatry, 2013, 47, 499-500.	2.3	2
176	Cortex Morphology in First-Episode Psychosis Patients With Neurological Soft Signs. Schizophrenia Bulletin, 2013, 39, 820-829.	4.3	70
177	Genetics of Schizophrenia. International Journal of Mental Health, 2013, 42, 5-22.	1.3	4
178	Schizophrenia: Current Trends. International Journal of Mental Health, 2013, 42, 3-4.	1.3	2
179	Schizophrenia and OCD: comparative characteristics. , 0, , 1-21.		1
180	D-Amino Acid Oxidase and Metagenomics. Cloning & Transgenesis, 2013, 02, .	0.1	0
181	The Association between Intelligence Scores and Family History of Psychiatric Disorder in Schizophrenia Patients, Their Siblings and Healthy Controls. PLoS ONE, 2013, 8, e77215.	2.5	5
182	Profile of blonanserin for the treatment of schizophrenia. Neuropsychiatric Disease and Treatment, 2013, 9, 587.	2.2	55
183	â€œTo see or not to see: that is the question.â€•The â€œProtection-Against-Schizophreniaâ€•(PaSZ) model: evidence from congenital blindness and visuo-cognitive aberrations. Frontiers in Psychology, 2013, 4, 352.	2.1	46
184	Near-Infrared Spectroscopy in Schizophrenia: A Possible Biomarker for Predicting Clinical Outcome and Treatment Response. Frontiers in Psychiatry, 2013, 4, 145.	2.6	55
185	Connectivity, Pharmacology, and Computation: Toward a Mechanistic Understanding of Neural System Dysfunction in Schizophrenia. Frontiers in Psychiatry, 2013, 4, 169.	2.6	68

#	Article	IF	Citations
186	NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia. Frontiers in Cellular Neuroscience, 2013, 7, 31.	3.7	198
187	Serotonin homeostasis and serotonin receptors as actors of cortical construction: special attention to the 5-HT3A and 5-HT6 receptor subtypes. Frontiers in Cellular Neuroscience, 2013, 7, 93.	3.7	65
188	Dopamine, cognitive function, and gamma oscillations: role of D4 receptors. Frontiers in Cellular Neuroscience, 2013, 7, 102.	3.7	66
189	Comorbid Obsessive-Compulsive Symptoms in Schizophrenia: Insight into Pathomechanisms Facilitates Treatment. Advances in Medicine, 2014, 2014, 1-18.	0.8	38
190	Biological Basis for Cerebral Dysfunction in Schizophrenia in Contrast with Alzheimerâ€™s Disease. Frontiers in Psychiatry, 2013, 4, 119.	2.6	0
191	Magnetic Resonance Imaging in Studying Schizophrenia, Negative Symptoms, and the Glutamate System. Frontiers in Psychiatry, 2014, 5, 32.	2.6	37
192	Consequences at adulthood of transient inactivation of the parahippocampal and prefrontal regions during early development: new insights from a disconnection animal model for schizophrenia. Frontiers in Behavioral Neuroscience, 2013, 7, 118.	2.0	73
193	Consequences at adulthood of transient inactivation of the parahippocampal and prefrontal regions during early development: new insights from a disconnection animal model for schizophrenia. Frontiers in Behavioral Neuroscience, 2014, 8, 118.	2.0	11
194	Distinct phenotypes of new transmembrane-domain neuregulin 1 mutant mice and the rescue effects of valproate on the observed schizophrenia-related cognitive deficits. Frontiers in Behavioral Neuroscience, 2014, 8, 126.	2.0	21
195	Maternal care affects the phenotype of a rat model for schizophrenia. Frontiers in Behavioral Neuroscience, 2014, 8, 268.	2.0	13
196	Schizophrenia: susceptibility genes and oligodendroglial and myelin related abnormalities. Frontiers in Cellular Neuroscience, 2014, 8, 5.	3.7	78
197	Converging on a core cognitive deficit: the impact of various neurodevelopmental insults on cognitive control. Frontiers in Neuroscience, 2014, 8, 153.	2.8	16
198	Pro-/Anti-inflammatory Dysregulation in Patients With First Episode of Psychosis: Toward an Integrative Inflammatory Hypothesis of Schizophrenia. Schizophrenia Bulletin, 2014, 40, 376-387.	4.3	156
199	Sensitive periods in fear learning and memory. Stress, 2014, 17, 13-21.	1.8	26
200	DISC1 as a genetic risk factor for schizophrenia and related major mental illness: response to Sullivan. Molecular Psychiatry, 2014, 19, 141-143.	7.9	62
201	Mental disorders, brain disorders, neurodevelopmental disorders: challenges for the philosophy of psychopathology after DSM-5. South African Journal of Philosophy, 2014, 33, 131-144.	0.4	0
202	Head Injury as Risk Factor for Psychiatric Disorders: A Nationwide Register-Based Follow-Up Study of 113,906 Persons With Head Injury. American Journal of Psychiatry, 2014, 171, 463-469.	7.2	132
203	Role of the Axonal Initial Segment in Psychiatric Disorders: Function, Dysfunction, and Intervention. Frontiers in Psychiatry, 2014, 5, 109.	2.6	32

#	Article	IF	Citations
204	Investigation of the involvement of MIR185 and its target genes in the development of schizophrenia. Journal of Psychiatry and Neuroscience, 2014, 39, 386-396.	2.4	23
205	Specific Glial Functions Contribute to Schizophrenia Susceptibility. Schizophrenia Bulletin, 2014, 40, 925-935.	4.3	105
206	Research Strategies and Priorities to Improve the Lives of People With Schizophrenia: Executive Summary of the Ernst Struungmann Forum on Schizophrenia. Schizophrenia Bulletin, 2014, 40, 259-265.	4.3	7
207	Antipsychotic dosing: found in translation. Journal of Psychiatry and Neuroscience, 2014, 39, 223-231.	2.4	13
208	The Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability. Frontiers in Psychiatry, 2014, 5, 159.	2.6	30
210	Treatment Seeking and Unmet Need for Care Among Persons Reporting Psychosis-Like Experiences. Psychiatric Services, 2014, 65, 774-780.	2.0	67
212	Subclinical Psychotic Experiences in Healthy Young Adults: Associations with Stress and Genetic Predisposition. Genetic Testing and Molecular Biomarkers, 2014, 18, 683-689.	0.7	16
213	Quinoline- and isoquinoline-sulfonamide analogs of aripiprazole: novel antipsychotic agents?. Future Medicinal Chemistry, 2014, 6, 57-75.	2.3	69
214	Hypomethylation of the paternally inherited LRRTM1 promoter linked to schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2014, 165, 555-563.	1.7	21
215	The 4th Schizophrenia International Research Society Conference, 5â€“9 April 2014, Florence, Italy: A summary of topics and trends. Schizophrenia Research, 2014, 159, e1-e22.	2.0	2
216	Effects of Multidimensional Treatment Foster Care on Psychotic Symptoms in Girls. Journal of the American Academy of Child and Adolescent Psychiatry, 2014, 53, 1279-1287.	0.5	34
217	A Brainâ€wide association study of DISC1 genetic variants reveals a relationship with the structure and functional connectivity of the precuneus in schizophrenia. Human Brain Mapping, 2014, 35, 5414-5430.	3.6	27
218	A <scp>N</scp>euregulinâ€1 schizophrenia susceptibility variant causes perihippocampal fiber tract anomalies in healthy young subjects. Brain and Behavior, 2014, 4, 215-226.	2.2	13
219	Antipsychotic treatment modulates glutamate transport and NMDA receptor expression. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 67-82.	3.2	20
220	Altered functional connectivity links in neuroleptic-naÃ¯ve and neuroleptic-treated patients with schizophrenia, and their relation to symptoms including volition. NeuroImage: Clinical, 2014, 6, 463-474.	2.7	24
221	Changing Perceptions of Illness in the Early Course of Psychosis: Psychological Pathways to Self-Determination and Self-Management of Treatment. Psychiatry (New York), 2014, 77, 344-359.	0.7	7
222	Future in Psychopathology Research. Schizophrenia Bulletin, 2014, 40, S147-S151.	4.3	6
223	Emerging evidence of insulin-like growth factor 2 as a memory enhancer: a unique animal model of cognitive dysfunction with impaired adult neurogenesis. Reviews in the Neurosciences, 2014, 25, 559-74.	2.9	22

#	Article	IF	Citations
224	Prefrontal Brain Network Connectivity Indicates Degree of Both Schizophrenia Risk and Cognitive Dysfunction. Schizophrenia Bulletin, 2014, 40, 653-664.	4.3	69
225	Characterizing Thalamo-Cortical Disturbances in Schizophrenia and Bipolar Illness. Cerebral Cortex, 2014, 24, 3116-3130.	2.9	415
226	Prenatal Immune Activation Induces Maturation-Dependent Alterations in the Prefrontal GABAergic Transcriptome. Schizophrenia Bulletin, 2014, 40, 351-361.	4.3	117
227	Key functional circuitry altered in schizophrenia involves parietal regions associated with sense of self. Human Brain Mapping, 2014, 35, 123-139.	3.6	73
228	A novel, online social cognitive training program for young adults with schizophrenia: A pilot study. Schizophrenia Research: Cognition, 2014, 1, e11-e19.	1.3	93
229	Transcription factor 4 (TCF4) and schizophrenia: integrating the animal and the human perspective. Cellular and Molecular Life Sciences, 2014, 71, 2815-2835.	5.4	61
230	Schizophrenia: from dopaminergic to glutamatergic interventions. Current Opinion in Pharmacology, 2014, 14, 97-102.	3.5	139
231	Identification of Subgroups of Schizophrenia Patients With Changes in Either Immune or Growth Factor and Hormonal Pathways. Schizophrenia Bulletin, 2014, 40, 787-795.	4.3	84
232	Psychosis Prediction: Stratification of Risk Estimation With Information-Processing and Premorbid Functioning Variables. Schizophrenia Bulletin, 2014, 40, 1482-1490.	4.3	91
233	Transcriptional landscape of the prenatal human brain. Nature, 2014, 508, 199-206.	27.8	1,147
234	Enriched environment prevents cognitive and motor deficits associated with postnatal MK-801 treatment. Psychopharmacology, 2014, 231, 4361-4370.	3.1	39
236	Default mode network connectivity and reciprocal social behavior in 22q11.2 deletion syndrome. Social Cognitive and Affective Neuroscience, 2014, 9, 1261-1267.	3.0	68
237	The neurobiology of social environmental risk for schizophrenia: an evolving research field. Social Psychiatry and Psychiatric Epidemiology, 2014, 49, 507-517.	3.1	72
238	Astrogliopathology. Neuroscientist, 2014, 20, 576-588.	3.5	126
239	Prefrontal Inefficiency Is Associated With Polygenic Risk for Schizophrenia. Schizophrenia Bulletin, 2014, 40, 1263-1271.	4.3	53
240	Stratified medicine for mental disorders. European Neuropsychopharmacology, 2014, 24, 5-50.	0.7	152
241	Pyrroloquinoline quinone prevents MK-801-induced stereotypical behavior and cognitive deficits in mice. Behavioural Brain Research, 2014, 258, 153-159.	2.2	15
242	Differential Neurodevelopmental Trajectories in Patients With Early-Onset Bipolar and Schizophrenia Disorders. Schizophrenia Bulletin, 2014, 40, S138-S146.	4.3	100

#	Article	IF	Citations
243	Targeting Dopamine D3 and Serotonin 5-HT1A and 5-HT2A Receptors for Developing Effective Antipsychotics: Synthesis, Biological Characterization, and Behavioral Studies. Journal of Medicinal Chemistry, 2014, 57, 9578-9597.	6.4	46
244	Computational Psychiatry. Neuron, 2014, 84, 638-654.	8.1	291
245	Etiology, triggers and neurochemical circuits associated with unexpected, expected, and laboratory-induced panic attacks. Neuroscience and Biobehavioral Reviews, 2014, 46, 429-454.	6.1	48
246	The RDoC framework: continuing commentary. World Psychiatry, 2014, 13, 196-197.	10.4	26
248	Abnormal Dynamics of EEG Oscillations in Schizophrenia Patients on Multiple Time Scales. IEEE Transactions on Biomedical Engineering, 2014, 61, 1756-1764.	4.2	44
249	The Adenosine Neuromodulation System in Schizophrenia. International Review of Neurobiology, 2014, 119, 395-449.	2.0	32
250	New therapeutic approaches for treatment-resistant schizophrenia: A look to the future. Journal of Psychiatric Research, 2014, 58, 1-6.	3.1	57
251	Comparison of serum BDNF levels in deficit and nondeficit chronic schizophrenia and healthy controls. Psychiatry Research, 2014, 220, 197-200.	3.3	17
252	Disrupted-In-Schizophrenia-1 (DISC1) interactome and mental disorders: Impact of mouse models. Neuroscience and Biobehavioral Reviews, 2014, 45, 271-294.	6.1	46
253	Myelination, oligodendrocytes, and serious mental illness. Glia, 2014, 62, 1856-1877.	4.9	203
254	Emerging drugs for schizophrenia: an update. Expert Opinion on Emerging Drugs, 2014, 19, 511-531.	2.4	44
255	Is Prophylactic Psychiatry around the Corner? Combating Adolescent Oxidative Stress for Adult Psychosis and Schizophrenia. Neuron, 2014, 83, 991-993.	8.1	28
256	VisiÃ³n de un residente espaÃ±ol de la psiquiatrÃa del siglo XXI. Psiquiatria Biologica, 2014, 21, 25-27.	0.1	0
257	Benefits and limits of anticholinergic use in schizophrenia: Focusing on its effect on cognitive function. Psychiatry and Clinical Neurosciences, 2014, 68, 37-49.	1.8	74
258	Imaging Genetics: Unraveling the Neurogenetic Risk Architecture of Mental Illness. , 2014, , 117-135.		1
259	Amygdala Connectivity Differs Among Chronic, Early Course, and Individuals at Risk for Developing Schizophrenia. Schizophrenia Bulletin, 2014, 40, 1105-1116.	4.3	67
260	Jung's views on causes and treatments of schizophrenia in light of current trends in cognitive neuroscience and psychotherapy research II: Psychological research and treatment. Journal of Analytical Psychology, 2014, 59, 263-283.	0.2	4
261	EphA7 signaling guides cortical dendritic development and spine maturation. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 4994-4999.	7.1	35

#	Article	IF	Citations
262	Beyond Critique: Rethinking Roles for the Anthropology of Mental Health. Culture, Medicine and Psychiatry, 2014, 38, 499-511.	1.2	13
263	Brain circuit dysfunction in a distinct subset of chronic psychotic patients. Schizophrenia Research, 2014, 157, 204-213.	2.0	13
264	Brainnetome and related projects. Science China Life Sciences, 2014, 57, 462-466.	4.9	5
265	The Future of Psychoses as Seen from the History of its Evolution. Current Behavioral Neuroscience Reports, 2014, 1, 94-99.	1.3	5
266	Five-Year Follow-Up of Supportive Psychodynamic Psychotherapy in First-Episode Psychosis: Long-Term Outcome in Social Functioning. Psychiatry (New York), 2014, 77, 155-168.	0.7	25
267	Â¿QuÃ© hemos aprendido de la investigaciÃ³n en primeros episodios psicÃ³ticos?. Revista De PsiquiatrÃa Y Salud Mental, 2014, 7, 61-63.	1.8	27
268	Folding of the anterior cingulate cortex partially explains inhibitory control during childhood: A longitudinal study. Developmental Cognitive Neuroscience, 2014, 9, 126-135.	4.0	55
269	Increased susceptibility to apoptosis in cultured fibroblasts from antipsychotic-naÃ¯ve first-episode schizophrenia patients. Journal of Psychiatric Research, 2014, 48, 94-101.	3.1	45
270	A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis. Schizophrenia Research, 2014, 155, 52-58.	2.0	48
271	The emerging roles of TCF4 in disease and development. Trends in Molecular Medicine, 2014, 20, 322-331.	6.7	136
272	An investigation into the effects of tDCS dose on cognitive performance over time in patients with schizophrenia. Schizophrenia Research, 2014, 155, 96-100.	2.0	111
273	Pro-inflammatory cytokine levels are raised in female schizophrenia patients treated with clozapine. Schizophrenia Research, 2014, 156, 1-8.	2.0	40
274	Resting EEG in psychosis and at-risk populations â€" A possible endophenotype?. Schizophrenia Research, 2014, 153, 96-102.	2.0	57
276	Stem Cells on the Brain: Modeling Neurodevelopmental and Neurodegenerative Diseases Using Human Induced Pluripotent Stem Cells. Journal of Neurogenetics, 2014, 28, 5-29.	1.4	52
277	High Solubility Crystalline Pharmaceutical Forms of Blonanserin. Crystal Growth and Design, 2014, 14, 2557-2570.	3.0	27
278	Specific disruption of thalamic inputs to the auditory cortex in schizophrenia models. Science, 2014, 344, 1178-1182.	12.6	107
279	What have we learned from research into first-episode psychosis?. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2014, 7, 61-63.	0.3	6
280	Human Stem Cells and Surrogate Tissues for Basic and Translational Study of Mental Disorders. Biological Psychiatry, 2014, 75, 918-919.	1.3	18

#	Article	IF	Citations
281	Effect of maternal immune activation on the kynurenine pathway in preadolescent rat offspring and on MK801-induced hyperlocomotion in adulthood: Amelioration by COX-2 inhibition. Brain, Behavior, and Immunity, 2014, 41, 173-181.	4.1	35
282	708 Common and 2010 rare DISC1 locus variants identified in 1542 subjects: analysis for association with psychiatric disorder and cognitive traits. Molecular Psychiatry, 2014, 19, 668-675.	7.9	59
283	Accelerating neuronal aging in in vitro model brain disorders: a focus on reactive oxygen species. Frontiers in Aging Neuroscience, 2014, 6, 292.	3.4	50
286	Toward Illness Phaseâ€“Specific Pharmacotherapy for Schizophrenia. Biological Psychiatry, 2015, 78, 738-740.	1.3	43
287	At risk or not at risk? A metaâ€analysis of the prognostic accuracy of psychometric interviews for psychosis prediction. World Psychiatry, 2015, 14, 322-332.	10.4	209
288	Schizophrenia. Nature Reviews Disease Primers, 2015, 1, 15067.	30.5	724
289	22q11.2 deletion syndrome. Nature Reviews Disease Primers, 2015, 1, 15071.	30.5	954
290	Course of neurological soft signs in first-episode schizophrenia: Relationship with negative symptoms and cognitive performances. Scientific Reports, 2015, 5, 11053.	3.3	26
291	Identification and Functional Studies of Regulatory Variants Responsible for the Association of <i>NRG3</i> with a Delusion Phenotype in Schizophrenia. Molecular Neuropsychiatry, 2015, 1, 36-46.	2.9	14
292	Symptom presentation and functioning in neurodevelopmental disorders: Intellectual disability and exposure to trauma. Ethics, Medicine and Public Health, 2015, 1, 348-358.	0.9	1
293	Increased Internet use and poorer ability to manage emotions in youth at high-risk for psychosis. Schizophrenia Research: Cognition, 2015, 2, 220-226.	1.3	10
294	An interaction between NDE1 and high birth weight increases schizophrenia susceptibility. Psychiatry Research, 2015, 230, 194-199.	3.3	9
295	Social behavior in a genetic model of dopamine dysfunction at different neurodevelopmental time points. Genes, Brain and Behavior, 2015, 14, 503-515.	2.2	13
296	Functional mental capacity, treatment as usual and time: magnitude of change in secure hospital patients with major mental illness. BMC Research Notes, 2015, 8, 566.	1.4	21
297	Pregnancy distress gets under fetal skin: Maternal ambulatory assessment & sex differences in prenatal development. Developmental Psychobiology, 2015, 57, 607-625.	1.6	50
298	Conventional and alternative preventive treatments in the first stages of schizophrenia. European Journal of Psychiatry, 2015, 29, 135-143.	1.3	1
299	Strategies to improve medication adherence in patients with schizophrenia: the role of support services. Neuropsychiatric Disease and Treatment, 2015, 11, 1077.	2.2	58
300	China is Prepared to Fight Against Emerging Mental Health Disorders?. International Journal of Emergency Mental Health, 0, s3, .	0.3	1

#	Article	IF	Citations
301	Sequence of Molecular Events during the Maturation of the Developing Mouse Prefrontal Cortex. Molecular Neuropsychiatry, 2015, 1, 94-104.	2.9	15
302	The autistic brain in the context of normal neurodevelopment. Frontiers in Neuroanatomy, 2015, 9, 115.	1.7	9
303	Patterns of Spontaneous Local Network Activity in Developing Cerebral Cortex: Relationship to Adult Cognitive Function. PLoS ONE, 2015, 10, e0131259.	2.5	0
304	Intrinsic Functional Connectivity in Salience and Default Mode Networks and Aberrant Social Processes in Youth at Ultra-High Risk for Psychosis. PLoS ONE, 2015, 10, e0134936.	2.5	33
305	Structural and functional neuroimaging findings associated with the use of clozapine in schizophrenia: a systematic review. Revista Brasileira De Psiquiatria, 2015, 37, 71-79.	1.7	15
306	Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia Therapy. BioMed Research International, 2015, 2015, 1-21.	1.9	103
307	Early Visual Processing Abnormalities Related to Schizophrenia and Autism Spectrum Disorder. , 0, , 1029-1050.		0
308	Auditory hallucinations: A review of the ERC â€œVOICEâ€•project. World Journal of Psychiatry, 2015, 5, 193.	2.7	66
309	Changes in neurocognitive functioning during transition to manifest disease: comparison of individuals at risk for schizophrenic and bipolar affective psychoses. Psychological Medicine, 2015, 45, 2123-2134.	4.5	20
310	Local-to-remote cortical connectivity in early- and adulthood-onset schizophrenia. Translational Psychiatry, 2015, 5, e566-e566.	4.8	48
311	Staging of Bipolar Disorder. , 2015, , 437-459.		2
312	Effects of prenatal immune activation on amphetamine-induced addictive behaviors: Contributions from animal models. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 63, 63-69.	4.8	22
313	Targeting Oxidative Stress and Aberrant Critical Period Plasticity in the Developmental Trajectory to Schizophrenia. Schizophrenia Bulletin, 2015, 41, 835-846.	4.3	135
315	Homeoprotein Signaling in the Developing and Adult Nervous System. Neuron, 2015, 85, 911-925.	8.1	67
316	Excitation-Inhibition Discoordination in Rodent Models of Mental Disorders. Biological Psychiatry, 2015, 77, 1079-1088.	1.3	54
317	Transcriptome outlier analysis implicates schizophrenia susceptibility genes and enriches putatively functional rare genetic variants. Human Molecular Genetics, 2015, 24, 4674-4685.	2.9	9
318	Schizophrenia and Depression Co-Morbidity: What We have Learned from Animal Models. Frontiers in Psychiatry, 2015, 6, 13.	2.6	55
319	Linking <scp>GABA</scp> and glutamate levels to cognitive skill acquisition during development. Human Brain Mapping, 2015, 36, 4334-4345.	3.6	57

#	Article	IF	Citations
320	Attachment and coping in psychosis in relation to spiritual figures. BMC Psychiatry, 2015, 15, 237.	2.6	13
321	Functional Variants in DPYSL2 Sequence Increase Risk of Schizophrenia and Suggest a Link to mTOR Signaling. G3: Genes, Genomes, Genetics, 2015, 5, 61-72.	1.8	39
322	Feeding the brain and nurturing the mind: Linking nutrition and the gut microbiota to brain development. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14105-14112.	7.1	114
323	Where are patients who have co-occurring mental and physical diseases located?. International Journal of Social Psychiatry, 2015, 61, 456-464.	3.1	7
324	Prodromal psychotic symptoms and psychological distress among secondary school students in Abeokuta, Nigeria. Journal of Child and Adolescent Mental Health, 2015, 27, 215-225.	1.7	17
325	The search for new biomarkers for cognition in schizophrenia. Schizophrenia Research: Cognition, 2015, 2, 172-178.	1.3	28
326	Early Adolescent Emergence of Reversal Learning Impairments in Isolation-Reared Rats. Developmental Neuroscience, 2015, 37, 253-262.	2.0	23
327	Schizotypy: Looking Back and Moving Forward. Schizophrenia Bulletin, 2015, 41, S366-S373.	4.3	265
328	Early-Course Unmedicated Schizophrenia Patients Exhibit Elevated Prefrontal Connectivity Associated with Longitudinal Change. Journal of Neuroscience, 2015, 35, 267-286.	3.6	153
329	N-Methyl-D-Aspartate Receptor Antagonist Effects on Prefrontal Cortical Connectivity Better Model Early Than Chronic Schizophrenia. Biological Psychiatry, 2015, 77, 569-580.	1.3	144
330	Abnormal white matter integrity in antipsychotic-naÃ¯ve first-episode psychosis patients assessed by a DTI principal component analysis. Schizophrenia Research, 2015, 162, 14-21.	2.0	30
331	Prolonged Period of Cortical Plasticity upon Redox Dysregulation in Fast-Spiking Interneurons. Biological Psychiatry, 2015, 78, 396-402.	1.3	80
332	Etiologic, Phenomenologic, and Endophenotypic Overlap of Schizophrenia and Bipolar Disorder. Annual Review of Clinical Psychology, 2015, 11, 251-281.	12.3	127
333	Graph analysis of dream reports is especially informative about psychosis. Scientific Reports, 2014, 4, 3691.	3.3	95
334	Obsessive-Compulsive Symptoms in Schizophrenia. , 2015, , .		13
335	Schizophrenia Gene Expression Profile Reverted to Normal Levels by Antipsychotics. International Journal of Neuropsychopharmacology, 2015, 18, .	2.1	37
336	A direct GABAergic output from the basal ganglia to frontal cortex. Nature, 2015, 521, 85-89.	27.8	242
337	Cognitive Decline Preceding the Onset of Psychosis in Patients With 22q11.2 Deletion Syndrome. JAMA Psychiatry, 2015, 72, 377.	11.0	196

#	Article	IF	Citations
338	PTPN21 exerts pro-neuronal survival and neuritic elongation via ErbB4/NRG3 signaling. International Journal of Biochemistry and Cell Biology, 2015, 61, 53-62.	2.8	17
339	Reductions in synaptic proteins and selective alteration of prepulse inhibition in male C57BL/6 mice after postnatal administration of a VIP receptor (VIPR2) agonist. Psychopharmacology, 2015, 232, 2181-2189.	3.1	21
340	Longitudinal Development of Hormone Levels and Grey Matter Density in 9 and 12-Year-Old Twins. Behavior Genetics, 2015, 45, 313-323.	2.1	33
341	Midline Brain Abnormalities Across Psychotic and Mood Disorders. Schizophrenia Bulletin, 2015, 42, sbv097.	4.3	25
342	Overdiagnosis in the Era of Neuropsychiatric Imaging. Academic Radiology, 2015, 22, 995-999.	2.5	3
343	Resequencing and association analysis of coding regions at twenty candidate genes suggest a role for rare risk variation at AKAP9 and protective variation at NRXN1 in schizophrenia susceptibility. Journal of Psychiatric Research, 2015, 66-67, 38-44.	3.1	18
344	Experiential pleasure deficits in different stages of schizophrenia. Schizophrenia Research, 2015, 166, 98-103.	2.0	39
345	Perinatal oxytocin increases the risk of offspring bipolar disorder and childhood cognitive impairment. Journal of Affective Disorders, 2015, 173, 65-72.	4.1	38
346	Prevalence of cavum vergae in psychosis and mood spectrum disorders. Journal of Affective Disorders, 2015, 186, 53-57.	4.1	5
347	Neuroplasticity-Based Auditory Training Via Laptop Computer Improves Cognition in Young Individuals With Recent Onset Schizophrenia. Schizophrenia Bulletin, 2015, 41, 250-258.	4.3	176
348	Genomics and epigenomics in novel schizophrenia drug discovery: translating animal models to clinical research and back. Expert Opinion on Drug Discovery, 2015, 10, 125-139.	5.0	15
349	Glutamatergic agents for schizophrenia: current evidence and perspectives. Expert Review of Clinical Pharmacology, 2015, 8, 335-352.	3.1	29
350	Age-dependency of sevoflurane-induced electroencephalogram dynamics in children. British Journal of Anaesthesia, 2015, 115, i66-i76.	3.4	87
351	Insight and subjective measures of quality of life in chronic schizophrenia. Schizophrenia Research: Cognition, 2015, 2, 127-132.	1.3	47
352	Developmental Disabilities and Metabolic Disorders. , 2015, , 18-41.		7
353	Inflammation in schizophrenia: A question of balance. Neuroscience and Biobehavioral Reviews, 2015, 55, 612-626.	6.1	155
354	Finding the missing-stimulus mismatch negativity (MMN) in early psychosis: Altered MMN to violations of an auditory gestalt. Schizophrenia Research, 2015, 166, 158-163.	2.0	29
355	The Longitudinal Course of Gross Motor Activity in Schizophrenia Ã¢â‚¬â€œ Within and between Episodes. Frontiers in Psychiatry, 2015, 6, 10.	2.6	26

#	Article	IF	Citations
356	Modeling a model: Mouse genetics, 22q11.2 Deletion Syndrome, and disorders of cortical circuit development. Progress in Neurobiology, 2015, 130, 1-28.	5.7	82
357	Psychosis risk screening among secondary school students in Abeokuta, Nigeria: Validity of the Prodromal Questionnaire â€" Brief Version (PQ-B). Schizophrenia Research, 2015, 164, 281-282.	2.0	18
358	Glutamate Decarboxylase 67 Deficiency in a Subset of GABAergic Neurons Induces Schizophrenia-Related Phenotypes. Neuropsychopharmacology, 2015, 40, 2475-2486.	5.4	60
359	Quantitative tract-based white matter heritability in twin neonates. NeuroImage, 2015, 111, 123-135.	4.2	43
360	Effects of depression on the cytokine profile in drug naÃ¯ve first-episode psychosis. Schizophrenia Research, 2015, 164, 53-58.	2.0	48
361	Ophthalmology Issues in Schizophrenia. Current Psychiatry Reports, 2015, 17, 28.	4.5	28
362	Prefrontal dysfunction and a monkey model of schizophrenia. Neuroscience Bulletin, 2015, 31, 235-241.	2.9	6
363	Interneuron epigenomes during the critical period of cortical plasticity: Implications for schizophrenia. Neurobiology of Learning and Memory, 2015, 124, 104-110.	1.9	36
364	Understanding Schizophrenia as a Disorder of Consciousness: Biological Correlates and Translational Implications from Quantum Theory Perspectives. Clinical Psychopharmacology and Neuroscience, 2015, 13, 36-47.	2.0	15
365	A novel d-amino acid oxidase from a contaminated agricultural soil metagenome and its characterization. Antonie Van Leeuwenhoek, 2015, 107, 1615-1623.	1.7	8
366	A splitting brain: Imbalanced neural networks in schizophrenia. Psychiatry Research - Neuroimaging, 2015, 232, 145-153.	1.8	22
367	Early Intervention in Psychosis. Journal of Nervous and Mental Disease, 2015, 203, 310-318.	1.0	220
368	The effect of transcranial Direct Current Stimulation on gamma activity and working memory in schizophrenia. Psychiatry Research, 2015, 228, 191-196.	3.3	59
369	Disintegration of Sensorimotor Brain Networks in Schizophrenia. Schizophrenia Bulletin, 2015, 41, 1326-1335.	4.3	146
370	Spine pruning drives antipsychotic-sensitive locomotion via circuit control of striatal dopamine. Nature Neuroscience, 2015, 18, 883-891.	14.8	113
371	Converging models of schizophrenia â€" Network alterations of prefrontal cortex underlying cognitive impairments. Progress in Neurobiology, 2015, 134, 178-201.	5.7	71
372	Psychomotor symptoms of schizophrenia map on the cerebral motor circuit. Psychiatry Research - Neuroimaging, 2015, 233, 293-298.	1.8	84
373	â€œ[L]abels of Themselves Condition Our Perceptionsâ€: The DSM and the Diagnostic Sign of Schizophrenia. Sociology Compass, 2015, 9, 35-48.	2.5	1

#	Article	IF	Citations
374	hVGAT-mCherry: A novel molecular tool for analysis of GABAergic neurons derived from human pluripotent stem cells. Molecular and Cellular Neurosciences, 2015, 68, 244-257.	2.2	22
375	Phenomenology and neurobiology of self disorder in schizophrenia: Secondary factors. Schizophrenia Research, 2015, 169, 474-482.	2.0	42
376	Association study of GRM7 polymorphisms and schizophrenia in the Chinese Han population. Neuroscience Letters, 2015, 604, 109-112.	2.1	8
377	Association of Thalamic Dysconnectivity and Conversion to Psychosis in Youth and Young Adults at Elevated Clinical Risk. JAMA Psychiatry, 2015, 72, 882.	11.0	284
378	Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study. Nature Communications, 2015, 6, 7934.	12.8	152
379	How Schizophrenia Develops: Cognitive and Brain Mechanisms Underlying Onset of Psychosis. Trends in Cognitive Sciences, 2015, 19, 744-756.	7.8	163
380	BÃºsqueda De Nuevos Biomarcadores De La CogniciÃ³n En Esquizofrenia. Schizophrenia Research: Cognition, 2015, 2, 196-203.	1.3	1
381	Cognitive intervention in early psychosis â€" preserving abilities versus remediating deficits. Current Opinion in Behavioral Sciences, 2015, 4, 63-72.	3.9	35
382	The NEWMEDS rodent touchscreen test battery for cognition relevant to schizophrenia. Psychopharmacology, 2015, 232, 3853-3872.	3.1	43
383	Early-life lead exposure recapitulates the selective loss of parvalbumin-positive GABAergic interneurons and subcortical dopamine system hyperactivity present in schizophrenia. Translational Psychiatry, 2015, 5, e522-e522.	4.8	51
384	Reduced cortical thickness in right Heschlâ€™s gyrus associated with auditory verbal hallucinations severity in first-episode schizophrenia. BMC Psychiatry, 2015, 15, 152.	2.6	38
385	Nodal centrality of functional network in the differentiation of schizophrenia. Schizophrenia Research, 2015, 168, 345-352.	2.0	57
386	Auditory dysfunction in schizophrenia: integrating clinical and basic features. Nature Reviews Neuroscience, 2015, 16, 535-550.	10.2	312
387	Translational Perspectives for Computational Neuroimaging. Neuron, 2015, 87, 716-732.	8.1	154
388	Reciprocal causation models of cognitive vs volumetric cerebral intermediate phenotypes for schizophrenia in a pan-European twin cohort. Molecular Psychiatry, 2015, 20, 1386-1396.	7.9	41
389	Connectome-wide network analysis of youth with Psychosis-Spectrum symptoms. Molecular Psychiatry, 2015, 20, 1508-1515.	7.9	110
390	Genetic Mapping in Mice Reveals the Involvement of Pcdh9 in Long-Term Social and Object Recognition and Sensorimotor Development. Biological Psychiatry, 2015, 78, 485-495.	1.3	47
391	Adolescent cannabis exposure interacts with mutant DISC1 to produce impaired adult emotional memory. Neurobiology of Disease, 2015, 82, 176-184.	4.4	39

#	Article	IF	Citations
392	Detection and treatment of at-risk mental state for developing a first psychosis: making up the balance. Lancet Psychiatry,the, 2015, 2, 825-834.	7.4	42
393	Fatty acid and vitamin interventions in adults with schizophrenia: a systematic review of the current evidence. Journal of Neural Transmission, 2015, 122, 1721-1732.	2.8	10
394	Closing the translational gap between mutant mouse models and the clinical reality of psychotic illness. Neuroscience and Biobehavioral Reviews, 2015, 58, 19-35.	6.1	30
395	The PsychENCODE project. Nature Neuroscience, 2015, 18, 1707-1712.	14.8	371
396	The impact of obsessive dimension on symptoms and functioning in schizophrenia. Psychiatry Research, 2015, 230, 581-584.	3.3	14
397	Phenomenology and neurobiology of self disorder in schizophrenia: Primary factors. Schizophrenia Research, 2015, 169, 464-473.	2.0	55
398	Aberrant Current Source-Density and Lagged Phase Synchronization of Neural Oscillations as Markers for Emerging Psychosis. Schizophrenia Bulletin, 2015, 41, 919-929.	4.3	60
399	Converging Evidence Implicates the Abnormal MicroRNA System in Schizophrenia. Schizophrenia Bulletin, 2015, 41, 728-735.	4.3	32
400	Oscillations and Neuronal Dynamics in Schizophrenia: The Search for Basic Symptoms and Translational Opportunities. Biological Psychiatry, 2015, 77, 1001-1009.	1.3	198
401	Mitochondrial dysfunction in schizophrenia: Pathways, mechanisms and implications. Neuroscience and Biobehavioral Reviews, 2015, 48, 10-21.	6.1	214
402	A Double-Blind Randomized Controlled Trial of Oxytocin Nasal Spray and Social Cognition Training for Young People With Early Psychosis. Schizophrenia Bulletin, 2015, 41, 483-493.	4.3	115
403	Effect of ketamine on oxidative stress following lipopolysaccharide administration. Comparative Clinical Pathology, 2015, 24, 53-63.	0.7	13
404	Eyeblink Conditioning: A Non-invasive Biomarker for Neurodevelopmental Disorders. Journal of Autism and Developmental Disorders, 2015, 45, 376-394.	2.7	47
405	Neurodevelopment, GABA System Dysfunction, and Schizophrenia. Neuropsychopharmacology, 2015, 40, 190-206.	5.4	172
406	Critical Periods in Speech Perception: New Directions. Annual Review of Psychology, 2015, 66, 173-196.	17.7	483
407	How can studies of resting-state functional connectivity help us understand psychosis as a disorder of brain development?. Current Opinion in Neurobiology, 2015, 30, 85-91.	4.2	68
408	Towards stage specific treatments: Effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 57, 69-75.	4.8	29
409	DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequencesâ€"part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessiveâ€"compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 87-106.	3.2	26

#	Article	IF	Citations
410	Present and future of developmental neuropsychopharmacology. European Neuropsychopharmacology, 2015, 25, 703-712.	0.7	16
411	Ankyrin-G regulates neurogenesis and Wnt signaling by altering the subcellular localization of Î²-catenin. Molecular Psychiatry, 2015, 20, 388-397.	7.9	54
412	Molecular signature of rapid estrogen regulation of synaptic connectivity and cognition. Frontiers in Neuroendocrinology, 2015, 36, 72-89.	5.2	72
413	The neurobiology and treatment of first-episode schizophrenia. Molecular Psychiatry, 2015, 20, 84-97.	7.9	173
414	Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A â€œcentral hubâ€•in schizophrenia pathophysiology?. Schizophrenia Research, 2016, 176, 41-51.	2.0	194
415	Cortical thickness and surface area in neonates at high risk for schizophrenia. Brain Structure and Function, 2016, 221, 447-461.	2.3	52
416	Modeling Dimensions of Psychopathology. Handbook of Behavioral Neuroscience, 2016, 23, 33-38.	0.7	0
417	Modeling Cognitive Impairment. Handbook of Behavioral Neuroscience, 2016, , 69-84.	0.7	1
418	The Microbiota and Gut-Brain Axis: Contributions to the Immunopathogenesis of Schizophrenia. Current Pharmaceutical Design, 2016, 22, 6122-6133.	1.9	39
419	Statistical Learning of the Neurobiology of Schizophrenia. , 2016, , 337-350.		0
420	Otx2-PNN Interaction to Regulate Cortical Plasticity. Neural Plasticity, 2016, 2016, 1-7.	2.2	74
421	Toward a Diathesis-Stress Model of Schizophrenia in a Neurodevelopmental Perspective. Handbook of Behavioral Neuroscience, 2016, 23, 209-224.	0.7	0
422	Glutamate Pharmacological Models Relevant to Schizophrenia and Psychosis. Handbook of Behavioral Neuroscience, 2016, , 139-174.	0.7	3
423	From Asperger's Autistischen Psychopathen to DSM-5 Autism Spectrum Disorder and Beyond: A Subthreshold Autism Spectrum Model. Clinical Practice and Epidemiology in Mental Health, 2016, 12, 120-131.	1.2	49
424	Modeling Schizophrenia in Animals. , 2016, , 353-381.		0
425	The Role of Psychiatric Drugs and their Minimal-Medication Alternatives in the Treatment of Schizophrenia. Journal of Psychiatry, 2016, 20, .	0.1	0
426	Psychosis Risk: What Is It and How Should We Talk About It?. AMA Journal of Ethics, 2016, 18, 624-632.	0.7	11
427	Role of Redox Dysregulation in White Matter Anomalies Associated with Schizophrenia. Handbook of Behavioral Neuroscience, 2016, , 481-500.	0.7	6

#	Article	IF	Citations
428	Arterial spin labeling in patients with schizophrenia: a systematic review. Revista De Psiquiatria Clinica, 2016, 43, 151-156.	0.6	10
429	Exploring Neurogenomics of Schizophrenia With Allen Institute for Brain Science Resources. , 2016, , 83-106.		0
430	ReducedÎ³-Aminobutyric Acid and Glutamate+Glutamine Levels in Drug-NaÃ¯ve Patients with First-Episode Schizophrenia but Not in Those at Ultrahigh Risk. Neural Plasticity, 2016, 2016, 1-9.	2.2	34
431	Reelin and Neuropsychiatric Disorders. Frontiers in Cellular Neuroscience, 2016, 10, 229.	3.7	143
432	Genetic Feedback Regulation of Frontal Cortical Neuronal Ensembles Through Activity-Dependent Arc Expression and Dopaminergic Input. Frontiers in Neural Circuits, 2016, 10, 100.	2.8	7
433	DNA Damage and Repair in Schizophrenia and Autism: Implications for Cancer Comorbidity and Beyond. International Journal of Molecular Sciences, 2016, 17, 856.	4.1	66
434	Relationship between negative symptoms and neurocognitive functions in adolescent and adult patients with first-episode schizophrenia. BMC Psychiatry, 2016, 16, 344.	2.6	22
435	Altered Cortico-Striatal Connectivity in Offspring of Schizophrenia Patients Relative to Offspring of Bipolar Patients and Controls. PLoS ONE, 2016, 11, e0148045.	2.5	51
436	A new look at an old drug: neuroprotective effects and therapeutic potentials of lithium salts. Neuropsychiatric Disease and Treatment, 2016, Volume 12, 1687-1703.	2.2	64
437	Globally Efficient Brain Organization and Treatment Response in Psychosis: A Connectomic Study of Gyrification. Schizophrenia Bulletin, 2016, 42, 1446-1456.	4.3	47
438	Modeling Geneâ€“Environment Interaction in Schizophrenia. Handbook of Behavioral Neuroscience, 2016, 23, 345-360.	0.7	2
439	Multiple markers of cortical morphology reveal evidence of supragranular thinning in schizophrenia. Translational Psychiatry, 2016, 6, e780-e780.	4.8	50
440	Database methodology for therapy evaluation in auditory schizophrenia disorder based on continuity evolution of symptoms. , 2016, , .		5
441	Brain-specific Crmp2 deletion leads to neuronal development deficits and behavioural impairments in mice. Nature Communications, 2016, 7, .	12.8	84
442	Repetitive transcranial magnetic stimulation for persistent auditory hallucination: Initial worsening of hallucination may not be a predictor of poor outcome. Postepy Psychiatrii I Neurologii, 2016, 25, 251-254.	0.2	0
443	A 12 year chart review of childhood and adolescent onset psychosis at a Nigerian tertiary mental health facility. Journal of Child and Adolescent Mental Health, 2016, 28, 189-197.	1.7	4
444	The role of P2X7 receptors in a rodent PCP-induced schizophrenia model. Scientific Reports, 2016, 6, 36680.	3.3	36
445	GABAergic Function as a Limiting Factor for Prefrontal Maturation during Adolescence. Trends in Neurosciences, 2016, 39, 441-448.	8.6	130

#	Article	IF	Citations
446	Abnormal involuntary movements are linked to psychosis-risk in children and adolescents: Results of a population-based study. Schizophrenia Research, 2016, 174, 58-64.	2.0	33
447	Subject-level measurement of local cortical coupling. NeuroImage, 2016, 133, 88-97.	4.2	23
448	Liability indicators aggregate many years before transition to illness in offspring descending from kindreds affected by schizophrenia or bipolar disorder. Schizophrenia Research, 2016, 175, 186-192.	2.0	21
449	Adult autism spectrum as a transnosographic dimension. CNS Spectrums, 2016, 21, 131-133.	1.2	56
450	Neurocognitive, Neuroprotective, and Cardiometabolic Effects of Raloxifene: Potential for Improving Therapeutic Outcomes in Schizophrenia. CNS Drugs, 2016, 30, 589-601.	5.9	13
451	Diffusion magnetic resonance imaging study of schizophrenia in the context of abnormal neurodevelopment using multiple site data in a Chinese Han population. Translational Psychiatry, 2016, 6, e715-e715.	4.8	7
452	Mitochondrial Dysfunction in Schizophrenia: Determination of Mitochondrial Respiratory Activity in a Two-Hit Mouse Model. Journal of Molecular Neuroscience, 2016, 59, 440-451.	2.3	3
453	Predictors and longitudinal course of cognitive functioning in schizophrenia spectrum disorders, 10 years after baseline: The OPUS study. Schizophrenia Research, 2016, 175, 57-63.	2.0	61
454	SUMOylation of DISC1: A Potential Role in Neural Progenitor Proliferation in the Developing Cortex. Molecular Neuropsychiatry, 2016, 2, 20-27.	2.9	4
455	Increased Frontal Gyrification Negatively Correlates with Executive Function in Patients with First-Episode Schizophrenia. Cerebral Cortex, 2016, 27, bhw101.	2.9	39
456	Preliminary investigation of the effects of Î³-tACS on working memory in schizophrenia. Journal of Neural Transmission, 2016, 123, 1205-1212.	2.8	33
457	Listening to Schneiderian Voices: A Novel Phenomenological Analysis. Psychopathology, 2016, 49, 163-171.	1.5	10
458	Reduced load-dependent default mode network deactivation across executive tasks in schizophrenia spectrum disorders. NeuroImage: Clinical, 2016, 12, 389-396.	2.7	21
459	Neurocognition in help-seeking individuals at risk for psychosis: Prediction of outcome after 24 months. Psychiatry Research, 2016, 246, 188-194.	3.3	16
460	Association of the brain-derived neurotrophic factor Val66Met polymorphism with negative symptoms severity, but not cognitive function, in first-episode schizophrenia spectrum disorders. European Psychiatry, 2016, 38, 61-69.	0.2	17
461	Elevated levels of Insulin-like Growth Factor-1 (IGF-1) in drug-naÃ¯ve patients with psychosis. Psychiatry Research, 2016, 246, 348-352.	3.3	11
462	Ultra high risk status and transition to psychosis in 22q11.2 deletion syndrome. World Psychiatry, 2016, 15, 259-265.	10.4	52
463	Magnetic resonance imaging DTI-FT study on schizophrenic patients with typical negative first symptoms. Experimental and Therapeutic Medicine, 2016, 12, 1450-1454.	1.8	11

#	Article	IF	Citations
464	Memory deficits with intact cognitive control in the methylazoxymethanol acetate (MAM) exposure model of neurodevelopmental insult. Neurobiology of Learning and Memory, 2016, 134, 294-303.	1.9	14
465	Default mode network maturation and psychopathology in children and adolescents. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2016, 57, 55-64.	5.2	31
466	Neurological dysfunctions associated with altered <scp>BACE</scp>1â€dependent Neuregulinâ€1 signaling. Journal of Neurochemistry, 2016, 136, 234-249.	3.9	40
468	Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review. Neurology and Therapy, 2016, 5, 105-130.	3.2	22
469	From Shortage to Surge: A Developmental Switch in Hippocampalâ€“Prefrontal Coupling in a Geneâ€“Environment Model of Neuropsychiatric Disorders. Cerebral Cortex, 2016, 26, 4265-4281.	2.9	49
470	Metabolic pathways in the periphery and brain: Contribution to mental disorders?. International Journal of Biochemistry and Cell Biology, 2016, 80, 19-30.	2.8	10
471	MicroRNA-137 Inhibits EFNB2 Expression Affected by a Genetic Variant and Is Expressed Aberrantly in Peripheral Blood of Schizophrenia Patients. EBioMedicine, 2016, 12, 133-142.	6.1	41
472	Linking Neuromodulated Spike-Timing Dependent Plasticity with the Free-Energy Principle. Neural Computation, 2016, 28, 1859-1888.	2.2	8
473	Multivalent approaches and beyond: novel tools for the investigation of dopamine D₂ receptor pharmacology. Future Medicinal Chemistry, 2016, 8, 1349-1372.	2.3	8
474	Structure of the Psychotic Disorders Classification in DSM-5. Focus (American Psychiatric) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5C	0.8	3
475	The Glutamate mGluR5 Receptor as a Pharmacological Target to Enhance Cognitive Function: Emerging Evidence from Psychosis Models. , 2016, , 731-750.		0
476	Association study of 5-HT1A, 5-HT2A polymorphisms with schizophrenia and major depressive disorder in the Han Chinese population. Neuroscience Letters, 2016, 635, 39-43.	2.1	11
477	Developmental timing and critical windows for the treatment of psychiatric disorders. Nature Medicine, 2016, 22, 1229-1238.	30.7	277
478	Using model systems to understand errant plasticity mechanisms in psychiatric disorders. Nature Neuroscience, 2016, 19, 1418-1425.	14.8	20
479	Detection of changes in the ventral tegmental area of patients with schizophrenia using neuromelanin-sensitive MRI. NeuroReport, 2016, 27, 289-294.	1.2	19
480	Electrophysiological insights into connectivity anomalies in schizophrenia: a systematic review. Neuropsychiatric Electrophysiology, 2016, 2, .	4.1	46
481	Visual Perception Disturbances in Schizophrenia: A Unified Model. Nebraska Symposium on Motivation, 2016, 63, 77-132.	0.9	83
482	Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review. Molecular Psychiatry, 2016, 21, 1009-1026.	7.9	272

#	Article	IF	Citations
483	Possible natural therapeutics against schizophrenia and its acute and treatment resistant forms: a review. Journal of Biologically Active Products From Nature, 2016, 6, 1-24.	0.3	3
484	The Neuropsychopathology of Schizophrenia. Nebraska Symposium on Motivation, 2016, , .	0.9	1
485	Temporal Coordination of Hippocampal Neurons Reflects Cognitive Outcome Post-febrile Status Epilepticus. EBioMedicine, 2016, 7, 175-190.	6.1	30
486	Amygdala volume is reduced in early course schizophrenia. Psychiatry Research - Neuroimaging, 2016, 250, 50-60.	1.8	33
488	Drama therapy to empower patients with schizophrenia: Is justice possible?. Arts in Psychotherapy, 2016, 50, 91-100.	1.2	8
489	GSK3Î² Hyperactivity during an Early Critical Period Impairs Prefrontal Synaptic Plasticity and Induces Lasting Deficits in Spine Morphology and Working Memory. Neuropsychopharmacology, 2016, 41, 3003-3015.	5.4	23
490	Behavioral sequelae of astrocyte dysfunction: focus on animal models of schizophrenia. Schizophrenia Research, 2016, 176, 72-82.	2.0	35
491	Neuropharmacology of altered brain oscillations in schizophrenia. International Journal of Psychophysiology, 2016, 103, 62-68.	1.0	17
492	Are there glutamate abnormalities in subjects at high risk mental state for psychosis? A review of the evidence. Schizophrenia Research, 2016, 171, 166-175.	2.0	26
493	Is it still correct to differentiate between early and very early onset psychosis?. Schizophrenia Research, 2016, 170, 211-216.	2.0	19
494	Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis. Nature Reviews Neuroscience, 2016, 17, 125-134.	10.2	256
495	Schizophrenia. Lancet, The, 2016, 388, 86-97.	13.7	1,328
496	In vivo modeling of neuronal function, axonal impairment and connectivity in neurodegenerative and neuropsychiatric disorders using induced pluripotent stem cells. Molecular and Cellular Neurosciences, 2016, 73, 3-12.	2.2	19
497	Metabotropic glutamate receptors as targets for new antipsychotic drugs: Historical perspective and critical comparative assessment. , 2016, 157, 10-27.		44
498	Effect of Name Change of Schizophrenia on Mass Media Between 1985 and 2013 in Japan: A Text Data Mining Analysis. Schizophrenia Bulletin, 2016, 42, 552-559.	4.3	39
499	Electroencephalogram signatures of ketamine anesthesia-induced unconsciousness. Clinical Neurophysiology, 2016, 127, 2414-2422.	1.5	154
500	Environmental enrichment rescues the effects of early life inflammation on markers of synaptic transmission and plasticity. Brain, Behavior, and Immunity, 2016, 57, 151-160.	4.1	52
501	Structural Brain Abnormalities in Youth With Psychosis Spectrum Symptoms. JAMA Psychiatry, 2016, 73, 515.	11.0	116

#	Article	IF	Citations
502	Toward dissecting the etiology of schizophrenia: HDAC1 and DAXX regulate GAD67 expression in an in vitro hippocampal GABA neuron model. Translational Psychiatry, 2016, 6, e723-e723.	4.8	18
503	The involvement of <italic>N</italic>-methyl-d-aspartate receptor (NMDAR) subunit NR1 in the pathophysiology of schizophrenia. Acta Biochimica Et Biophysica Sinica, 2016, 48, 209-219.	2.0	36
504	Obsessiveâ€“compulsive symptoms interact with disorganization in influencing social functioning in schizophrenia. Schizophrenia Research, 2016, 171, 35-41.	2.0	18
505	Role of MTHFR C677T gene polymorphism in the susceptibility of schizophrenia: An updated meta-analysis. Asian Journal of Psychiatry, 2016, 20, 41-51.	2.0	59
506	White Matter Microstructure in Early-Onset Schizophrenia: A Systematic Review of Diffusion Tensor Imaging Studies. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, 269-279.	0.5	57
507	Aberrant expression of microRNAs as biomarker for schizophrenia: from acute state to partial remission, and from peripheral blood to cortical tissue. Translational Psychiatry, 2016, 6, e717-e717.	4.8	64
508	Neural oscillations in antipsychotic-naÃ¯ve patients with a first psychotic episode. World Journal of Biological Psychiatry, 2016, 17, 296-307.	2.6	12
509	Healthy adolescent performance on the MATRICS Consensus Cognitive Battery (MCCB): Developmental data from two samples of volunteers. Schizophrenia Research, 2016, 172, 106-113.	2.0	20
510	Exercise may benefit patients with schizophrenia. International Journal of Sport and Exercise Psychology, 2016, 14, 103-114.	2.1	5
511	Diagnostic Stability of ICD/DSM First Episode Psychosis Diagnoses: Meta-analysis. Schizophrenia Bulletin, 2016, 42, 1395-1406.	4.3	151
512	Altering the course of schizophrenia: progress and perspectives. Nature Reviews Drug Discovery, 2016, 15, 485-515.	46.4	410
513	Differential Patterns of Dysconnectivity in Mirror Neuron and Mentalizing Networks in Schizophrenia. Schizophrenia Bulletin, 2016, 42, 1135-1148.	4.3	51
514	Syndrome of Electrical Status Epilepticus During Sleep: Epileptic Encephalopathy Related to Brain Development. Pediatric Neurology, 2016, 56, 35-41.	2.1	7
515	Genome-Wide Association Study Suggested thePTPRDPolymorphisms Were Associated With Weight Gain Effects of Atypical Antipsychotic Medications. Schizophrenia Bulletin, 2016, 42, 814-823.	4.3	32
516	Clinical Utility and Lifespan Profiling of Neurological Soft Signs in Schizophrenia Spectrum Disorders. Schizophrenia Bulletin, 2016, 42, 560-570.	4.3	47
517	The early identification of psychosis: can lessons be learnt from cardiac stress testing?. Psychopharmacology, 2016, 233, 19-37.	3.1	5
518	Levels of Red Blood Cell Fatty Acids in Patients With Psychosis, Their Unaffected Siblings, and Healthy Controls. Schizophrenia Bulletin, 2016, 42, 358-368.	4.3	28
519	Molecular substrates of schizophrenia: homeostatic signaling to connectivity. Molecular Psychiatry, 2016, 21, 10-28.	7.9	85

#	Article	IF	Citations
520	Different Paths to Core Pathology: The Equifinal Model of the Schizophrenia Syndrome. Schizophrenia Bulletin, 2016, 42, 542-549.	4.3	32
521	Tcf4 transgenic female mice display delayed adaptation in an auditory latent inhibition paradigm. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 505-512.	3.2	8
522	Fetal growth and gestational factors as predictors of schizophrenia in 22q11.2 deletion syndrome. Genetics in Medicine, 2016, 18, 350-355.	2.4	29
523	Animal models of geneâ€“environment interaction in schizophrenia: A dimensional perspective. Progress in Neurobiology, 2016, 136, 1-27.	5.7	67
524	Effects of Anodal Transcranial Direct Current Stimulation on Working Memory: A Systematic Review and Meta-Analysis of Findings From Healthy and Neuropsychiatric Populations. Brain Stimulation, 2016, 9, 197-208.	1.6	342
525	Prediction of psychosis using neural oscillations and machine learning in neuroleptic-naÃ¯ve at-risk patients. World Journal of Biological Psychiatry, 2016, 17, 285-295.	2.6	43
526	Extending the â€˜crossâ€disorderâ€™ relevance of executive functions to dimensional neuropsychiatric traits in youth. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2016, 57, 462-471.	5.2	38
527	Hypothyroxinemia During Gestation and Offspring Schizophrenia in a National Birth Cohort. Biological Psychiatry, 2016, 79, 962-970.	1.3	69
528	Clinical studies of neuroinflammatory mechanisms in schizophrenia. Schizophrenia Research, 2016, 176, 14-22.	2.0	64
529	The Philadelphia Neurodevelopmental Cohort: A publicly available resource for the study of normal and abnormal brain development in youth. NeuroImage, 2016, 124, 1115-1119.	4.2	268
530	Indicated prevention with longâ€chain polyunsaturated omegaâ€3 fatty acids in patients with 22q11<scp>DS</scp> genetically at high risk for psychosis. Protocol of a randomized, doubleâ€blind, placeboâ€controlled treatment trial. Microbial Biotechnology, 2016, 10, 390-396.	1.7	6
531	Mismatch Negativity in First-Episode Schizophrenia. Clinical EEG and Neuroscience, 2017, 48, 3-10.	1.7	100
532	Functional Connectivity of the Infant Human Brain. Neuroscientist, 2017, 23, 169-184.	3.5	265
533	Climbing Brain Levels of Organisation from Genes to Consciousness. Trends in Cognitive Sciences, 2017, 21, 168-181.	7.8	50
534	Hippocampalâ€“prefrontal connectivity as a translational phenotype for schizophrenia. European Neuropsychopharmacology, 2017, 27, 93-106.	0.7	62
535	Glutamate imaging (GluCEST) reveals lower brain GluCEST contrast in patients on the psychosis spectrum. Molecular Psychiatry, 2017, 22, 1298-1305.	7.9	74
536	Autism Spectrum and psychosis risk in the 22q11.2 deletion syndrome. Findings from a prospective longitudinal study. Schizophrenia Research, 2017, 188, 59-62.	2.0	51
537	Juvenile treatment with a novel mGluR2 agonist/mGluR3 antagonist compound, LY395756, reverses learning deficits and cognitive flexibility impairments in adults in a neurodevelopmental model of schizophrenia. Neurobiology of Learning and Memory, 2017, 140, 52-61.	1.9	15

#	Article	IF	Citations
538	Delayed stabilization and individualization in connectome development are related to psychiatric disorders. Nature Neuroscience, 2017, 20, 513-515.	14.8	197
539	Functional near infra-red spectroscopy (fNIRS) in schizophrenia: A review. Asian Journal of Psychiatry, 2017, 27, 18-31.	2.0	44
540	Blonanserin versus risperidone for schizophrenia. The Cochrane Library, 2017, , .	2.8	0
541	Thinking on writing a critical essay. Australasian Psychiatry, 2017, 25, 187-190.	0.7	3
542	Adopting a cognitive neuroscience approach to study clinically ultraâ€highâ€risk individuals. PsyCh Journal, 2017, 6, 100-101.	1.1	0
543	Effect of risperidone on serum homocysteine levels in first-episode, drug-naÃ¯ve patients with schizophrenia. Neuroscience Letters, 2017, 650, 168-173.	2.1	17
544	Multi-center machine learning in imaging psychiatry: A meta-model approach. NeuroImage, 2017, 155, 10-24.	4.2	42
545	IQ, the Urban Environment, and Their Impact on Future Schizophrenia Risk in Men. Schizophrenia Bulletin, 2017, 43, 1056-1063.	4.3	25
546	Differences of temporal dynamics and signal complexity of gamma band oscillations in first-episode psychosis during a working memory task. Journal of Neural Transmission, 2017, 124, 853-862.	2.8	3
547	A molecular pathway analysis stresses the role of inflammation and oxidative stress towards cognition in schizophrenia. Journal of Neural Transmission, 2017, 124, 765-774.	2.8	10
548	Investigational dopamine antagonists for the treatment of schizophrenia. Expert Opinion on Investigational Drugs, 2017, 26, 687-698.	4.1	18
549	Predictors for drug effects with brain disease: Shed new light from EEG parameters to brain connectomics. European Journal of Pharmaceutical Sciences, 2017, 110, 26-36.	4.0	4
551	DNA Methylation in Schizophrenia. Advances in Experimental Medicine and Biology, 2017, 978, 211-236.	1.6	49
552	Disturbances of novel object exploration and recognition in a chronic ketamine mouse model of schizophrenia. Behavioural Brain Research, 2017, 332, 316-326.	2.2	22
553	Oculomotricity and Neurological Soft Signs: Can we refine the endophenotype? A study in subjects belonging to the spectrum of schizophrenia. Psychiatry Research, 2017, 256, 490-497.	3.3	14
554	Modular Segregation of Structural Brain Networks Supports the Development of Executive Function in Youth. Current Biology, 2017, 27, 1561-1572.e8.	3.9	305
555	The Neuroendocrine System and General Mechanisms of Endocrine Disruption. , 2017, , .		0
556	Elevated mRNA expression of CASPR3 in patients with schizophrenia. Nordic Journal of Psychiatry, 2017, 71, 312-314.	1.3	4

#	Article	IF	Citations
557	Are schizophrenia, autistic, and obsessive spectrum disorders dissociable on the basis of neuroimaging morphological findings?: A voxelâ€based metaâ€analysis. Autism Research, 2017, 10, 1079-1095.	3.8	35
558	Open chromatin profiling of human postmortem brain infers functional roles for non-coding schizophrenia loci. Human Molecular Genetics, 2017, 26, 1942-1951.	2.9	69
559	Predictive Processing, Source Monitoring, and Psychosis. Annual Review of Clinical Psychology, 2017, 13, 265-289.	12.3	75
560	Abnormal parietal encephalomalacia associated with schizophrenia. Medicine (United States), 2017, 96, e6310.	1.0	4
561	Potential drug targets and treatment of schizophrenia. Inflammopharmacology, 2017, 25, 277-292.	3.9	22
562	Genetic evidence for role of integration of fast and slow neurotransmission in schizophrenia. Molecular Psychiatry, 2017, 22, 792-801.	7.9	79
563	Stem cell-derived neurons in the development of targeted treatment for schizophrenia and bipolar disorder. Pharmacogenomics, 2017, 18, 471-479.	1.3	14
564	Movement disorders and chronic psychosis. Neurology: Clinical Practice, 2017, 7, 163-169.	1.6	5
565	Cerebello-thalamo-cortical networks predict positive symptom progression in individuals at ultra-high risk for psychosis. NeuroImage: Clinical, 2017, 14, 622-628.	2.7	101
566	The relationship between level of cognitive impairments and functional outcome trajectories in first-episode schizophrenia. Schizophrenia Research, 2017, 190, 144-149.	2.0	43
567	A developmental approach to dimensional expression of psychopathology in child and adolescent offspring of parents with bipolar disorder. European Child and Adolescent Psychiatry, 2017, 26, 1165-1175.	4.7	10
568	Methamphetamineâ€related psychosis: an opportunity for assertive intervention and prevention. Addiction, 2017, 112, 927-928.	3.3	16
569	Evolution of structural abnormalities in the rat brain following in utero exposure to maternal immune activation: A longitudinal in vivo MRI study. Brain, Behavior, and Immunity, 2017, 63, 50-59.	4.1	64
570	Interleukin-17 Alteration in First-Episode Psychosis: A Meta-Analysis. Molecular Neuropsychiatry, 2017, 3, 135-140.	2.9	22
571	NMDA Receptors in the Central Nervous System. Methods in Molecular Biology, 2017, 1677, 1-80.	0.9	105
573	30 Years on: How the Neurodevelopmental Hypothesis of Schizophrenia Morphed Into the Developmental Risk Factor Model of Psychosis. Schizophrenia Bulletin, 2017, 43, 1190-1196.	4.3	213
574	Electroencephalogram dynamics in children during different levels of anaesthetic depth. Clinical Neurophysiology, 2017, 128, 2014-2021.	1.5	16
575	Oxytocin and Schizophrenia Spectrum Disorders. Current Topics in Behavioral Neurosciences, 2017, 35, 515-527.	1.7	9

#	Article	IF	Citations
576	Comprehensive review: Computational modelling of schizophrenia. Neuroscience and Biobehavioral Reviews, 2017, 83, 631-646.	6.1	62
577	Dopaminergic responses in the core part of the nucleus accumbens to subcutaneous MK801 administration are increased following postnatal transient blockade of the prefrontal cortex. Behavioural Brain Research, 2017, 335, 191-198.	2.2	9
578	Crosstalk between endoplasmic reticulum stress and oxidative stress in schizophrenia: The dawn of new therapeutic approaches. Neuroscience and Biobehavioral Reviews, 2017, 83, 589-603.	6.1	47
579	Escalating patterns of emergency health care prior to first admission with amphetamine psychosis: A window of opportunity?. Drug and Alcohol Dependence, 2017, 180, 171-177.	3.2	11
580	Low dietary intake of n-3 fatty acids, niacin, folate, and vitamin C in Korean patients with schizophrenia and the development of dietary guidelines for schizophrenia. Nutrition Research, 2017, 45, 10-18.	2.9	24
581	Reasons associated with treatment non-adherence in schizophrenia in a Pakistan cohort. Asian Journal of Psychiatry, 2017, 30, 39-43.	2.0	18
582	Spironolactone is an antagonist of <scp>NRG</scp> 1â€•<scp>ERBB</scp> 4 signaling and schizophreniaâ€relevant endophenotypes in mice. EMBO Molecular Medicine, 2017, 9, 1448-1462.	6.9	34
583	A neurogenetic model for the study of schizophrenia spectrum disorders: the International 22q11.2 Deletion Syndrome Brain Behavior Consortium. Molecular Psychiatry, 2017, 22, 1664-1672.	7.9	65
584	Graph Theory Applied to Speech: Insights on Cognitive Deficit Diagnosis and Dream Research. , 0, , 81-98.		1
585	Inhibiting Rho kinase promotes goal-directed decision making and blocks habitual responding for cocaine. Nature Communications, 2017, 8, 1861.	12.8	42
586	Altered DLPFCâ€“Hippocampus Connectivity During Working Memory: Independent Replication and Disorder Specificity of a Putative Genetic Risk Phenotype for Schizophrenia. Schizophrenia Bulletin, 2017, 43, 1114-1122.	4.3	32
587	A Prospective Study of Age-dependent Changes in Propofol-induced Electroencephalogram Oscillations in Children. Anesthesiology, 2017, 127, 293-306.	2.5	52
588	Acute systemic MKâ€801 induced functional uncoupling between hippocampal areas CA3 and CA1 with distant effect in the retrosplenial cortex. Hippocampus, 2017, 27, 134-144.	1.9	7
589	Association of anandamide with altered binocular depth inversion illusion in schizophrenia. World Journal of Biological Psychiatry, 2017, 18, 483-488.	2.6	22
590	Increased serum G72 protein levels in patients with schizophrenia: a potential candidate biomarker. Acta Neuropsychiatrica, 2017, 29, 80-86.	2.1	11
591	New drug developments in psychosis: Challenges, opportunities and strategies. Progress in Neurobiology, 2017, 152, 3-20.	5.7	57
592	Factors associated with psychotic relapse in patients with schizophrenia in a Pakistani cohort. International Journal of Mental Health Nursing, 2017, 26, 384-390.	3.8	26
593	Myelination of parvalbumin interneurons: a parsimonious locus of pathophysiological convergence in schizophrenia. Molecular Psychiatry, 2017, 22, 4-12.	7.9	94

#	Article	IF	Citations
594	Saccadic eye movements as markers of schizophrenia spectrum: Exploration in at-risk mental states. Schizophrenia Research, 2017, 181, 30-37.	2.0	29
596	Cortical high gamma network oscillations and connectivity: a translational index for antipsychotics to normalize aberrant neurophysiological activity. Translational Psychiatry, 2017, 7, 1285.	4.8	47
599	A combined VBM and DTI study of schizophrenia: bilateral decreased insula volume and cerebral white matter disintegrity corresponding to subinsular white matter projections unlinked to clinical symptomatology. Diagnostic and Interventional Radiology, 2017, 23, 390-397.	1.5	14
600	Social cognition in schizophrenia. Mental Illness, 2017, 9, 16-19.	0.8	10
601	Schizophrenia: An Impairment in the Capacity to Perceive Affordances. Frontiers in Psychology, 2017, 8, 1052.	2.1	5
602	Ethical Implications of the Mild Encephalitis Hypothesis of Schizophrenia. Frontiers in Psychiatry, 2017, 8, 38.	2.6	12
603	Paired-Associative Stimulation-Induced Long-term Potentiation-Like Motor Cortex Plasticity in Healthy Adolescents. Frontiers in Psychiatry, 2017, 8, 95.	2.6	9
604	Drug Abuse and Psychosis: New Insights into Drug-induced Psychosis. Experimental Neurobiology, 2017, 26, 11-24.	1.6	36
605	A Neurophysiological Perspective on a Preventive Treatment against Schizophrenia Using Transcranial Electric Stimulation of the Corticothalamic Pathway. Brain Sciences, 2017, 7, 34.	2.3	15
606	A Novel Bio-Psychosocial-Behavioral Treatment Model in Schizophrenia. International Journal of Molecular Sciences, 2017, 18, 734.	4.1	15
607	Reelin-Haploinsufficiency Disrupts the Developmental Trajectory of the E/I Balance in the Prefrontal Cortex. Frontiers in Cellular Neuroscience, 2017, 10, 308.	3.7	20
608	The Thymus/Neocortex Hypothesis of the Brain: A Cell Basis for Recognition and Instruction of Self. Frontiers in Cellular Neuroscience, 2017, 11, 340.	3.7	3
609	From Engrams to Pathologies of the Brain. Frontiers in Neural Circuits, 2017, 11, 23.	2.8	32
610	Disrupted Working Memory Circuitry in Adolescent Psychosis. Frontiers in Human Neuroscience, 2017, 11, 394.	2.0	4
611	The Energy Metabolism Dysfunction in Psychiatric Disorders Postmortem Brains: Focus on Proteomic Evidence. Frontiers in Neuroscience, 2017, 11, 493.	2.8	108
612	Brain-Specific SNAP-25 Deletion Leads to Elevated Extracellular Glutamate Level and Schizophrenia-Like Behavior in Mice. Neural Plasticity, 2017, 2017, 1-11.	2.2	29
613	No age effect in the prevalence and clinical significance of ultra-high risk symptoms and criteria for psychosis in 22q11 deletion syndrome: Confirmation of the genetically driven risk for psychosis?. PLoS ONE, 2017, 12, e0174797.	2.5	12
614	TAILOR â€“ tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial. Trials, 2017, 18, 445.	1.6	26

#	Article	IF	Citations
615	Gray matter morphological anomalies in the cerebellar vermis in first-episode schizophrenia patients with cognitive deficits. BMC Psychiatry, 2017, 17, 374.	2.6	15
616	Social cognition in schizophrenia. Mental Illness, 2017, 9, 7054.	0.8	11
617	PKA activation and endothelial claudin-5 breakdown in the schizophrenic prefrontal cortex. Oncotarget, 2017, 8, 93382-93391.	1.8	36
618	Impaired reward responsiveness in schizophrenia. Schizophrenia Research, 2018, 199, 46-52.	2.0	6
619	Micro RNA profiling during directed differentiation of cortical interneurons from humanâ€induced pluripotent stem cells. FEBS Open Bio, 2018, 8, 502-512.	2.3	9
620	Sodium nitroprusside is effective in preventing and/or reversing the development of schizophreniaâ€related behaviors in an animal model: The SHR strain. CNS Neuroscience and Therapeutics, 2018, 24, 624-632.	3.9	12
621	Schizophrenic patient identification using graph-theoretic features of resting-state fMRI data. Biomedical Signal Processing and Control, 2018, 43, 289-299.	5.7	26
622	Cerebellar abnormalities in first-episode, drug-naive schizophrenia at rest. Psychiatry Research - Neuroimaging, 2018, 276, 73-79.	1.8	29
624	An optimization approach for agent-based computational models of biological development. Advances in Engineering Software, 2018, 121, 262-275.	3.8	9
625	Immune and metabolic alterations in first episode psychosis (FEP) patients. Brain, Behavior, and Immunity, 2018, 70, 315-324.	4.1	31
626	Understanding the Emergence of Neuropsychiatric Disorders With Network Neuroscience. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2018, 3, 742-753.	1.5	61
627	Time-Dependent Alterations in the Expression of NMDA Receptor Subunits along the Dorsoventral Hippocampal Axis in an Animal Model of Nascent Psychosis. ACS Chemical Neuroscience, 2018, 9, 2241-2251.	3.5	4
628	Effects of adolescent alcohol consumption on the brain and behaviour. Nature Reviews Neuroscience, 2018, 19, 197-214.	10.2	360
629	The morphometric coâ€atrophy networking of schizophrenia, autistic and obsessive spectrum disorders. Human Brain Mapping, 2018, 39, 1898-1928.	3.6	56
630	The Candidate Schizophrenia Risk Gene DGCR2 Regulates Early Steps of Corticogenesis. Biological Psychiatry, 2018, 83, 692-706.	1.3	23
631	Detection of early psychotic symptoms: Validation of the Spanish version of the â€œSymptom Onset in Schizophrenia (SOS) inventoryâ€• Psychiatry Research, 2018, 261, 68-72.	3.3	7
632	Altered avalanche dynamics in a developmental NMDAR hypofunction model of cognitive impairment. Translational Psychiatry, 2018, 8, 3.	4.8	32
633	Abdominal Vagal Afferents Modulate the Brain Transcriptome and Behaviors Relevant to Schizophrenia. Journal of Neuroscience, 2018, 38, 1634-1647.	3.6	28

#	Article	IF	Citations
634	Multisite Machine Learning Analysis Provides a Robust Structural Imaging Signature of Schizophrenia Detectable Across Diverse Patient Populations and Within Individuals. Schizophrenia Bulletin, 2018, 44, 1035-1044.	4.3	118
635	Genetic Correlation Profile of Schizophrenia Mirrors Epidemiological Results and Suggests Link Between Polygenic and Rare Variant (22q11.2) Cases of Schizophrenia. Schizophrenia Bulletin, 2018, 44, 1350-1361.	4.3	26
636	Brain morphologic changes in early stages of psychosis: Implications for clinical application and early intervention. Psychiatry and Clinical Neurosciences, 2018, 72, 556-571.	1.8	68
637	Biomarcadores de estrÃ©s oxidativo y dimensiones clÃnicas en los 10 primeros aÃ±os de esquizofrenia. Revista De PsiquiatrÃa Y Salud Mental, 2018, 11, 130-140.	1.8	15
638	Procalcitonin and C - reactive protein as peripheral inflammatory markers in antipsychotic drug-free schizophrenia patients. Asian Journal of Psychiatry, 2018, 35, 11-14.	2.0	7
639	10-year CVD risk in Han Chinese mainland patients with schizophrenia. Psychiatry Research, 2018, 264, 322-326.	3.3	14
640	Cross Cultural Validation and Extension of the Clinical Assessment Interview for Negative Symptoms (CAINS) in the Chinese Context: Evidence from a Spectrum Perspective. Schizophrenia Bulletin, 2018, 44, S547-S555.	4.3	29
641	Meta-analytical prognostic accuracy of the Comprehensive Assessment of at Risk Mental States (CAARMS): The need for refined prediction. European Psychiatry, 2018, 49, 62-68.	0.2	39
642	Coping Strategies Mediate the Effect of Stressful Life Events on Schizotypal Traits and Psychotic Symptoms in 22q11.2 Deletion Syndrome. Schizophrenia Bulletin, 2018, 44, S525-S535.	4.3	29
643	Perspectives on Machine Learning for Classification of Schizotypy Using fMRI Data. Schizophrenia Bulletin, 2018, 44, S480-S490.	4.3	19
644	Deletion of dopamine D ₂ receptors from parvalbumin interneurons in mouse causes schizophrenia-like phenotypes. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 3476-3481.	7.1	29
645	How Effective is Cognitive Remediation in Enhancing Vocational Outcomes for Job Seekers with Severe Mental Illness in Australia?. Australian Psychologist, 2018, 53, 144-150.	1.6	2
646	Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms. Schizophrenia Research, 2018, 191, 70-79.	2.0	88
647	Evidence of microglial activation following exposure to serum from first-onset drug-naÃ¯ve schizophrenia patients. Brain, Behavior, and Immunity, 2018, 67, 364-373.	4.1	17
648	Modeling Olanzapine Solution Growth Morphologies. Crystal Growth and Design, 2018, 18, 905-911.	3.0	32
649	Social cognition and self-other distinctions in neuropsychiatry: Insights from schizophrenia and Tourette syndrome. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 82, 69-85.	4.8	36
650	Association study of NDST3 gene for schizophrenia, bipolar disorder, major depressive disorder in the Han Chinese population. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2018, 177, 3-9.	1.7	6
651	White matter abnormalities in 22q11.2 deletion syndrome patients showing cognitive decline. Psychological Medicine, 2018, 48, 1655-1663.	4.5	12

#	Article	IF	Citations
652	Neurological soft signs precede the onset of schizophrenia: a study of individuals with schizotypy, ultra-high-risk individuals, and first-onset schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 49-56.	3.2	27
653	Multisite Schizophrenia Classification Based on Brainnetome Atlas by Deep Learning. , 2018, , .		4
654	The many roads to psychosis: recent advances in understanding risk and mechanisms. F1000Research, 2018, 7, 1883.	1.6	14
655	Clozapine versus olanzapine for people with schizophrenia. The Cochrane Library, 2018, , .	2.8	1
656	Clozapine versus quetiapine for people with schizophrenia. The Cochrane Library, 2018, , .	2.8	0
657	Clozapine versus risperidone for people with schizophrenia. The Cochrane Library, 2018, , .	2.8	0
660	Translational Significance of Selective Estrogen Receptor Modulators in Psychiatric Disorders. International Journal of Endocrinology, 2018, 2018, 1-12.	1.5	9
661	Crossing Borders in Schizotypy Research: 2017 Beijing International Conference. Schizophrenia Bulletin, 2018, 44, NP-NP.	4.3	0
662	Axon guidance pathway genes are associated with schizophrenia risk. Experimental and Therapeutic Medicine, 2018, 16, 4519-4526.	1.8	22
663	Studying and modulating schizophrenia-associated dysfunctions of oligodendrocytes with patient-specific cell systems. NPJ Schizophrenia, 2018, 4, 23.	3.6	31
664	The Danish High Risk and Resilience Studyâ€"VIA 11: Study Protocol for the First Follow-Up of the VIA 7 Cohort â^'522 Children Born to Parents With Schizophrenia Spectrum Disorders or Bipolar Disorder and Controls Being Re-examined for the First Time at Age 11. Frontiers in Psychiatry, 2018, 9, 661.	2.6	27
665	Low Field Magnetic Stimulation Ameliorates Schizophrenia-Like Behavior and Up-Regulates Neuregulin-1 Expression in a Mouse Model of Cuprizone-Induced Demyelination. Frontiers in Psychiatry, 2018, 9, 675.	2.6	10
666	Maternal Diabetes and Fetal Programming Toward Neurological Diseases: Beyond Neural Tube Defects. Frontiers in Endocrinology, 2018, 9, 664.	3.5	26
667	White matter aberrations and age-related trajectories in patients with schizophrenia and bipolar disorder revealed by diffusion tensor imaging. Scientific Reports, 2018, 8, 14129.	3.3	53
668	Tracing Early Neurodevelopment in Schizophrenia with Induced Pluripotent Stem Cells. Cells, 2018, 7, 140.	4.1	35
669	Symposium Oral Presentations. Journal of Theoretical Social Psychology, 2018, 28, 297-391.	1.9	1
670	How early media exposure may affect cognitive function: A review of results from observations in humans and experiments in mice. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 9851-9858.	7.1	70
671	Haploinsufficiency of autism spectrum disorder candidate gene NUAK1 impairs cortical development and behavior in mice. Nature Communications, 2018, 9, 4289.	12.8	21

#	Article	IF	Citations
672	The neuropsychology of emerging psychosis and the role of working memory in episodic memory encoding. Psychology Research and Behavior Management, 2018, Volume 11, 157-168.	2.8	8
673	The effects of donepezil on phencyclidine-induced cognitive deficits in a mouse model of schizophrenia. Pharmacology Biochemistry and Behavior, 2018, 175, 69-76.	2.9	12
674	Understanding the pediatric psychiatric phenotype of 22q11.2 deletion syndrome. American Journal of Medical Genetics, Part A, 2018, 176, 2182-2191.	1.2	51
675	Optogenetic induction of the schizophrenia-related endophenotype of ventral hippocampal hyperactivity causes rodent correlates of positive and cognitive symptoms. Scientific Reports, 2018, 8, 12871.	3.3	22
676	Using mouse transgenic and human stem cell technologies to model genetic mutations associated with schizophrenia and autism. Philosophical Transactions of the Royal Society B: Biological Sciences, 2018, 373, 20170037.	4.0	20
677	White matter integrity associated with severity reductions in positive symptoms after amisulpride treatment in drug-free patients with schizophrenia. Neuroscience Letters, 2018, 685, 131-136.	2.1	8
678	The Ambit of Phytotherapy in Psychotic Care. , 2018, , .		0
679	The relationship between schizotypal traits and hoarding symptoms: An examination of symptom specificity and the role of perceived cognitive failures. Journal of Affective Disorders, 2018, 237, 10-17.	4.1	9
680	The Predictive Coding Account of Psychosis. Biological Psychiatry, 2018, 84, 634-643.	1.3	507
682	Sub-circuit alterations in dorsal hippocampus structure and function after global neurodevelopmental insult. Brain Structure and Function, 2018, 223, 3543-3556.	2.3	4
683	Oxidative stress biomarkers and clinical dimensions in first 10 years of schizophrenia. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2018, 11, 130-140.	0.3	7
684	Is the serious ambient air pollution associated with increased admissions for schizophrenia?. Science of the Total Environment, 2018, 644, 14-19.	8.0	56
685	Crossing Boundaries in Schizotypy Research: An Introduction to the Special Supplement. Schizophrenia Bulletin, 2018, 44, S457-S459.	4.3	5
688	Quercetin Reduces Cortical GABAergic Transmission and Alleviates MK-801-Induced Hyperactivity. EBioMedicine, 2018, 34, 201-213.	6.1	22
689	The developing significance of context and function: Neuroscience and law. Behavioral Sciences and the Law, 2018, 36, 411-425.	0.8	4
690	The Role of theÂInsula in Schizophrenia. , 2018, , 239-251.		0
691	Stereological Assessments of Neuronal Pathology in Auditory Cortex in Schizophrenia. Frontiers in Neuroanatomy, 2017, 11, 131.	1.7	16
692	Transcranial Direct Current Stimulation, Symptomatology, and Cognition in Psychosis: A Qualitative Review. Frontiers in Behavioral Neuroscience, 2018, 12, 94.	2.0	20

#	Article	IF	Citations
693	PV Interneurons: Critical Regulators of E/I Balance for Prefrontal Cortex-Dependent Behavior and Psychiatric Disorders. Frontiers in Neural Circuits, 2018, 12, 37.	2.8	403
694	Top-Down Disconnectivity in Schizophrenia During P300 Tasks. Frontiers in Computational Neuroscience, 2018, 12, 33.	2.1	17
695	Development of Structural Covariance From Childhood to Adolescence: A Longitudinal Study in 22q11.2DS. Frontiers in Neuroscience, 2018, 12, 327.	2.8	16
696	Characterization of Noise Signatures of Involuntary Head Motion in the Autism Brain Imaging Data Exchange Repository. Frontiers in Integrative Neuroscience, 2018, 12, 7.	2.1	16
697	Blood Gene Expression Profile Predicts Response to Antipsychotics. Frontiers in Molecular Neuroscience, 2018, 11, 73.	2.9	18
698	Stem Cells to Inform the Neurobiology of Mental Illness. Current Topics in Behavioral Neurosciences, 2018, 40, 13-43.	1.7	4
699	Development of brain-wide connectivity architecture in awake rats. NeuroImage, 2018, 176, 380-389.	4.2	23
700	Where to seek help? Barriers to beginning treatment during the first-episode psychosis. International Journal of Nursing Sciences, 2018, 5, 249-254.	1.3	6
701	Patients with schizophrenia assessing psychiatristsâ€™ communication skills. Psychiatry Research, 2018, 269, 13-20.	3.3	11
702	Prenatal inflammation and risk for schizophrenia: A role for immune proteins in neurodevelopment. Development and Psychopathology, 2018, 30, 1157-1178.	2.3	29
703	GABAergic deficits and schizophrenia-like behaviors in a mouse model carrying patient-derived neuroligin-2 R215H mutation. Molecular Brain, 2018, 11, 31.	2.6	21
704	Cannabidiol Administered During Peri-Adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia. Frontiers in Pharmacology, 2018, 9, 901.	3.5	36
705	Blocking NMDAR Disrupts Spike Timing and Decouples Monkey Prefrontal Circuits: Implications for Activity-Dependent Disconnection in Schizophrenia. Neuron, 2018, 98, 1243-1255.e5.	8.1	40
706	Neuroepigenetics of Schizophrenia. Progress in Molecular Biology and Translational Science, 2018, 158, 195-226.	1.7	20
707	Variations in Dysbindin-1 are associated with cognitive response to antipsychotic drug treatment. Nature Communications, 2018, 9, 2265.	12.8	38
708	Dysregulated Brain Dynamics in a Triple-Network Saliency Model of Schizophrenia and Its Relation to Psychosis. Biological Psychiatry, 2019, 85, 60-69.	1.3	141
709	Impaired GAD1 expression in schizophreniaâ€related WISKET rat model with sexâ€dependent aggressive behavior and motivational deficit. Genes, Brain and Behavior, 2019, 18, e12507.	2.2	9
710	Effects of antipsychotic drugs on neurites relevant to schizophrenia treatment. Medicinal Research Reviews, 2019, 39, 386-403.	10.5	36

#	Article	IF	Citations
711	Altered brain gyrification in deficit and non-deficit schizophrenia. Psychological Medicine, 2019, 49, 573-580.	4.5	29
712	County-level social factors and schizophrenia: A multilevel study of 1.9 million Chinese adults. Psychiatry Research, 2019, 271, 286-290.	3.3	6
713	Neurocognition and adaptive functioning in a genetic high risk model of schizophrenia. Psychological Medicine, 2019, 49, 1047-1054.	4.5	14
714	Chronic schizophrenia with the absence of the septum pellucidum: A case report. Schizophrenia Research, 2019, 204, 430-431.	2.0	1
715	Focus on eye care in schizophrenia. Australasian journal of optometry, The, 2019, 102, 385-393.	1.3	7
716	The Future of Psychoneuroimmunology: Promises and Challenges. , 2019, , 235-266.		4
717	Can Animal Models of Copy Number Variants That Predispose to Schizophrenia Elucidate Underlying Biology?. Biological Psychiatry, 2019, 85, 13-24.	1.3	34
718	SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D₂ Receptor Mechanism of Action. Journal of Pharmacology and Experimental Therapeutics, 2019, 371, 1-14.	2.5	118
719	Classification of social anhedonia using temporal and spatial network features from a social cognition fMRI task. Human Brain Mapping, 2019, 40, 4965-4981.	3.6	12
720	Antipsychotics and risk of natural death in patients with schizophrenia . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 1863-1871.	2.2	12
721	Psychostimulant use and the brain. Addiction, 2019, 114, 2065-2077.	3.3	59
722	Age-dependent effects of (+)-MK801 treatment on glutamate release and metabolism in the rat medial prefrontal cortex. Neurochemistry International, 2019, 129, 104503.	3.8	5
723	Onset of schizophrenia diagnoses in a large clinical cohort. Scientific Reports, 2019, 9, 9865.	3.3	16
724	The functional near-infrared spectroscopy in the diagnosis of schizophrenia. European Journal of Psychiatry, 2019, 33, 97-103.	1.3	5
725	Mind wandering in schizophrenia: A thought-sampling study. Consciousness and Cognition, 2019, 74, 102774.	1.5	6
726	The effect of anticholinergic burden on cognitive and daily living functions in patients with schizophrenia. Asian Journal of Psychiatry, 2019, 46, 111-117.	2.0	22
727	Chromatin profiling of cortical neurons identifies individual epigenetic signatures in schizophrenia. Translational Psychiatry, 2019, 9, 256.	4.8	18
728	Late-onset psychosis and very-late-onset-schizophrenia-like-psychosis: an updated systematic review. International Review of Psychiatry, 2019, 31, 523-542.	2.8	26

#	Article	IF	Citations
729	Prenatal THC exposure produces a hyperdopaminergic phenotype rescued by pregnenolone. Nature Neuroscience, 2019, 22, 1975-1985.	14.8	93
730	Brexpiprazole has a low risk of dopamine D₂ receptor sensitization and inhibits rebound phenomena related to D₂ and serotonin 5â€HT_{2A} receptors in rats. Neuropsychopharmacology Reports, 2019, 39, 279-288.	2.3	19
731	Cannabidiol as a potential treatment for psychosis. Therapeutic Advances in Psychopharmacology, 2019, 9, 204512531988191.	2.7	74
732	One decade of the first episodes project (PEPs): Advancing towards a precision psychiatry. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2019, 12, 135-140.	0.3	5
733	Mortality of site-specific cancer in patients with schizophrenia: a systematic review and meta-analysis. BMC Psychiatry, 2019, 19, 323.	2.6	31
734	Prevalence of Non-Affective Psychoses in Individuals with Autism Spectrum Disorders: A Systematic Review. Journal of Clinical Medicine, 2019, 8, 1304.	2.4	34
736	Memory Systems and Memory Stages. , 2019, , 14-49.		0
737	Agency, Identity and Dementia. , 2019, , 50-83.		0
738	Anesthesia, Amnesia and Recall. , 2019, , 84-111.		0
739	Disorders of Memory Content and Interventions. , 2019, , 112-139.		0
740	Disorders of Memory Capacity and Interventions. , 2019, , 140-168.		0
741	Legal Issues Involving Memory. , 2019, , 169-195.		0
744	Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. CNS Spectrums, 2019, 24, 38-69.	1.2	87
745	Ketamine-Treatment During Late Adolescence Impairs Inhibitory Synaptic Transmission in the Prefrontal Cortex and Working Memory in Adult Rats. Frontiers in Cellular Neuroscience, 2019, 13, 372.	3.7	12
746	Cognitive functioning in patients with first-episode psychosis stratified by level of negative symptoms: A 1-year follow-up study. Psychiatry Research, 2019, 281, 112554.	3.3	10
747	Characterising the structure of cognitive heterogeneity in schizophrenia spectrum disorders. A systematic review and narrative synthesis. Neuroscience and Biobehavioral Reviews, 2019, 107, 252-278.	6.1	74
748	Common brain disorders are associated with heritable patterns of apparent aging of the brain. Nature Neuroscience, 2019, 22, 1617-1623.	14.8	358
749	Eye movement abnormalities and their association with cognitive impairments in schizophrenia. Schizophrenia Research, 2019, 209, 255-262.	2.0	23

#	Article	IF	Citations
750	Commentary: Do Complement factors â€œconnect the dotsâ€•in schizophrenia?. Schizophrenia Research, 2019, 204, 4-6.	2.0	2
751	The interrelationship between schizotypy, clinical high risk for psychosis and related symptoms: Cognitive disturbances matter. Schizophrenia Research, 2019, 210, 188-196.	2.0	27
752	Psychiatristsâ€™ reflections on a medication-free program for patients with psychosis. Journal of Psychopharmacology, 2019, 33, 459-465.	4.0	12
753	A systematic review of clinical guidelines on choice, dose, and duration of antipsychotics treatment in first- and multi-episode schizophrenia. International Review of Psychiatry, 2019, 31, 441-459.	2.8	27
754	Discriminating schizophrenia disease progression using a P50 sensory gating task with dense-array EEG, clinical assessments, and cognitive tests. Expert Review of Neurotherapeutics, 2019, 19, 459-470.	2.8	15
755	The immune system and psychiatric disease: a basic science perspective. Clinical and Experimental Immunology, 2019, 197, 294-307.	2.6	86
756	Integrative Bodyâ€“Mindâ€“Spirit (I-BMS) Practices for Schizophrenia: An Outcome Literature Review on Randomized Controlled Trials. Community Mental Health Journal, 2019, 55, 1135-1146.	2.0	3
757	Normal Versus Pathological Mood: Implications for Diagnosis. Annual Review of Clinical Psychology, 2019, 15, 179-205.	12.3	31
758	Repetitive transcranial magnetic stimulation as an adjunctive treatment for negative symptoms and cognitive impairment in patients with schizophrenia: a randomized, double-blind, sham-controlled trial . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 1141-1150.	2.2	27
759	Diagnostic stability of schizophrenia: A systematic review. Psychiatry Research, 2019, 279, 306-314.	3.3	15
760	Diminished Fear Extinction in Adolescents Is Associated With an Altered Somatostatin Interneuronâ€“Mediated Inhibition in the Infralimbic Cortex. Biological Psychiatry, 2019, 86, 682-692.	1.3	23
761	Translational Potential of Neuroimaging Genomic Analyses to Diagnosis and Treatment in Mental Disorders. Proceedings of the IEEE, 2019, 107, 912-927.	21.3	4
762	Sex differences in gene expression related to antipsychotic induced weight gain. PLoS ONE, 2019, 14, e0215477.	2.5	13
763	Large-Scale Brain Network Dynamics Provide a Measure of Psychosis and Anxiety in 22q11.2 Deletion Syndrome. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2019, 4, 881-892.	1.5	35
764	Developmental social vulnerability as the intrinsic origin of psychopathology: A paradigm shift from disease entities to psychiatric derivatives within human diversity. Medical Hypotheses, 2019, 126, 95-108.	1.5	5
765	Altered gene expression in antipsychotic-induced weight gain. NPJ Schizophrenia, 2019, 5, 7.	3.6	16
766	Differentiation of Schizophrenia by Combining the Spatial EEG Brain Network Patterns of Rest and Task P300. IEEE Transactions on Neural Systems and Rehabilitation Engineering, 2019, 27, 594-602.	4.9	84
767	Effects of clonidine on MMN and P3a amplitude in schizophrenia patients on stable medication. Neuropsychopharmacology, 2019, 44, 1062-1067.	5.4	5

#	Article	IF	Citations
768	Unconjugated bilirubin and schizophrenia: a systematic review. CNS Spectrums, 2019, 24, 577-588.	1.2	9
769	Morin decreases cortical pyramidal neuron degeneration via inhibition of neuroinflammation in mouse model of schizophrenia. International Immunopharmacology, 2019, 70, 338-353.	3.8	51
770	Social Cognition, Language, and Social Behavior in 7-Year-Old Children at Familial High-Risk of Developing Schizophrenia or Bipolar Disorder: The Danish High Risk and Resilience Study VIA 7â€"A Population-Based Cohort Study. Schizophrenia Bulletin, 2019, 45, 1218-1230.	4.3	34
771	Early Identification and Intervention of Schizophrenia: Insight From Hypotheses of Glutamate Dysfunction and Oxidative Stress. Frontiers in Psychiatry, 2019, 10, 93.	2.6	51
772	Neuroscience and mental state issues in forensic assessment. International Journal of Law and Psychiatry, 2019, 65, 101437.	0.9	13
773	Brain Heterogeneity in Schizophrenia and Its Association With Polygenic Risk. JAMA Psychiatry, 2019, 76, 739.	11.0	195
774	Distinct and opposite profiles of connectivity during selfâ€reference task and rest in youth at clinical high risk for psychosis. Human Brain Mapping, 2019, 40, 3254-3264.	3.6	25
775	Exposure to cannabinoids can lead to persistent cognitive and psychiatric disorders. European Journal of Pain, 2019, 23, 1225-1233.	2.8	37
776	Age-Related Reduction in Cortical Thickness in First-Episode Treatment-NaÃ¯ve Patients with Schizophrenia. Neuroscience Bulletin, 2019, 35, 688-696.	2.9	24
777	Changes in serum TNF-Î±, IL-18, and IL-6 concentrations in patients with chronic schizophrenia at admission and at discharge. Comprehensive Psychiatry, 2019, 90, 82-87.	3.1	49
778	History of Psychopharmacology. Annual Review of Clinical Psychology, 2019, 15, 25-50.	12.3	51
779	Omics in schizophrenia: current progress and future directions of antipsychotic treatments. Journal of Bio-X Research, 2019, 2, 145-152.	0.2	2
780	Altered Brain Structure and Functional Connectivity Associated with Pubertal Hormones in Girls with Precocious Puberty. Neural Plasticity, 2019, 2019, 1-10.	2.2	13
781	Research Domain Criteria: Strengths, Weaknesses, and Potential Alternatives for Future Psychiatric Research. Molecular Neuropsychiatry, 2019, 5, 218-236.	2.9	42
782	Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016â€"March 2019. Current Psychiatry Reports, 2019, 21, 124.	4.5	16
783	Oligodendrocytes as A New Therapeutic Target in Schizophrenia: From Histopathological Findings to Neuron-Oligodendrocyte Interaction. Cells, 2019, 8, 1496.	4.1	49
784	ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis. Trials, 2019, 20, 658.	1.6	7
785	The â€œObsessive Paradoxâ€• Journal of Nervous and Mental Disease, 2019, 207, 715-720.	1.0	3

#	Article	IF	Citations
786	The emerging pattern of shared polygenic architecture of psychiatric disorders, conceptual and methodological challenges. Psychiatric Genetics, 2019, 29, 152-159.	1.1	26
787	The Reeler Mouse: A Translational Model of Human Neurological Conditions, or Simply a Good Tool for Better Understanding Neurodevelopment?. Journal of Clinical Medicine, 2019, 8, 2088.	2.4	19
788	Uncoupled relationship in the brain between regional homogeneity and attention function in first-episode, drug-naÃ¯ve schizophrenia. Psychiatry Research - Neuroimaging, 2019, 294, 110990.	1.8	8
789	Uncanny Mirroring: A Developmental Perspective on the Neurocognitive Origins of Self-Disorders in Schizophrenia. Psychopathology, 2019, 52, 316-325.	1.5	8
790	Can N-Methyl-D-Aspartate Receptor Hypofunction in Schizophrenia Be Localized to an Individual Cell Type?. Frontiers in Psychiatry, 2019, 10, 835.	2.6	26
791	Hierarchical deficits in auditory information processing in schizophrenia. Schizophrenia Research, 2019, 206, 135-141.	2.0	28
792	Increased risk of type 2 diabetes among the siblings of patients with schizophrenia. CNS Spectrums, 2019, 24, 453-459.	1.2	8
793	Pharmacoinformatics and molecular docking reveal potential drug candidates against Schizophrenia to target TAAR6. Journal of Cellular Physiology, 2019, 234, 13263-13276.	4.1	16
794	Exploring the Dendritic Spine Pathology in a Schizophrenia-related Neurodevelopmental Animal Model. Neuroscience, 2019, 396, 36-45.	2.3	27
795	Rs7219 Regulates the Expression of GRB2 by Affecting miR-1288-Mediated Inhibition and Contributes to the Risk of Schizophrenia in the Chinese Han Population. Cellular and Molecular Neurobiology, 2019, 39, 137-147.	3.3	6
796	Dynamic changes of functional segregation and integration in vulnerability and resilience to schizophrenia. Human Brain Mapping, 2019, 40, 2200-2211.	3.6	21
797	Dimensional structure of first episode psychosis. Microbial Biotechnology, 2019, 13, 1431-1438.	1.7	20
798	Populationâ€neuroscience study of the Tokyo TEEN Cohort (pnâ€TTC): Cohort longitudinal study to explore the neurobiological substrates of adolescent psychological and behavioral development. Psychiatry and Clinical Neurosciences, 2019, 73, 231-242.	1.8	27
799	Transient Knock-Down of Prefrontal DISC1 in Immune-Challenged Mice Causes Abnormal Long-Range Coupling and Cognitive Dysfunction throughout Development. Journal of Neuroscience, 2019, 39, 1222-1235.	3.6	26
800	Effects and potential mechanisms of transcranial direct current stimulation (tDCS) on auditory hallucinations: A meta-analysis. Psychiatry Research, 2019, 273, 343-349.	3.3	26
801	Body mass index trajectories in childhood and adolescence - Risk for non-affective psychosis. Schizophrenia Research, 2019, 206, 313-317.	2.0	8
802	Implementation intention training for prospective memory in schizophrenia: A 3-month follow-up study. Schizophrenia Research, 2019, 206, 378-385.	2.0	8
803	Quantitative tractâ€based white matter heritability in 1â€and 2â€yearâ€old twins. Human Brain Mapping, 2019, 40, 1164-1173.	3.6	10

#	Article	IF	Citations
804	The mediating effect of family function and medication adherence between symptoms and mental disability among Chinese patients with schizophrenia: a cross-sectional study. Psychology, Health and Medicine, 2019, 24, 559-569.	2.4	10
805	Clinical high risk for psychosis in childhood and adolescence: findings from the 2-year follow-up of the ReARMS project. European Child and Adolescent Psychiatry, 2019, 28, 957-971.	4.7	37
806	Dissociable Disruptions in Thalamic and Hippocampal Resting-State Functional Connectivity in Youth with 22q11.2 Deletions. Journal of Neuroscience, 2019, 39, 1301-1319.	3.6	31
807	Creative, Person-Centered Psychopharmacology for Treatment Resistance in Psychiatry. , 2019, , 273-293.		1
808	Elevated cleavage of neuregulin-1 by beta-secretase 1 in plasma of schizophrenia patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 90, 161-168.	4.8	10
809	Probing Brain Developmental Patterns of Myelination and Associations With Psychopathology in Youths Using Gray/White Matter Contrast. Biological Psychiatry, 2019, 85, 389-398.	1.3	45
810	A possible key role of vision in the development of schizophrenia. Reviews in the Neurosciences, 2019, 30, 359-379.	2.9	8
811	Towards a neurodynamical understanding of the prodrome in schizophrenia. NeuroImage, 2019, 190, 144-153.	4.2	23
812	Cortical Morphometry in the Psychosis Risk Period: A Comprehensive Perspective of Surface Features. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2019, 4, 434-443.	1.5	9
813	Relationship between metacognitive beliefs and psychosocial performance in atâ€risk states of psychosis and patients with first psychotic episodes. Microbial Biotechnology, 2019, 13, 604-612.	1.7	6
814	A review on neuroimaging studies of genetic and environmental influences on early brain development. NeuroImage, 2019, 185, 802-812.	4.2	42
815	Altered voxel-wise gray matter structural brain networks in schizophrenia: Association with brain genetic expression pattern. Brain Imaging and Behavior, 2019, 13, 493-502.	2.1	49
816	Implications of Information Theory for Computational Modeling of Schizophrenia. Computational Psychiatry, 2020, 1, 82.	2.0	18
817	Dose response of the 16p11.2 distal copy number variant on intracranial volume and basal ganglia. Molecular Psychiatry, 2020, 25, 584-602.	7.9	49
818	Functional connectome organization predicts conversion to psychosis in clinical high-risk youth from the SHARP program. Molecular Psychiatry, 2020, 25, 2431-2440.	7.9	49
819	A Meta-analysis of Retinal Cytoarchitectural Abnormalities in Schizophrenia and Bipolar Disorder. Schizophrenia Bulletin, 2020, 46, 43-53.	4.3	65
820	What Causes the Onset of Psychosis in Individuals at Clinical High Risk? A Meta-analysis of Risk and Protective Factors. Schizophrenia Bulletin, 2020, 46, 110-120.	4.3	103
821	Relations Between Lexical and Biological Perspectives on Personality: New Evidence Based on HEXACO and Affective Neuroscience Theory. Journal of Personality Assessment, 2020, 102, 325-336.	2.1	9

#	Article	IF	Citations
822	NMDA receptor hypofunction for schizophrenia revisited: Perspectives from epigenetic mechanisms. Schizophrenia Research, 2020, 217, 60-70.	2.0	54
823	Hostâ€“parasite interaction associated with major mental illness. Molecular Psychiatry, 2020, 25, 194-205.	7.9	26
824	Cingulum bundle abnormalities and risk for schizophrenia. Schizophrenia Research, 2020, 215, 385-391.	2.0	19
825	Association of MAD1L1 polymorphism (rs871925) with prenatal famine exposure and schizophrenia in a Chinese population: A caseâ€“control study. IUBMB Life, 2020, 72, 259-265.	3.4	3
826	Tracking Language in Real Time in Psychosis. , 2020, , 663-685.		5
827	Glial cells in schizophrenia: a unified hypothesis. Lancet Psychiatry,the, 2020, 7, 272-281.	7.4	145
828	Global and Specific Cortical Volume Asymmetries in Individuals With Psychosis Risk Syndrome and Schizophrenia: A Mixed Cross-sectional and Longitudinal Perspective. Schizophrenia Bulletin, 2020, 46, 713-721.	4.3	12
829	Psychotic symptoms in 16p11.2 copyâ€number variant carriers. Autism Research, 2020, 13, 187-198.	3.8	11
830	Models of Schizophrenia. A Selective Review of Genetic, Neuropharmacological, Cognitive, and Social Approaches. , 2020, , 37-62.		0
831	Mechanisms of smooth pursuit eye movements in schizotypy. Cortex, 2020, 125, 190-202.	2.4	6
832	Odor identification in 7-year-old children at familial high risk of schizophrenia or bipolar disorder - the Danish high risk and resilience study VIA 7. Schizophrenia Research, 2020, 216, 77-84.	2.0	1
833	Disruption of gammaâ€“delta relationship related to working memory deficits in first-episode psychosis. Journal of Neural Transmission, 2020, 127, 103-115.	2.8	15
834	Energization by multiple substrates and calcium challenge reveal dysfunctions in brain mitochondria in a model related to acute psychosis. Journal of Bioenergetics and Biomembranes, 2020, 52, 1-15.	2.3	6
835	Psychotic Disorders. Current Clinical Psychiatry, 2020, , .	0.2	7
836	Rare copy number variants in individuals at clinical high risk for psychosis: Enrichment of synaptic/brainâ€related functional pathways. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2020, 183, 140-151.	1.7	0
837	Abnormal default-mode network homogeneity and its correlations with neurocognitive deficits in drug-naive first-episode adolescent-onset schizophrenia. Schizophrenia Research, 2020, 215, 140-147.	2.0	17
838	Altered resting-state functional connectivity in young children at familial high risk for psychotic illness: A preliminary study. Schizophrenia Research, 2020, 216, 496-503.	2.0	19
839	Glutamate in schizophrenia: Neurodevelopmental perspectives and drug development. Schizophrenia Research, 2020, 223, 59-70.	2.0	63

#	Article	IF	Citations
840	16p11.2 Copy Number Variations and Neurodevelopmental Disorders. Trends in Neurosciences, 2020, 43, 886-901.	8.6	75
841	Exploring Phenotypic and Genetic Overlap Between Cannabis Use and Schizotypy. Twin Research and Human Genetics, 2020, 23, 221-227.	0.6	7
842	Converging Resting State Networks Unravels Potential Remote Effects of Transcranial Magnetic Stimulation for Major Depression. Frontiers in Psychiatry, 2020, 11, 836.	2.6	12
843	Brain Age Prediction Reveals Aberrant Brain White Matter in Schizophrenia and Bipolar Disorder: A Multisample Diffusion Tensor Imaging Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 1095-1103.	1.5	28
844	Obstetric Complications and Brain Imaging in Schizophrenia: A Systematic Review. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 1077-1084.	1.5	5
845	Psychometric investigation of the French version of the Aberrant Salience Inventory (ASI): differentiating patients with psychosis, patients with other psychiatric diagnoses and non-clinical participants. Annals of General Psychiatry, 2020, 19, 58.	2.7	11
846	A Narrative Review on Clinical Applications of fNIRS. Journal of Digital Imaging, 2020, 33, 1167-1184.	2.9	53
847	Developmental influences on symptom expression in antipsychotic-naÃ¯ve first-episode psychosis. Psychological Medicine, 2022, 52, 1698-1709.	4.5	8
848	Schizophrenia and education in Chinese metropolises: a population-based study. Social Psychiatry and Psychiatric Epidemiology, 2020, 55, 1563-1569.	3.1	4
849	Altered Auditory Self-recognition in People with Schizophrenia. Spanish Journal of Psychology, 2020, 23, e52.	2.1	0
850	Identifying neurodevelopmental anomalies of white matter microstructure associated with high risk for psychosis in 22q11.2DS. Translational Psychiatry, 2020, 10, 408.	4.8	6
851	Apathy is not associated with reduced ventral striatal volume in patients with schizophrenia. Schizophrenia Research, 2020, 223, 279-288.	2.0	5
852	Maturation of cortical microstructure and cognitive development in childhood and adolescence: A T1w/T2w ratio <scp>MRI</scp> study. Human Brain Mapping, 2020, 41, 4676-4690.	3.6	30
853	The acute effects of cannabidiol on the neural correlates of reward anticipation and feedback in healthy volunteers. Journal of Psychopharmacology, 2020, 34, 969-980.	4.0	14
854	Poly(I:C) Challenge Alters Brain Expression of Oligodendroglia-Related Genes of Adult Progeny in a Mouse Model of Maternal Immune Activation. Frontiers in Molecular Neuroscience, 2020, 13, 115.	2.9	10
855	Multifractal and Entropy-Based Analysis of Delta Band Neural Activity Reveals Altered Functional Connectivity Dynamics in Schizophrenia. Frontiers in Systems Neuroscience, 2020, 14, 49.	2.5	38
856	Disembodiment and schizophrenia: Looking at the motor roots of minimal self disorders in a developmental perspective. Schizophrenia Research, 2020, 222, 480-481.	2.0	2
857	A meta-analysis of ultra-high field glutamate, glutamine, GABA and glutathione 1HMRS in psychosis: Implications for studies of psychosis risk. Schizophrenia Research, 2020, 226, 61-69.	2.0	46

#	Article	IF	Citations
858	The role of norepinephrine in the pathophysiology of schizophrenia. Neuroscience and Biobehavioral Reviews, 2020, 118, 298-314.	6.1	48
859	The association between resilience and psychosocial functioning in schizophrenia: A systematic review and meta-analysis. Psychiatry Research, 2020, 293, 113374.	3.3	18
860	Resting frontal EEG asymmetry and schizotypal traits: a test-retest study. Cognitive Neuropsychiatry, 2020, 25, 333-347.	1.3	4
861	Setd1a Insufficiency in Mice Attenuates Excitatory Synaptic Function and Recapitulates Schizophrenia-Related Behavioral Abnormalities. Cell Reports, 2020, 32, 108126.	6.4	44
862	Impaired brain glucose metabolism and presynaptic dopaminergic functioning in a mouse model of schizophrenia. EJNMMI Research, 2020, 10, 39.	2.5	5
863	Developmental Psychotic Risk: Toward a Neurodevelopmentally Informed Staging of Vulnerability to Psychosis. Harvard Review of Psychiatry, 2020, 28, 271-278.	2.1	14
865	Long-term sustained release Poly(lactic-co-glycolic acid) microspheres of asenapine maleate with improved bioavailability for chronic neuropsychiatric diseases. Drug Delivery, 2020, 27, 1283-1291.	5.7	19
866	Plasma Î²-III tubulin, neurofilament light chain and glial fibrillary acidic protein are associated with neurodegeneration and progression in schizophrenia. Scientific Reports, 2020, 10, 14271.	3.3	20
867	Biomarkers for Prediction of Schizophrenia: Insights From Resting-State EEG Microstates. IEEE Access, 2020, 8, 213078-213093.	4.2	20
868	Decreased Plasma Levels of Growth Differentiation Factor 11 in Patients With Schizophrenia: Correlation With Psychopathology and Cognition. Frontiers in Psychiatry, 2020, 11, 555133.	2.6	3
869	Improved Operationalization and Measurement Are Central to the Future of Cluster A Personality Disorders: Commentary on Cluster A Personality Disorders. , 2020, , 217-220.		0
870	Using common genetic variation to examine phenotypic expression and risk prediction in 22q11.2 deletion syndrome. Nature Medicine, 2020, 26, 1912-1918.	30.7	90
871	Timing of menarche and abnormal hippocampal connectivity in youth at clinical-high risk for psychosis. Psychoneuroendocrinology, 2020, 117, 104672.	2.7	16
872	The relevance of transdiagnostic shared networks to the severity of symptoms and cognitive deficits in schizophrenia: a multimodal brain imaging fusion study. Translational Psychiatry, 2020, 10, 149.	4.8	16
873	Controlled sleep deprivation as an experimental medicine model of schizophrenia: An update. Schizophrenia Research, 2020, 221, 4-11.	2.0	9
874	Beyond quantitative and qualitative traits: three telling cases in the life sciences. Biology and Philosophy, 2020, 35, 1.	1.4	13
875	Abnormal Development and Dysconnectivity of Distinct Thalamic Nuclei in Patients With 22q11.2 Deletion Syndrome Experiencing Auditory Hallucinations. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 875-890.	1.5	21
876	The polygenic architecture of schizophrenia â€" rethinking pathogenesis and nosology. Nature Reviews Neurology, 2020, 16, 366-379.	10.1	122

#	Article	IF	Citations
877	Altered gamma and theta oscillations during multistable perception in schizophrenia. International Journal of Psychophysiology, 2020, 155, 127-139.	1.0	12
878	Early magnetic resonance imaging biomarkers of schizophrenia spectrum disorders: Toward a fetal imaging perspective. Development and Psychopathology, 2020, 33, 1-15.	2.3	1
879	The positive allosteric modulator of the mGlu2 receptor JNJ-46356479 partially improves neuropathological deficits and schizophrenia-like behaviors in a postnatal ketamine mice model. Journal of Psychiatric Research, 2020, 126, 8-18.	3.1	9
880	An attachment perspective on the risk for psychosis: Clinical correlates and the predictive value of attachment patterns and mentalization. Schizophrenia Research, 2020, 222, 209-217.	2.0	27
881	Autism Spectrum Disorder and Schizophrenia Are Better Differentiated by Positive Symptoms Than Negative Symptoms. Frontiers in Psychiatry, 2020, 11, 548.	2.6	44
882	Bridging the associations between dopamine, brain volumetric variation and IQ in drug-naÃ¯ve schizophrenia. Schizophrenia Research, 2020, 220, 248-253.	2.0	8
883	A High-Powered Brain Age Prediction Model Based on Convolutional Neural Network. , 2020, , .		2
884	Common vs. Distinct Visuomotor Control Deficits in Autism Spectrum Disorder and Schizophrenia. Autism Research, 2020, 13, 885-896.	3.8	8
885	Atypical processing of uncertainty in individuals at risk for psychosis. NeuroImage: Clinical, 2020, 26, 102239.	2.7	37
886	22q11.2 deletion syndrome. , 2020, , 143-164.		0
887	Biomarkers for moral cognition: Current status and future prospects for neurotransmitters and neuropeptides. Neuroscience and Biobehavioral Reviews, 2020, 113, 88-97.	6.1	3
888	A mutant vesicular stomatitis virus with reduced cytotoxicity and enhanced anterograde trans-synaptic efficiency. Molecular Brain, 2020, 13, 45.	2.6	15
889	Validation and extension of the Motivation and Pleasure Scale-Self Report (MAP-SR) across the schizophrenia spectrum in the Chinese context. Asian Journal of Psychiatry, 2020, 49, 101971.	2.0	12
890	Binding of clozapine to the GABAB receptor: clinical and structural insights. Molecular Psychiatry, 2020, 25, 1910-1919.	7.9	52
891	Abnormal amygdala subregional-sensorimotor connectivity correlates with positive symptom in schizophrenia. NeuroImage: Clinical, 2020, 26, 102218.	2.7	14
892	Implications of early life stress on fetal metabolic programming of schizophrenia: A focus on epiphenomena underlying morbidity and early mortality. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 101, 109910.	4.8	32
893	Neural noise and cortical inhibition in schizophrenia. Brain Stimulation, 2020, 13, 1298-1304.	1.6	6
894	Two Thalamic Regions Screened Using Laser Capture Microdissection with Whole Human Genome Microarray in Schizophrenia Postmortem Samples. Schizophrenia Research and Treatment, 2020, 2020, 1-11.	1.5	2

#	Article	IF	Citations
895	Deletion of the Mitochondrial Matrix Protein CyclophilinD Prevents Parvalbumin Interneuron Dysfunctionand Cognitive Deficits in a Mouse Model of NMDA Hypofunction. Journal of Neuroscience, 2020, 40, 6121-6132.	3.6	7
896	Plasticity of DNA methylation, functional brain connectivity and efficiency in cognitive remediation for schizophrenia. Journal of Psychiatric Research, 2020, 126, 122-133.	3.1	6
897	Polymorphs and pharmacokinetics of an antipsychotic drug candidate. International Journal of Pharmaceutics, 2020, 586, 119600.	5.2	4
898	Functional annotation of regulatory single nucleotide polymorphisms associated with schizophrenia. Schizophrenia Research, 2020, 218, 326-328.	2.0	4
899	Prefrontal parvalbumin interneurons require juvenile social experience to establish adult social behavior. Nature Communications, 2020, 11, 1003.	12.8	95
900	Favorable effects of omega-3 polyunsaturated fatty acids in attentional control and conversion rate to psychosis in 22q11.2 deletion syndrome. Neuropharmacology, 2020, 168, 107995.	4.1	9
901	Thinking, believing, and hallucinating self in schizophrenia. Lancet Psychiatry,the, 2020, 7, 638-646.	7.4	26
902	Lithium for schizophrenia: supporting evidence from a 12-year, nationwide health insurance database and from Akt1-deficient mouse and cellular models. Scientific Reports, 2020, 10, 647.	3.3	9
903	Negative and disorganized symptoms mediate the relationship between verbal learning and global functioning in adolescents with early-onset psychosis. European Child and Adolescent Psychiatry, 2020, 29, 1693-1703.	4.7	7
904	Impairment of motor but not anxietyâ€like behavior caused by the increase of dopamine during development is sustained in zebrafish larvae at later stages. International Journal of Developmental Neuroscience, 2020, 80, 106-122.	1.6	3
905	Clinical high risk for psychosis in children and adolescents: A meta-analysis of transition prevalences. Schizophrenia Research, 2022, 243, 254-261.	2.0	30
906	Rethinking Schizophrenia and Depression Comorbidity as One Psychiatric Disorder Entity: Evidence From Mouse Model. Frontiers in Neuroscience, 2020, 14, 115.	2.8	12
907	Whole-Genome and RNA Sequencing Reveal Variation and Transcriptomic Coordination in the Developing Human Prefrontal Cortex. Cell Reports, 2020, 31, 107489.	6.4	91
908	Targeting cognition in schizophrenia through transcranial direct current stimulation: A systematic review and perspective. Schizophrenia Research, 2020, 220, 300-310.	2.0	36
909	Dysregulation of Epigenetic Control Contributes to Schizophrenia-Like Behavior in Ebp1+/â˜’ Mice. International Journal of Molecular Sciences, 2020, 21, 2609.	4.1	2
910	Pathways from performance monitoring to negative symptoms and functional outcomes in psychotic disorders. Psychological Medicine, 2021, 51, 2012-2022.	4.5	13
911	Altered peripheral blood compounds in drug-naÃ¯ve first-episode patients with either schizophrenia or major depressive disorder: a meta-analysis. Brain, Behavior, and Immunity, 2020, 88, 547-558.	4.1	96
912	Maternal Immune Activation by Poly I:C as a preclinical Model for Neurodevelopmental Disorders: A focus on Autism and Schizophrenia. Neuroscience and Biobehavioral Reviews, 2020, 113, 546-567.	6.1	108

#	Article	IF	Citations
913	The role of the gut microbiome in the development of schizophrenia. Schizophrenia Research, 2021, 234, 4-23.	2.0	60
914	The place of the retina in psychiatry: Uniting neurobiological and neurodevelopmental research with clinical research in psychiatric disorders. Schizophrenia Research, 2020, 219, 1-4.	2.0	4
915	How do education and experience with mental illness interact with causal beliefs, eligible treatments and stigmatising attitudes towards schizophrenia? A comparison between mental health professionals, psychology students, relatives and patients. BMC Psychiatry, 2020, 20, 167.	2.6	18
916	Establishing a Causal Role for Medial Prefrontal Cortex in Reality Monitoring. Frontiers in Human Neuroscience, 2020, 14, 106.	2.0	12
917	Models Predicting Psychosis in Patients With High Clinical Risk: A Systematic Review. Frontiers in Psychiatry, 2020, 11, 223.	2.6	15
918	Strategies to solve the reverse inference fallacy in future MRI studies of schizophrenia: a review. Brain Imaging and Behavior, 2021, 15, 1115-1133.	2.1	5
919	Genetic underpinnings of schizophrenia-related electroencephalographical intermediate phenotypes: A systematic review and meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 104, 110001.	4.8	7
920	Spiritual belief and its link with potentially addictive behaviors in a youth sample in Switzerland. International Journal of Adolescent Medicine and Health, 2021, 33, .	1.3	3
921	Impaired Sensorimotor Gating Using the Acoustic Prepulse Inhibition Paradigm in Individuals at a Clinical High Risk for Psychosis. Schizophrenia Bulletin, 2021, 47, 128-137.	4.3	10
922	Increased wiring cost during development is driven by long-range cortical, but not subcortical connections. NeuroImage, 2021, 225, 117463.	4.2	6
923	Association of Urbanicity with Schizophrenia and Related Mortality in China: Association de lâ€™urbanicitÃ© avec la schizophrÃ©nie et la mortalitÃ© qui y est reliÃ©e en Chine. Canadian Journal of Psychiatry, 2021, 66, 385-394.	1.9	13
924	Social Cognition Training for Enhancing Affective and Cognitive Theory of Mind in Schizophrenia: A Systematic Review and a Meta-Analysis. Journal of Psychology: Interdisciplinary and Applied, 2021, 155, 26-58.	1.6	24
925	Kava decreases the stereotyped behavior induced by amphetamine in mice. Journal of Ethnopharmacology, 2021, 265, 113293.	4.1	6
926	Spinophilin expression in postmortem prefrontal cortex of schizophrenic subjects: Effects of antipsychotic treatment. European Neuropsychopharmacology, 2021, 42, 12-21.	0.7	2
927	Prefrontal Cortex Development in Health and Disease: Lessons from Rodents and Humans. Trends in Neurosciences, 2021, 44, 227-240.	8.6	123
928	The prefrontal cortex as a target for atypical antipsychotics in schizophrenia, lessons of neurodevelopmental animal models. Progress in Neurobiology, 2021, 199, 101967.	5.7	18
929	A transdiagnostic examination of anxiety and stress on executive function outcomes in disorders with social impairment. Journal of Affective Disorders, 2021, 281, 695-707.	4.1	8
930	Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders?. Frontiers in Pharmacology, 2020, 11, 635763.	3.5	9

#	Article	IF	Citations
931	Within-family influences on dimensional neurobehavioral traits in a high-risk genetic model. Psychological Medicine, 2022, 52, 3184-3192.	4.5	11
932	Implications of Adult Neural Stem Cell Abnormalities in the Pathophysiological Mechanism of Schizophrenia. Journal of Korean Neuropsychiatric Association, 2021, 60, 28.	0.5	0
933	Computerized Assessment of Psychosis Risk. Journal of Psychiatry and Brain Science, 2021, 6, .	0.5	3
934	Breast cancer surgery in patients with schizophrenia: short-term outcomes from a nationwide cohort. British Journal of Surgery, 2021, 108, 168-173.	0.3	7
936	Dance therapy: Explorations of a bottom-up intervention for schizophrenia. Advances in Psychological Science, 2021, 29, 1371-1380.	0.3	1
937	Long range temporal correlations (LRTCs) in MEG-data during emerging psychosis: Relationship to symptoms, medication-status and clinical trajectory. NeuroImage: Clinical, 2021, 31, 102722.	2.7	7
938	Recent Advances and Future Directions in Brain MR Imaging Studies in Schizophrenia: Toward Elucidating Brain Pathology and Developing Clinical Tools. Magnetic Resonance in Medical Sciences, 2022, 21, 539-552.	2.0	4
939	Dopamine Receptor Supersensitivity and Schizophrenia. , 2021, , 1-15.		0
940	Structural and Functional Features of Developing Brain Capillaries, and Their Alteration in Schizophrenia. Frontiers in Cellular Neuroscience, 2020, 14, 595002.	3.7	14
941	Functional variants fineâ€mapping and gene function characterization provide insights into the role of ZNF323 in schizophrenia pathogenesis. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2021, 186, 28-39.	1.7	8
942	Development-Dependent Plasticity in Vasoactive Intestinal Polypeptide Neurons in the Infralimbic Cortex. Cerebral Cortex Communications, 2021, 2, tgab007.	1.6	5
943	Genomic Variation, Evolvability, and the Paradox of Mental Illness. Frontiers in Psychiatry, 2020, 11, 593233.	2.6	2
944	Environmental enrichment or selective activation of parvalbumin-expressing interneurons ameliorates synaptic and behavioral deficits in animal models with schizophrenia-like behaviors during adolescence. Molecular Psychiatry, 2021, 26, 2533-2552.	7.9	29
945	Stem cell-based models and therapies: a key approach into schizophrenia treatment. Cell and Tissue Banking, 2021, 22, 207-223.	1.1	12
947	Astrocytes in schizophrenia. Brain and Neuroscience Advances, 2021, 5, 239821282110091.	3.4	32
948	Glutamate NMDA Receptor Antagonists with Relevance to Schizophrenia: A Review of Zebrafish Behavioral Studies. Current Neuropharmacology, 2022, 20, 494-509.	2.9	6
949	Acute Physiological and Psychological Stress Response in Youth at Clinical High-Risk for Psychosis. Frontiers in Psychiatry, 2021, 12, 641762.	2.6	9
950	Early Detection of Ultra High Risk for Psychosis in a Norwegian Catchment Area: The Two Year Follow-Up of the Prevention of Psychosis Study. Frontiers in Psychiatry, 2021, 12, 573905.	2.6	12

#	Article	IF	Citations
951	Structural control energy of restingâ€state functional brain states reveals less costâ€effective brain dynamics in psychosis vulnerability. Human Brain Mapping, 2021, 42, 2181-2200.	3.6	18
952	Shi-Zhen-An-Shen Decoction, a Herbal Medicine That Reverses Cuprizone-Induced Demyelination and Behavioral Deficits in Mice Independent of the Neuregulin-1 Pathway. Neural Plasticity, 2021, 2021, 1-12.	2.2	2
953	Integrative Analysis Identified Key Schizophrenia Risk Factors from an Abnormal Behavior Mouse Gene Set. Life, 2021, 11, 172.	2.4	2
954	Editorial: Antipsychotics of New Generation: Where Are We now?. Frontiers in Pharmacology, 2021, 12, 646286.	3.5	0
955	Oxytocin in Schizophrenia: Pathophysiology and Implications for Future Treatment. International Journal of Molecular Sciences, 2021, 22, 2146.	4.1	36
956	Multifactorial barriers in the implementation of schizophrenia and psychosocial therapies guidelines: A quantitative study across different professions. Schizophrenia Research, 2021, 228, 425-434.	2.0	10
957	Development of visual attention from age 7 to age 12 in children with familial high risk for schizophrenia or bipolar disorder. Schizophrenia Research, 2021, 228, 327-335.	2.0	0
958	Effects of repetitive transcranial magnetic and deep brain stimulation on longâ€range synchrony of oscillatory activity in a rat model of developmental schizophrenia. European Journal of Neuroscience, 2021, 53, 2848-2869.	2.6	10
959	Increased random exploration in schizophrenia is associated with inflammation. NPJ Schizophrenia, 2021, 7, 6.	3.6	19
960	â€œItâ€™s all about deliveryâ€• researchers and health professionalsâ€™ views on the moral challenges of accessing neurobiological information in the context of psychosis. BMC Medical Ethics, 2021, 22, 11.	2.4	3
961	Neurodevelopmental Trajectories and Psychiatric Morbidity: Lessons Learned From the 22q11.2 Deletion Syndrome. Current Psychiatry Reports, 2021, 23, 13.	4.5	20
962	Failure to engage the temporoparietal junction/posterior superior temporal sulcus predicts impaired naturalistic social cognition in schizophrenia. Brain, 2021, 144, 1898-1910.	7.6	14
963	Social cognition in individuals with 22q11.2 deletion syndrome and its link with psychopathology and social outcomes: a review. BMC Psychiatry, 2021, 21, 130.	2.6	9
964	The regionâ€selective regulation of endothelial claudinâ€5 expression and signaling in brain health and disorders. Journal of Cellular Physiology, 2021, 236, 7134-7143.	4.1	11
965	The CHALLENGE Project: Fighting Auditory Hallucinations by using Virtual Reality. , 2021, , .		0
966	Cortical myelin content mediates differences in affective temperaments. Journal of Affective Disorders, 2021, 282, 1263-1271.	4.1	4
967	Propagation and update of auditory perceptual priors through alpha and theta rhythms. European Journal of Neuroscience, 2022, 55, 3083-3099.	2.6	6
968	Do proinflammatory cytokines play a role in clozapine-associated glycometabolism disorders?. Psychopharmacology, 2021, 238, 1979-1990.	3.1	8

#	Article	IF	Citations
969	Effect of risperidone treatment on insulin-like growth factor-1 and interleukin-17 in drug naÃ¯ve first-episode schizophrenia. Psychiatry Research, 2021, 297, 113717.	3.3	9
970	A critical period that shapes neuronal motor circuits. Nature, 2021, 592, 360-361.	27.8	0
971	Cardiovascular autonomic neuropathy in patients with schizophrenia. Nordic Journal of Psychiatry, 2021, 75, 547-552.	1.3	1
972	Heterogeneous trajectories in schizophrenia: insights from neurodevelopment and neuroprogression models. Revista Brasileira De Psiquiatria, 2022, 44, 74-80.	1.7	7
973	Clozapine attenuates mitochondrial dysfunction, inflammatory gene expression, and behavioral abnormalities in an animal model of schizophrenia. Neuropharmacology, 2021, 187, 108503.	4.1	11
976	Betaine ameliorates schizophrenic traits by functionally compensating for KIF3-based CRMP2 transport. Cell Reports, 2021, 35, 108971.	6.4	14
977	Association Between ApoA1 Gene Polymorphisms and Antipsychotic Drug-Induced Dyslipidemia in Schizophrenia. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 1289-1297.	2.2	3
978	Effects of iTBS-rTMS on the Behavioral Phenotype of a Rat Model of Maternal Immune Activation. Frontiers in Behavioral Neuroscience, 2021, 15, 670699.	2.0	1
979	Advanced EEG-based learning approaches to predict schizophrenia: Promises and pitfalls. Artificial Intelligence in Medicine, 2021, 114, 102039.	6.5	54
980	Heschlâ€™s Gyrus Duplication Pattern in Individuals at Risk of Developing Psychosis and Patients With Schizophrenia. Frontiers in Behavioral Neuroscience, 2021, 15, 647069.	2.0	11
981	Genome-wide association study of antipsychotic-induced sinus bradycardia in Chinese schizophrenia patients. PLoS ONE, 2021, 16, e0249997.	2.5	3
982	Semaphorins in Adult Nervous System Plasticity and Disease. Frontiers in Synaptic Neuroscience, 2021, 13, 672891.	2.5	52
983	Long-term effects of early treatment with SSRIs on cognition and brain development in individuals with 22q11.2 deletion syndrome. Translational Psychiatry, 2021, 11, 336.	4.8	7
984	An Interpretable Machine Learning Method for the Detection of Schizophrenia Using EEG Signals. Frontiers in Systems Neuroscience, 2021, 15, 652662.	2.5	18
985	Assessing olfactory, memory, social and circadian phenotypes associated with schizophrenia in a genetic model based on Rim. Translational Psychiatry, 2021, 11, 292.	4.8	5
986	Global disruption in excitation-inhibition balance can cause localized network dysfunction and Schizophrenia-like context-integration deficits. PLoS Computational Biology, 2021, 17, e1008985.	3.2	21
987	Glutamate and microglia activation as a driver of dendritic apoptosis: a core pathophysiological mechanism to understand schizophrenia. Translational Psychiatry, 2021, 11, 271.	4.8	46
988	Clinical Staging in Schizophrenia Spectrum Disorders. , 0, , .		2

#	Article	IF	Citations
989	Cannabidiol for at risk for psychosis youth: A randomized controlled trial. Microbial Biotechnology, 2022, 16, 419-432.	1.7	9
990	A Deformation-Based Shape Study of the Corpus Callosum in First Episode Schizophrenia. Frontiers in Psychiatry, 2021, 12, 621515.	2.6	2
991	Chemokine MCP1 is associated with cognitive flexibility in schizophrenia: A preliminary analysis. Journal of Psychiatric Research, 2021, 138, 139-145.	3.1	11
992	Complicated Grief, Depression, Health and Attachment Style in First Degree Relatives of Individuals with a Chronic Psychotic Disorders. Community Mental Health Journal, 2022, 58, 526-535.	2.0	4
993	Patient-controlled admissions to inpatient care: A twelve-month naturalistic study of patients with schizophrenia spectrum diagnoses and the effects on admissions to and days in inpatient care. BMC Health Services Research, 2021, 21, 598.	2.2	7
994	Cannabinoid receptor gene polymorphisms and cognitive performance in patients with schizophrenia and controls. Revista Brasileira De Psiquiatria, 2021, , .	1.7	6
995	Ulk4, a Newly Discovered Susceptibility Gene for Schizophrenia, Regulates Corticogenesis in Mice. Frontiers in Cell and Developmental Biology, 2021, 9, 645368.	3.7	4
996	Electrophysiological Studies of Reception of Facial Communication in Autism Spectrum Disorder and Schizophrenia. Review Journal of Autism and Developmental Disorders, 2022, 9, 521-554.	3.4	2
997	Variability in Infants' Functional Brain Network Connectivity Is Associated With Differences in Affect and Behavior. Frontiers in Psychiatry, 2021, 12, 685754.	2.6	13
999	Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety. Advances in Therapy, 2021, 38, 3652-3673.	2.9	39
1000	14-3-3 proteins at the crossroads of neurodevelopment and schizophrenia. World Journal of Biological Psychiatry, 2022, 23, 14-32.	2.6	4
1001	Learning from atypical development: A systematic review of executive functioning in children and adolescents with the 22q11.2 deletion syndrome. Developmental Review, 2021, 60, 100962.	4.7	1
1002	Possible Biomarkers and Contributing Factors of Psychosis: a Review. Current Pharmacology Reports, 2021, 7, 123-134.	3.0	2
1003	Aberrant maturation and connectivity of prefrontal cortex in schizophreniaâ€"contribution of NMDA receptor development and hypofunction. Molecular Psychiatry, 2022, 27, 731-743.	7.9	30
1004	Investigating neurophysiological markers of impaired cognition in schizophrenia. Schizophrenia Research, 2021, 233, 34-43.	2.0	7
1005	The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study. Translational Psychiatry, 2021, 11, 393.	4.8	27
1006	Cortical thickness distinguishes between major depression and schizophrenia in adolescents. BMC Psychiatry, 2021, 21, 361.	2.6	6
1007	Management of systemic risk factors ahead of dental implant therapy: A beard well lathered is half shaved. Journal of Leukocyte Biology, 2021, 110, 591-604.	3.3	5

#	Article	IF	Citations
1008	Psychotic-like Experiences and Common Mental Disorders in Childhood and Adolescence: Bidirectional and Transdiagnostic Associations in a Longitudinal Community-based Study. Schizophrenia Bulletin Open, 2021, 2, .	1.7	10
1009	Interneuron Heterotopia in the Lis1 Mutant Mouse Cortex Underlies a Structural and Functional Schizophrenia-Like Phenotype. Frontiers in Cell and Developmental Biology, 2021, 9, 693919.	3.7	4
1010	Tracking Brain Development From Neonates to the Elderly by Hemoglobin Phase Measurement Using Functional Near-Infrared Spectroscopy. IEEE Journal of Biomedical and Health Informatics, 2021, 25, 2497-2509.	6.3	12
1011	Developments in Biological Mechanisms and Treatments for Negative Symptoms and Cognitive Dysfunction of Schizophrenia. Neuroscience Bulletin, 2021, 37, 1609-1624.	2.9	28
1012	Altered cortical thickness development in 22q11.2 deletion syndrome and association with psychotic symptoms. Molecular Psychiatry, 2021, 26, 7671-7678.	7.9	13
1013	Relevance of 5-HT2A Receptor Modulation of Pyramidal Cell Excitability for Dementia-Related Psychosis: Implications for Pharmacotherapy. CNS Drugs, 2021, 35, 727-741.	5.9	9
1014	Dysmaturation Observed as Altered Hippocampal Functional Connectivity at Rest Is Associated With the Emergence of Positive Psychotic Symptoms in Patients With 22q11 Deletion Syndrome. Biological Psychiatry, 2021, 90, 58-68.	1.3	18
1015	From Womb to Neighborhood: A Racial Analysis of Social Determinants of Psychosis in the United States. American Journal of Psychiatry, 2021, 178, 599-610.	7.2	129
1016	Brain ventricular volume changes in schizophrenia. A narrative review. Neuroscience Letters, 2021, 759, 136065.	2.1	4
1017	Neurological Soft Signs Are Associated With Altered White Matter in Patients With Schizophrenia. Schizophrenia Bulletin, 2022, 48, 220-230.	4.3	13
1018	A machine learning caseâ€“control classifier for schizophrenia based on DNA methylation in blood. Translational Psychiatry, 2021, 11, 412.	4.8	16
1019	A hidden Markov model reliably characterizes ketamine-induced spectral dynamics in macaque local field potentials and human electroencephalograms. PLoS Computational Biology, 2021, 17, e1009280.	3.2	13
1020	Oculomotor corollary discharge signaling is related to repetitive behavior in children with autism spectrum disorder. Journal of Vision, 2021, 21, 9.	0.3	7
1021	Engineered PLGA microspheres for extended release of brexpiprazole: in vitro and in vivo studies. Drug Development and Industrial Pharmacy, 2021, 47, 1-10.	2.0	6
1022	Enhancement of bioavailability through transdermal drug delivery of paliperidone palmitate-loaded nanostructured lipid carriers. Therapeutic Delivery, 2021, 12, 583-596.	2.2	5
1023	Sleep disturbances and cognitive impairment in schizophrenia spectrum disorders: a systematic review and narrative synthesis. Sleep Medicine, 2021, 84, 8-19.	1.6	9
1024	Binding of SEP-363856 within TAAR1 and the 5HT1A receptor: implications for the design of novel antipsychotic drugs. Molecular Psychiatry, 2022, 27, 88-94.	7.9	15
1025	Computational models of the â€œactive selfâ€•and its disturbances in schizophrenia. Consciousness and Cognition, 2021, 93, 103155.	1.5	5

#	Article	IF	Citations
1026	Response efficacy and heterogeneity of antipsychotic drugs in schizophrenia: Systemic review and metaâ€analysis. Human Psychopharmacology, 2022, 37, e2808.	1.5	1
1027	Schizophrenia: Antipsychotics and drug development. Behavioural Brain Research, 2021, 414, 113507.	2.2	13
1028	Durable Cognitive Gains and Symptom Improvement Are Observed in Individuals With Recent-Onset Schizophrenia 6 Months After a Randomized Trial of Auditory Training Completed Remotely. Schizophrenia Bulletin, 2022, 48, 262-272.	4.3	15
1029	Epigenetics of Schizophrenia. Psychiatry Research, 2021, 305, 114218.	3.3	32
1030	How do zebrafish (Danio rerio) respond to MKâ€801 and amphetamine? Relevance for assessing schizophreniaâ€related endophenotypes in alternative model organisms. Journal of Neuroscience Research, 2021, 99, 2844-2859.	2.9	10
1031	A schizophrenia risk factor induces marked anatomical deficits at GABAergic â€dopaminergic synapses in the rat ventral tegmental area: Essential evidence for new targeted therapies. Journal of Comparative Neurology, 2021, 529, 3946-3973.	1.6	0
1032	Impaired interaural correlation processing in people with schizophrenia. European Journal of Neuroscience, 2021, 54, 6646-6662.	2.6	1
1033	Characterization and prediction of clinical pathways of vulnerability to psychosis through graph signal processing. ELife, 2021, 10, .	6.0	7
1034	Regulatory variants at 2q33.1 confer schizophrenia risk by modulating distal gene TYW5 expression. Brain, 2022, 145, 770-786.	7.6	8
1035	Abnormal causal connectivity of left superior temporal gyrus in drug-naÃ¯ve first- episode adolescent-onset schizophrenia: A resting-state fMRI study. Psychiatry Research - Neuroimaging, 2021, 315, 111330.	1.8	5
1036	Ameliorating schizophrenia-like symptoms in vasopressin deficient male Brattleboro rat by chronic antipsychotic treatment. European Journal of Pharmacology, 2021, 909, 174383.	3.5	5
1037	The potential of the P2X7 receptor as a therapeutic target in a sub-chronic PCP-induced rodent model of schizophrenia. Journal of Chemical Neuroanatomy, 2021, 116, 101993.	2.1	10
1038	Association of altered cortical gyrification and psychopathological symptoms in patients with first-episode drug-naÃ¯ve schizophrenia. Asian Journal of Psychiatry, 2021, 64, 102749.	2.0	6
1039	Age-dependent cross frequency coupling features from children to adults during general anesthesia. NeuroImage, 2021, 240, 118372.	4.2	8
1040	Altered Heschl's gyrus duplication pattern in first-episode schizophrenia. Schizophrenia Research, 2021, 237, 174-181.	2.0	11
1041	The past and future of mapping the biomarkers of psychosis. Current Opinion in Behavioral Sciences, 2022, 43, 1-5.	3.9	4
1042	Increased Heschlâ€™s Gyrus Duplication in Schizophrenia Spectrum Disorders: A Cross-Sectional MRI Study. Journal of Personalized Medicine, 2021, 11, 40.	2.5	6
1043	Ahed: A Heterogeneous-Domain Deep Learning Model for IoT-Enabled Smart Health With Few-Labeled EEG Data. IEEE Internet of Things Journal, 2021, 8, 16787-16800.	8.7	8

#	Article	IF	Citations
1045	Effects of Antipsychotic Treatment on Obsessive-Compulsive Symptoms. , 2015, , 147-175.		6
1046	Polypharmacy for Obsessive-Compulsive Symptoms in Schizophrenia: Augmentation and Combination Strategies. , 2015, , 179-202.		3
1047	Una dÃ©cada del proyecto de primeros episodios psicÃ³ticos (PEPs): avanzando hacia una psiquiatrÃa de precisiÃ³n. Revista De PsiquiatrÃa Y Salud Mental, 2019, 12, 135-140.	1.8	35
1049	Associations between P3a and P3b amplitudes and cognition in antipsychotic-naÃ¯ve first-episode schizophrenia patients. Psychological Medicine, 2019, 49, 868-875.	4.5	18
1050	Basic symptoms and gray matter volumes of patients at clinical high risk for psychosis. Psychological Medicine, 2021, 51, 2666-2674.	4.5	5
1052	Coordination of hippocampal theta and gamma oscillations relative to spatial active avoidance reflects cognitive outcome after febrile status epilepticus.. Behavioral Neuroscience, 2020, 134, 562-576.	1.2	10
1053	Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion. Molecular Psychiatry, 2021, 26, 4496-4510.	7.9	87
1054	Orbitofrontal-Striatal Structural Alterations Linked to Negative Symptoms at Different Stages of the Schizophrenia Spectrum. Schizophrenia Bulletin, 2021, 47, 849-863.	4.3	13
1055	Behavioral Biomarkers of Schizophrenia in High Drinker Rats: A Potential Endophenotype of Compulsive Neuropsychiatric Disorders. Schizophrenia Bulletin, 2017, 43, 778-787.	4.3	27
1067	Functional Gene-Expression Analysis Shows Involvement of Schizophrenia-Relevant Pathways in Patients with 22q11 Deletion Syndrome. PLoS ONE, 2012, 7, e33473.	2.5	27
1068	Speech Graphs Provide a Quantitative Measure of Thought Disorder in Psychosis. PLoS ONE, 2012, 7, e34928.	2.5	173
1069	The Schizophrenia-Associated Kv11.1-3.1 Isoform Results in Reduced Current Accumulation during Repetitive Brief Depolarizations. PLoS ONE, 2012, 7, e45624.	2.5	24
1070	Temporal and Spatial Transcriptional Fingerprints by Antipsychotic or Propsychotic Drugs in Mouse Brain. PLoS ONE, 2015, 10, e0118510.	2.5	23
1071	Neurocognitive Impairments in Deficit and Non-Deficit Schizophrenia and Their Relationships with Symptom Dimensions and Other Clinical Variables. PLoS ONE, 2015, 10, e0138357.	2.5	39
1072	Neuronal correlates of ketamine and walking induced gamma oscillations in the medial prefrontal cortex and mediodorsal thalamus. PLoS ONE, 2017, 12, e0186732.	2.5	22
1073	Cognitive control deficit in patients with first-episode schizophrenia is associated with complex deviations of early brain development. Journal of Psychiatry and Neuroscience, 2017, 42, 87-94.	2.4	15
1074	Abnormalities of intrinsic regional brain activity in first-episode and chronic schizophrenia: a meta-analysis of resting-state functional MRI. Journal of Psychiatry and Neuroscience, 2020, 45, 55-68.	2.4	69
1075	Psychotic spectrum disorders: Definitions, classifications, neural correlates and clinical profiles. Annals of Psychiatry and Treatment, 2020, , 070-084.	0.3	20

#	Article	IF	Citations
1076	Signaling with Homeoprotein Transcription Factors in Development and Throughout Adulthood. Current Genomics, 2013, 14, 361-370.	1.6	10
1077	Feasibility and Acceptability of Using a Mobile Phone App for Characterizing Auditory Verbal Hallucinations in Adolescents With Early-Onset Psychosis: Exploratory Study. JMIR Formative Research, 2019, 3, e13882.	1.4	18
1078	Enhanced carbonyl stress induces irreversible multimerization of CRMP2 in schizophrenia pathogenesis. Life Science Alliance, 2019, 2, e201900478.	2.8	20
1079	Long-Term Grey Matter Changes in First Episode Psychosis: A Systematic Review. Psychiatry Investigation, 2019, 16, 336-345.	1.6	22
1080	Schizophrenia and abnormal brain network hubs. Dialogues in Clinical Neuroscience, 2013, 15, 339-349.	3.7	173
1081	Serotonin-related pathways and developmental plasticity: relevance for psychiatric disorders. Dialogues in Clinical Neuroscience, 2014, 16, 29-41.	3.7	53
1082	Connectome development and a novel extension to the neurodevelopmental model of schizophrenia. Dialogues in Clinical Neuroscience, 2018, 20, 101-111.	3.7	21
1083	Projective Technique Testing Approach to the Understanding of Psychological Pain in Suicidal and Non-Suicidal Psychiatric Inpatients. International Journal of Environmental Research and Public Health, 2020, 17, 284.	2.6	6
1084	The Concept of Schizophrenia: From the 1850s to the DSM-5. Psychiatric Annals, 2011, 41, 289-295.	0.1	18
1085	Time Windows of Interneuron Development: Implications to Our Understanding of the Aetiology and Treatment of Schizophrenia. AIMS Neuroscience, 2015, 2, 294-321.	2.3	2
1086	Frequent Comorbidity and Predictors of Social Anxiety in Persons With Schizophrenia. primary care companion for CNS disorders, The, 2015, 17, .	0.6	4
1087	Resilience: A psychobiological construct for psychiatric disorders. Indian Journal of Psychiatry, 2016, 58, 38.	0.7	62
1088	Brain-Derived Neurotrophic Factor and Suicide in Schizophrenia: Critical Role of Neuroprotective Mechanisms as an Emerging Hypothesis. Indian Journal of Psychological Medicine, 2016, 38, 499-504.	1.5	9
1089	Psychosis and related disorders in international classification of Disease-11 and their relationship to diagnostic and statistical Manual-5 and international classification of Disease-10. Indian Journal of Social Psychiatry, 2018, 34, 11.	0.3	1
1090	Behavioral and cognitive core domains shared between autism spectrum disorder and schizophrenia. Open Journal of Psychiatry, 2013, 03, 26-31.	0.6	3
1091	Resilience Improves Neurocognition and Treatment Outcomes in Schizophrenia: A Hypothesis. Open Journal of Psychiatry, 2016, 06, 173-187.	0.6	5
1092	Induced Pluripotent Stem Cells as a Novel Tool in Psychiatric Research. Psychiatry Investigation, 2016, 13, 8.	1.6	4
1093	Clozapine-resistant Schizophrenia: Strategies for the Busy Clinician. Indian Journal of Private Psychiatry, 2017, 11, 17-23.	0.1	1

#	Article	IF	Citations
1094	Effects of age and sex on clinical high-risk for psychosis in the community. World Journal of Psychiatry, 2020, 10, 101-124.	2.7	16
1095	Experiences of mental health service users on their empowerment and social integration in the community. European Journal of Counselling Psychology, 2018, 7, 165-180.	0.8	4
1096	Disorganization of Oscillatory Activity in Animal Models of Schizophrenia. Frontiers in Neural Circuits, 2021, 15, 741767.	2.8	6
1097	Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment. Pharmacological Research, 2021, 174, 105938.	7.1	21
1100	A 19-Year-Old Male with Mood Instability and Psychotic Symptoms. Psychiatric Annals, 2011, 41, 310-311.	0.1	0
1101	Les apports des donnÃ©es obtenues dans les schizophrÃ©nies Ã dÃ©but prÃ©coce au modÃ¨le neurodÃ©veloppemental. , 2012, , 109-118.		0
1102	The Negative Impact of the Misdiagnosis of Schizophrenia upon Patients, Their Families, and Their Caretakers. , 2012, , 297-351.		1
1104	I disturbi cognitivi nella schizofrenia. , 2013, , 3-12.		0
1105	Schizophrenie und Diabetes. , 2013, , 225-231.		0
1106	Rethinking the Contribution of Neuroimaging to Translation in Schizophrenia. , 2013, , 175-194.		1
1107	Cannabinoids, Monoamines, COMT and Schizophrenia: Pathobiological Mechanisms in Psychosis. , 2013, , 297-323.		0
1108	La mente come fenomeno emergente dell'intenzionalitÃ: la psicopatologia della schizofrenia in un modello sistemico oltre la dicotomia tra fenomenologia e neuroscienze. Rivista Sperimentale Di Freniatria, 2013, , 131-148.	0.1	1
1110	The Evolving Nosology of Schizophrenia: Relevance for Treatment. , 2014, , 13-23.		2
1111	Overview of Neurobiology. , 2014, , 27-33.		0
1114	Pathophysiology of Schizophrenia. , 2014, , 35-57.		0
1115	Perfil clÃnico e sociodemogrÃ¡fico de pacientes com esquizofrenia refratÃ¡ria tratados em um centro terciÃ¡rio. Jornal Brasileiro De Psiquiatria, 2014, 63, 185-190.	0.7	2
1116	Historical and Ethical Perspectives of Modern Neuroimaging. , 2015, , 535-550.		4
1117	CHAPTER 3. Developmental Neuroimmune Mechanisms in Schizophrenia. RSC Drug Discovery Series, 2015, , 46-69.	0.3	0

#	Article	IF	Citations
1118	Design for Values in Healthcare Technology. , 2015, , 717-738.		6
1119	CHAPTER 5. Modelling Schizophrenia: Strategies for Identifying Improved Platforms for Drug Discovery. RSC Drug Discovery Series, 2015, , 89-114.	0.3	0
1120	Therapeutic continuity in the treatment of psychiatric disorders. Global & Regional Health Technology Assessment, 2015, 2, GRHTA.5000197.	0.1	0
1121	Chronic Psychosis and its Prevention. Journal of Psychology & Clinical Psychiatry, 2015, 3, .	0.1	0
1122	A Review of Quality-of-Life Assessment Measures in Schizophrenia: Limitations and Future Developments. , 2016, , 65-77.		0
1123	The Connectome and Emotion. , 2016, , 45-55.		0
1124	The Idea of Recovery. Evidence-based Practices in Behavioral Health, 2016, , 3-38.	0.3	5
1125	Receptors and Related Drug Development for Schizophrenia: Research Advances. Pharmacy Information, 2016, 05, 19-24.	0.0	0
1126	Insights into the Brain: Neuroimaging of Brain Development and Maturation. Journal of Neuroimaging in Psychiatry & Neurology, 2016, 1, 10-19.	0.3	2
1127	Synaptic Abnormalities and Neuroplasticity. Handbook of Behavioral Neuroscience, 2016, , 375-390.	0.7	0
1131	Preventive strategies for severe mental disorders. Indian Journal of Social Psychiatry, 2017, 33, 95.	0.3	1
1134	Distinct pattern of cerebral blood flow alterations specific to schizophrenics experiencing auditory verbal hallucinations with and without insight: a pilot study. Oncotarget, 2018, 9, 6763-6770.	1.8	2
1135	Difficulties in functional recovery in schizophrenia: negative and cognitive symptoms. Psihiatru Ro, 2018, 3, 30.	0.0	0
1137	Esordio psicotico o blocco evolutivo. Un dilemma difficile. Psicobiettivo, 2018, , 32-48.	0.1	0
1138	Plasma homocysteine in first-episode schizophrenia. Middle East Current Psychiatry, 2018, 25, 42-49.	1.2	0
1140	PERFIL SOCIODEMOGRÃFICO E CLÃNICO DE PACIENTES COM ESQUIZOFRENIA ATENDIDOS EM AMBULATORIO DE UM HOSPITAL PÃšBLICO. Revista Interdisciplinar De Estudos Em SaÃºde, 2018, 7, 12-24.	0.2	0
1142	An Integrated Bio-psycho-social Approach to Psychiatric Disorders. Advances in Experimental Medicine and Biology, 2019, 1192, 331-340.	1.6	6
1143	Attenuated Psychosis Syndromes Among Nigerian Youth and Young Adults: Early Identification and Intervention. , 2019, , 289-300.		0

#	Article	IF	Citations
1150	ProgramaciÃ³n fetal metabÃ³lica en la salud mental. Revista De PsiquiatrÃa Infanto-Juvenil, 2019, 36, 3-5.	0.3	0
1151	Cognition in Schizophrenia. Current Clinical Psychiatry, 2020, , 385-397.	0.2	0
1152	Culture and family-based intervention for schizophrenia, bipolar, and other psychotic-related spectrum disorders. , 2020, , 645-674.		0
1154	The Effects of a Gluten-Free Diet on Immune Markers and Kynurenic Acid Pathway Metabolites in Patients With Schizophrenia Positive for Antigliadin Antibodies Immunoglobulin G. Journal of Clinical Psychopharmacology, 2020, 40, 317-319.	1.4	3
1155	Evaluation of the potential toxicity of haloperidol, clozapine and a new putative antipsychotic molecule, PT-31, in an alternative toxicity model, C. elegans. International Journal for Innovation Education and Research, 2020, 8, 502-512.	0.1	3
1158	Cortical and subcortical neuroanatomical signatures of schizotypy in 3004 individuals assessed in a worldwide ENIGMA study. Molecular Psychiatry, 2022, 27, 1167-1176.	7.9	22
1160	Attenuated Psychosis Syndrome. , 2020, , 159-176.		0
1161	Corticolimbic brain anomalies are associated with cognitive subtypes in psychosis: A longitudinal study. European Psychiatry, 2020, 63, e40.	0.2	3
1162	ÐÐ½Ñ‚Ð¿Ð¿Ñ‰Ð¸Ñ…Ð¾Ñ‚Ð¸Ðº Ð½Ð¾Ð²Ð¾Ð³Ð¾ Ð¿Ð¾ÐºÐ¾Ð»ÐµÐ½Ð¸Ñ•ÐºÐ°Ñ€Ð¸Ð¿Ñ€Ð°Ð·Ð¸Ð½ (ÐÐµÐ°Ð³Ð¸Ð»Ð°) Ð¸ Ð»ÐµÑ‡		
1163	Predicting Outcome in Schizophrenia: Neuroimaging and Clinical Assessments. , 2020, , 343-353.		2
1164	Suicide and Schizophrenia: Factors Affecting Recovery. , 2020, , 125-131.		0
1165	Resilience as a Measure of Outcome and Recovery in Schizophrenia. , 2020, , 133-143.		0
1166	Early Childhood Brain Development and Schizophrenia: An Imaging Perspective. , 2020, , 303-317.		0
1167	Genetics and Neuroimaging in Schizophrenia. , 2020, , 319-342.		1
1168	Schizophrenia-like behavior is not altered by melatonin supplementation in rodents. Anais Da Academia Brasileira De Ciencias, 2020, 92, e20190981.	0.8	3
1171	The relation of integrated psychological therapy to resting state functional brain connectivity networks in patients with schizophrenia. Psychiatry Research, 2021, 306, 114270.	3.3	6
1174	Safety and Tolerability of Repeated Application of Blonanserin Transdermal Patch (DSP-5423P) in Patients with Schizophrenia. Japanese Journal of Clinical Pharmacology and Therapeutics, 2020, 51, 247-253.	0.1	1
1177	Re-opening Windows: Manipulating Critical Periods for Brain Development. Cerebrum: the Dana Forum on Brain Science, 2012, 2012, 11.	0.1	74

#	Article	IF	Citations
1178	Challenges in the early detection and intervention of the psychosis-risk syndrome. Shanghai Archives of Psychiatry, 2015, 27, 45-7.	0.7	0
1179	Self, Voices and Embodiment: A Phenomenological Analysis. Journal of Schizophrenia Research, 2015, 2, .	1.0	4
1180	No molecular evidence of Borna disease virus among schizophrenia and bipolar disorder patients in Iran. Iranian Journal of Microbiology, 2017, 9, 112-118.	0.8	0
1181	Generation and Characterization of Induced Pluripotent Stem Cells from Mononuclear Cells in Schizophrenic Patients. Cell Journal, 2019, 21, 161-168.	0.2	1
1182	Contribution of Human Pluripotent Stem Cell-Based Models to Drug Discovery for Neurological Disorders. Cells, 2021, 10, 3290.	4.1	4
1183	Developmental decrease of entorhinal-hippocampal communication in immune-challenged DISC1 knockdown mice. Nature Communications, 2021, 12, 6810.	12.8	8
1184	High-sucrose diets contribute to brain angiopathy with impaired glucose uptake and psychosis-related higher brain dysfunctions in mice. Science Advances, 2021, 7, eabl6077.	10.3	12
1185	Functional and Structural Brain Abnormalities in Schizophrenia: A Multimodal Meta-Analysis of Neuroimaging Studies. SSRN Electronic Journal, 0, , .	0.4	0
1186	Resting state functional connectivity in pediatric populations. Advances in Magnetic Resonance Technology and Applications, 2021, 2, 65-87.	0.1	0
1187	The status of serum cortisol before and after treatment of schizophrenia and its correlation to disease severity and improvement: A longitudinal study. SAGE Open Medicine, 2021, 9, 205031212110562.	1.8	4
1188	Brain age prediction using fMRI network coupling in youths and associations with psychiatric symptoms. NeuroImage: Clinical, 2022, 33, 102921.	2.7	14
1189	The enduring behavioral and neurobiological effects of a flavor cue paired with alcohol drinking during adolescence on the incentive properties of the flavor cue in adulthood in female alcohol-preferring (P) rats. Drug and Alcohol Dependence, 2022, 232, 109289.	3.2	1
1190	Prenatal and Childhood Immuno-Metabolic Risk Factors for Adult Depression and Psychosis. Harvard Review of Psychiatry, 2022, 30, 8-23.	2.1	6
1191	Beyond a blunted ERN - Biobehavioral correlates of performance monitoring in schizophrenia. Neuroscience and Biobehavioral Reviews, 2022, 133, 104504.	6.1	9
1192	Chapitre 4. ModÃ¨les physiopathologiquesÂ: modÃ¨le neurodÃ©veloppemental, maturation cÃ©rÃ©brale etÂÂ«ÂdoubleÂhitÂÂ». , 2015, , 53-66.		0
1194	SLC6A1 and Neuropsychiatric Diseases: The Role of Mutations and Prospects for Treatment with Genome Editing Systems. Neurochemical Journal, 2021, 15, 376-389.	0.5	0
1195	Inferring the Individual Psychopathologic Deficits With Structural Connectivity in a Longitudinal Cohort of Schizophrenia. IEEE Journal of Biomedical and Health Informatics, 2022, 26, 2536-2546.	6.3	3
1196	Paradigm shift on the concept of schizophrenia that matches with both academic and clinical needs. Schizophrenia Research, 2022, 242, 123-125.	2.0	3

#	Article	IF	Citations
1197	Perceived Burdens and Educational Needs of Caregivers of People with Schizophrenia: Results of a National Survey Study. Patient Preference and Adherence, 2022, Volume 16, 159-168.	1.8	5
1198	Through the prism of comorbidity: A strategic rethinking of early intervention in obsessive-compulsive disorder. Schizophrenia Research, 2022, 239, 128-133.	2.0	7
1199	LY395756 promotes NR2B expression via activation of AKT/CREB signaling in the juvenile methylazoxymethanol mice model of schizophrenia. Brain and Behavior, 2022, 12, e2466.	2.2	5
1200	Anandamide Hydrolysis Inhibition Reverses the Long-Term Behavioral and Gene Expression Alterations Induced by MK-801 in Male Rats: Differential CB1 and CB2 Receptor-Mediated Effects. Schizophrenia Bulletin, 2022, 48, 795-803.	4.3	6
1201	A novel H129-based anterograde monosynaptic tracer exhibits features of strong labeling intensity, high tracing efficiency, and reduced retrograde labeling. Molecular Neurodegeneration, 2022, 17, 6.	10.8	2
1202	Glycogen Synthase Kinase-3 Inhibitors: Preclinical and Clinical Focus on CNS-A Decade Onward. Frontiers in Molecular Neuroscience, 2021, 14, 792364.	2.9	33
1204	Mapping Normative Trajectories of Cognitive Function and Its Relation to Psychopathology Symptoms and Genetic Risk in Youth. Biological Psychiatry Global Open Science, 2023, 3, 255-263.	2.2	8
1206	Premorbid adjustment in childhood is associated with later emotion management in first-episode schizophrenia. Schizophrenia Research, 2022, 240, 233-238.	2.0	1
1207	Auditory acuity and musical ability in young adults with high schizotypal traits. Comprehensive Psychiatry, 2022, 114, 152297.	3.1	3
1209	Childhood trauma exposure and personality traits in schizophrenia patients. Schizophrenia Research, 2022, 241, 221-227.	2.0	1
1210	Psychiatric genomics: brain pathophysiology and genetic factors. , 2022, , 269-287.		0
1211	Modulation of Gut Microbial Diversity through Non-Pharmaceutical Approaches to Treat Schizophrenia. International Journal of Molecular Sciences, 2022, 23, 2625.	4.1	10
1212	EntraÃ®ner les cerveaux schizophrÃ©niques. Terrain, 2022, , 64-83.	0.0	0
1213	The importance of studying psychopathology in subclinical populations. PsyCh Journal, 2022, 11, 147-148.	1.1	4
1214	10-Year Trends in Healthcare Spending among Patients with Schizophrenia in Alberta, Canada. Canadian Journal of Psychiatry, 2022, , 070674372210828.	1.9	2
1215	Identification and predictive analysis for participants at ultra-high risk of psychosis: A comparison of three psychometric diagnostic interviews. World Journal of Clinical Cases, 2022, 10, 2420-2428.	0.8	2
1218	Histone Acetylation and Methylation Underlie Oligodendroglial and Myelin Susceptibility in Schizophrenia. Frontiers in Cellular Neuroscience, 2022, 16, 823708.	3.7	4
1219	Temporal Trends in the Incidence and Disability Adjusted Life Years of Schizophrenia in China Over 30 Years. Frontiers in Psychiatry, 2022, 13, 831188.	2.6	11

#	Article	IF	Citations
1221	Altered temporal variability in brain functional connectivity identified by fuzzy entropy underlines schizophrenia deficits. Journal of Psychiatric Research, 2022, 148, 315-324.	3.1	6
1222	Dopamine-induced pruning in monocyte-derived-neuronal-like cells (MDNCs) from patients with schizophrenia. Molecular Psychiatry, 2022, 27, 2787-2802.	7.9	11
1223	Schizophrenia: A view of immediate future. Schizophrenia Research, 2022, 242, 15-16.	2.0	6
1224	Psychosis and fever revisited. Schizophrenia Research, 2022, 242, 17-19.	2.0	4
1225	Abnormal functional connectivity of the striatum in firstâ€episode drugâ€naive earlyâ€onset Schizophrenia. Brain and Behavior, 2022, 12, e2535.	2.2	5
1226	The Danish High-Risk and Resilience Studyâ€"VIA 15 â€" A Study Protocol for the Third Clinical Assessment of a Cohort of 522 Children Born to Parents Diagnosed With Schizophrenia or Bipolar Disorder and Population-Based Controls. Frontiers in Psychiatry, 2022, 13, 809807.	2.6	3
1228	Trust and Psychotic Disorders. , 2021, , 389-429.		0
1229	Autism spectrum disorder and schizophrenia: An updated conceptual review. Autism Research, 2022, 15, 384-412.	3.8	40
1230	P.0479 Obstetric complications and cognition in schizophrenia: A systematic review and meta-analysis. European Neuropsychopharmacology, 2021, 53, S352-S353.	0.7	0
1231	Investigating the Relationships of P3b with Negative Symptoms and Neurocognition in Subjects with Chronic Schizophrenia. Brain Sciences, 2021, 11, 1632.	2.3	12
1232	Anticholinergic Burden and Cognitive Performance in Patients With Schizophrenia: A Systematic Literature Review. Frontiers in Psychiatry, 2021, 12, 779607.	2.6	12
1233	Mismatch Negativity and P3a Impairment through Different Phases of Schizophrenia and Their Association with Real-Life Functioning. Journal of Clinical Medicine, 2021, 10, 5838.	2.4	8
1234	Early Detection and Prevention of Schizophrenic Psychosisâ€"A Review. Brain Sciences, 2022, 12, 11.	2.3	7
1235	Comprehensive DNA Methylation Analysis of Human Neuroblastoma Cells Treated With Haloperidol and Risperidone. Frontiers in Molecular Neuroscience, 2021, 14, 792874.	2.9	4
1237	The instrumental role of operant paradigms in translational psychiatric research: Insights from a maternal immune activation model of schizophrenia risk. Journal of the Experimental Analysis of Behavior, 2022, 117, 560-575.	1.1	1
1239	Effect of Co-Treatment of Olanzapine with SEP-363856 in Mice Models of Schizophrenia. Molecules, 2022, 27, 2550.	3.8	5
1240	Study of the acute and repeated dose 28-day oral toxicity in mice treated with PT-31, a molecule with a potential antipsychotic profile. Toxicology Mechanisms and Methods, 2022, 32, 705-715.	2.7	1
1270	Before Schizophrenia: Schizophrenic Vulnerability in Developmental Age and Its Detection.. , 2021, 18, 293-295.		2

#	Article	IF	Citations
1272	Styles of Coping with Stress among Healthy People and People with Diagnosis of Schizophrenia and Selected Personality Dimensions. International Journal of Environmental Research and Public Health, 2022, 19, 5129.	2.6	0
1273	Mammalian Dâ€cysteine: A novel regulator of neural progenitor cell proliferation. BioEssays, 2022, 44, e2200002.	2.5	11
1274	Pineal morphology of the clinical high-risk state for psychosis and different psychotic disorders. Schizophrenia Research, 2022, 244, 1-7.	2.0	1
1275	WHODAS 2.0: Associations of functional disability with sex, age, and length of care in outpatients with schizophrenia-spectrum disorders. Psychiatry Research, 2022, 313, 114583.	3.3	1
1276	Chapitre 5. Psychoses Ã lâ€™adolescence. , 2014, , 143-178.		0
1277	Feature and decision-level fusion for schizophrenia detection based on resting-state fMRI data. PLoS ONE, 2022, 17, e0265300.	2.5	7
1278	Identification of Peripheral Blood miRNA Biomarkers in First-Episode Drug-Free Schizophrenia Patients Using Bioinformatics Strategy. Molecular Neurobiology, 2022, 59, 4730-4746.	4.0	9
1280	Prognostic Associations of Cortical Gyrification in Minimally Medicated Schizophrenia in an Early Intervention Setting. SSRN Electronic Journal, 0, , .	0.4	0
1281	Neural substrates of psychosis revealed by altered dependencies between brain activity and white-matter architecture in individuals with 22q11 deletion syndrome. NeuroImage: Clinical, 2022, 35, 103075.	2.7	2
1282	Exploring Brain Structural and Functional Biomarkers in Schizophrenia via Brain-Network-Constrained Multi-View SCCA. Frontiers in Neuroscience, 0, 16, .	2.8	2
1283	Application of positron emission tomography in psychiatryâ€"methodological developments and future directions. Translational Psychiatry, 2022, 12, .	4.8	8
1284	Different Frequency of Heschlâ€™s Gyrus Duplication Patterns in Neuropsychiatric Disorders: An MRI Study in Bipolar and Major Depressive Disorders. Frontiers in Human Neuroscience, 0, 16, .	2.0	2
1286	Integrating the Neurodevelopmental and Dopamine Hypotheses of Schizophrenia and the Role of Cortical Excitation-Inhibition Balance. Biological Psychiatry, 2022, 92, 501-513.	1.3	59
1287	Disturbance of Ecological Self and Impairment of Affordance Perception. Frontiers in Psychology, 0, 13, .	2.1	2
1288	Machine Learning Algorithm-Based Prediction Model for the Augmented Use of Clozapine with Electroconvulsive Therapy in Patients with Schizophrenia. Journal of Personalized Medicine, 2022, 12, 969.	2.5	3
1289	Elevated brain-derived cell-free DNA among patients with first psychotic episode â€“ a proof-of-concept study. ELife, 0, 11, .	6.0	9
1290	Correlation of <scp>BDNF</scp>, <scp>VEGF</scp>, <scp>TNF</scp>â€Î±, and <scp>S100B</scp> with cognitive impairments in chronic, medicated schizophrenia patients. Neuropsychopharmacology Reports, 2022, 42, 281-287.	2.3	11
1291	Consideration of the adaptive randomization allocation ratio in the presence of treatment group heteroscedasticity in clinical trials. Journal of Biopharmaceutical Statistics, 0, , 1-16.	0.8	0

#	Article	IF	Citations
1292	Schizophrenia-derived hiPSC brain microvascular endothelial-like cells show impairments in angiogenesis and bloodâ€“brain barrier function. Molecular Psychiatry, 2022, 27, 3708-3718.	7.9	9
1293	Personal Recovery in Schizophrenia: A Narrative Review. Comprehensive Approach To Psychiatry, 2022, , 45-56.	1.0	3
1294	Optimizing functional near-infrared spectroscopy (fNIRS) channels for schizophrenic identification during a verbal fluency task using metaheuristic algorithms. Frontiers in Psychiatry, 0, 13, .	2.6	5
1295	Impaired migration of autologous induced neural stem cells from patients with schizophrenia and implications for genetic risk for psychosis. Schizophrenia Research, 2022, 246, 225-234.	2.0	2
1296	Developmental disabilities and metabolic disorders. , 2023, , 7-27.		1
1297	Psychosis and Its Treatment. , 2022, , 207-262.		0
1298	Investigating the Role of GABA in Neural Development and Disease Using Mice Lacking GAD67 or VGAT Genes. International Journal of Molecular Sciences, 2022, 23, 7965.	4.1	12
1299	22q11.2 deletion syndrome: Setting the stage. , 2022, , 2-32.		2
1302	Clinical and Biological Overlap between Schizophrenia, Autism Spectrum Disorder, and Trauma and Stress-Related Disorders: The Three-Tree Model of SCZ-ASD-TSRD. , 0, , .		0
1303	Optical coherence tomography reveals retinal thinning in schizophrenia spectrum disorders. European Archives of Psychiatry and Clinical Neuroscience, 2023, 273, 575-588.	3.2	10
1305	Associations of cognitive impairment in patients with schizophrenia with genetic features and with schizophrenia-related structural and functional brain changes. Frontiers in Genetics, 0, 13, .	2.3	1
1306	Caregiversâ€™ burden and schizophrenia patientsâ€™ quality of life: Sequential mediating effects of expressed emotion and perceived expressed emotion. Frontiers in Psychiatry, 0, 13, .	2.6	7
1307	Obstetric complications and cognition in schizophrenia: a systematic review and meta-analysis. Psychological Medicine, 2022, 52, 2874-2884.	4.5	5
1308	The phenomenology of auditory verbal hallucinations in schizophrenia and the challenge from pseudohallucinations. Frontiers in Psychiatry, 0, 13, .	2.6	1
1309	Associations of Duration of Preadoption Out-of-home Care, Genetic Risk for Schizophrenia Spectrum Disorders and Adoptive Family Functioning with Later Psychiatric Disorders of Adoptees. Child Psychiatry and Human Development, 2024, 55, 350-360.	1.9	0
1310	Schizophrenia Polygenic Risk During Typical Development Reflects Multiscale Cortical Organization. Biological Psychiatry Global Open Science, 2023, 3, 1083-1093.	2.2	4
1312	Superior temporal gyrus functional connectivity predicts transcranial direct current stimulation response in Schizophrenia: A machine learning study. Frontiers in Psychiatry, 0, 13, .	2.6	4
1313	Olfactory impairment in psychiatric disorders: Does nasal inflammation impact disease psychophysiology?. Translational Psychiatry, 2022, 12, .	4.8	14

#	Article	IF	Citations
1314	Temporal-spatial dynamic functional connectivity analysis in schizophrenia classification. Frontiers in Neuroscience, 0, 16, .	2.8	5
1315	Low income and schizophrenia risk: A narrative review. Behavioural Brain Research, 2022, 435, 114047.	2.2	5
1316	Dissociation and misdiagnosis of schizophrenia in populations experiencing chronic discrimination and social defeat. Journal of Trauma and Dissociation, 2024, 25, 334-348.	1.9	4
1317	Associations between brain imaging and polygenic scores of mental health and educational attainment in children aged 9â€“11. NeuroImage, 2022, 263, 119611.	4.2	11
1318	Biological hypotheses, risk factors, and biomarkers of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2023, 120, 110626.	4.8	26
1319	Commentary on: Antipsychotic agents: elucidation of their mode of action by Arvid Carlsson. , 2023, , 101-106.		0
1320	Modeling Schizophrenia In Vitro: Challenges and Insights on Studying Brain Cells. Advances in Experimental Medicine and Biology, 2022, , 35-51.	1.6	0
1321	Psychiatric profile in children and youth with 22q11.2 deletion syndrome. , 2022, , 302-321.		0
1322	Polypharmacology in Clinical Applications: Neurological Polypharmacology. , 2022, , 231-269.		0
1324	Schizophrenia: A Narrative Review of Etiopathogenetic, Diagnostic and Treatment Aspects. Journal of Clinical Medicine, 2022, 11, 5040.	2.4	5
1325	Visual system assessment for predicting a transition to psychosis. Translational Psychiatry, 2022, 12, .	4.8	6
1326	A WeChat-based self-compassion training to improve the treatment adherence of patients with schizophrenia in China: Protocol for a randomized controlled trial. Frontiers in Psychology, 0, 13, .	2.1	0
1327	Neuroscience robotics for controlled induction and real-time assessment of hallucinations. Nature Protocols, 2022, 17, 2966-2989.	12.0	9
1328	Cerebral, Psychosocial, Family Functioning and Disability of Persons with Schizophrenia. Neuropsychiatric Disease and Treatment, 0, Volume 18, 2069-2082.	2.2	2
1329	The Critical Roles of Early Development, Stress, and Environment in the Course of Psychosis. Annual Review of Developmental Psychology, 2022, 4, 423-445.	2.9	4
1330	Decreased cortical gyrification and surface area in the left medial parietal cortex in patients with <scp>treatmentâ€resistant</scp> and <scp>ultratreatmentâ€resistant</scp> schizophrenia. Psychiatry and Clinical Neurosciences, 2023, 77, 2-11.	1.8	5
1331	Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions. Neuroscience and Biobehavioral Reviews, 2022, 142, 104896.	6.1	25
1332	Comprehensive metabolomic characterization of the hippocampus in a ketamine mouse model of schizophrenia. Biochemical and Biophysical Research Communications, 2022, 632, 150-157.	2.1	4

#	Article	IF	Citations
1333	Psychosen im Kindes- und Jugendalter. Springer Reference Medizin, 2021, , 1-37.	0.0	0
1334	A rabies virusâ€“ based toolkit for efficient retrograde labeling and monosynaptic tracing. Neural Regeneration Research, 2022, .	3.0	1
1335	Effects of risperidone on psychotic symptoms and cognitive functions in 22q11.2 deletion syndrome: Results from a clinical trial. Frontiers in Psychiatry, 0, 13, .	2.6	0
1336	Disembodiment and Language in Schizophrenia: An Integrated Psychopathological and Evolutionary Perspective. Schizophrenia Bulletin, 2023, 49, 161-171.	4.3	2
1337	Decision support system for the differentiation of schizophrenia and mood disorders using multiple deep learning models on wearable devices data. Health Informatics Journal, 2022, 28, 146045822211375.	2.1	4
1338	Mitochondrial Damage of Lymphocytes in Patients with Acute Relapse of Schizophrenia: A Correlational Study with Efficacy and Clinical Symptoms. Neuropsychiatric Disease and Treatment, 0, Volume 18, 2455-2466.	2.2	7
1339	Baseline global brain structural and functional alterations at the time of symptom onset can predict subsequent cognitive deterioration in drug-naÃ¯ve first-episode schizophrenia patients: Evidence from a follow-up study. Frontiers in Psychiatry, 0, 13, .	2.6	1
1340	Involvement of Intestinal Enteroendocrine Cells in Neurological and Psychiatric Disorders. Biomedicines, 2022, 10, 2577.	3.2	6
1341	Prognostic associations of cortical gyrification in minimally medicated schizophrenia in an early intervention setting. , 2022, 8, .		3
1342	A deep learning based model using RNN-LSTM for the Detection of Schizophrenia from EEG data. Computers in Biology and Medicine, 2022, 151, 106225.	7.0	19
1343	Deviations from normative brain white and gray matter structure are associated with psychopathology in youth. Developmental Cognitive Neuroscience, 2022, 58, 101173.	4.0	6
1344	Family therapy as predictor of wellbeing and recovery among patients with schizophrenia. International Journal of Health Sciences, 0, , 5795-5808.	0.1	0
1345	Inhibition of MicroRNA-182/183 Cluster Ameliorates Schizophrenia by Activating the Axon Guidance Pathway and Upregulating DCC. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-17.	4.0	2
1346	Schizophrenia, Curcumin and Minimizing Side Effects of Antipsychotic Drugs: Possible Mechanisms. Neurochemical Research, 2023, 48, 713-724.	3.3	3
1347	Increased Striatal Presynaptic Dopamine in a Nonhuman Primate Model of Maternal Immune Activation: A Longitudinal Neurodevelopmental Positron Emission Tomography Study With Implications for Schizophrenia. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2023, 8, 505-513.	1.5	0
1348	Understanding stigma toward schizophrenia. Psychiatry Research, 2022, 318, 114970.	3.3	6
1349	A Novel Stereospecific Bioluminescent Assay for Detection of Endogenous <scp>d</scp>-Cysteine. ACS Chemical Neuroscience, 2022, 13, 3257-3262.	3.5	5
1350	Early treatment with JNJ-46356479, a mGluR2 modulator, improves behavioral and neuropathological deficits in a postnatal ketamine mouse model of schizophrenia. Biomedicine and Pharmacotherapy, 2023, 158, 114079.	5.6	1

#	Article	IF	Citations
1351	Integrative analysis to identify shared mechanisms between schizophrenia and bipolar disorder and their comorbidities. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2023, 122, 110688.	4.8	5
1352	Thinking and Schizophrenia: Challenges and Opportunities. Annals of the Academy of Medicine, Singapore, 2013, 42, 213-215.	0.4	0
1353	Microglia sequelae: brain signature of innate immunity in schizophrenia. Translational Psychiatry, 2022, 12, .	4.8	9
1354	How can we obtain truly translational mouse models to improve clinical outcomes in schizophrenia?. DMM Disease Models and Mechanisms, 2022, 15, .	2.4	3
1355	Effect of Virtual Reality on Cognitive Impairment and Clinical Symptoms among Patients with Schizophrenia in the Remission Stage: A Randomized Controlled Trial. Brain Sciences, 2022, 12, 1572.	2.3	1
1357	The critical periods of cerebral plasticity: A key aspect in a dialog between psychoanalysis and neuroscience centered on the psychopathology of schizophrenia. Frontiers in Molecular Neuroscience, 0, 15, .	2.9	3
1358	Clinical case of the use of cariprazine in treatment-resistant simple schizophrenia. V M Bekhterev Review of Psychiatry and Medical Psychology, 2022, 56, 101-106.	0.4	0
1359	Functional connectivity directionality between large-scale resting-state networks across typical and non-typical trajectories in children and adolescence. PLoS ONE, 2022, 17, e0276221.	2.5	1
1360	Brain-wide N2cG compensation permits glycoprotein-deleted rabies virus to trace neural circuits across multiple synapses. Journal of Innovative Optical Health Sciences, 0, , .	1.0	1
1361	Using Nonhuman Primate Models to Reverse-Engineer Prefrontal Circuit Failure Underlying Cognitive Deficits in Schizophrenia. Current Topics in Behavioral Neurosciences, 2022, , .	1.7	0
1362	The combined use of DTI and MR elastography for monitoring microstructural changes in the developing brain of a neurodevelopmental disorder model: Poly (I:C)-induced maternal immune-activated rats. PLoS ONE, 2023, 18, e0280498.	2.5	1
1363	Correlations between cortical gyrification and schizophrenia symptoms with and without comorbid hostility symptoms. Frontiers in Psychiatry, 0, 13, .	2.6	0
1364	Stress and the brain: Emotional support mediates the association between myelination in the right supramarginal gyrus and perceived chronic stress. Neurobiology of Stress, 2023, 22, 100511.	4.0	4
1365	Different Phases of Schizophrenia Patients: From the Psychological Perspective. , 2023, , 197-213.		0
1366	Neural correlates of schizotypal traits: Findings from connectome-based predictive modelling. Asian Journal of Psychiatry, 2023, 81, 103430.	2.0	0
1367	Inflammation and cognition in severe mental illness: patterns of covariation and subgroups. Molecular Psychiatry, 2023, 28, 1284-1292.	7.9	6
1368	Transitionsphasen in der Entwicklung von Kindern und Jugendlichen. Springer Reference Medizin, 2021, , 1-9.	0.0	0
1369	Molecular Abnormalities in BTBR Mice and Their Relevance to Schizophrenia and Autism Spectrum Disorders: An Overview of Transcriptomic and Proteomic Studies. Biomedicines, 2023, 11, 289.	3.2	2

#	Article	IF	Citations
1370	Personality traits and transition to psychosis one year after the first assessment. Frontiers in Psychology, 0, 14, .	2.1	2
1371	Genetic association of the rs17782313 polymorphism with antipsychotic-induced weight gain. Psychopharmacology, 0, , .	3.1	0
1372	Early auditory processing dysfunction in schizophrenia: Mechanisms and implications. Neuroscience and Biobehavioral Reviews, 2023, 148, 105098.	6.1	7
1373	Speech graph analysis in obsessive-compulsive disorder: The relevance of dream reports. Journal of Psychiatric Research, 2023, 161, 358-363.	3.1	0
1374	Risk of psychiatric comorbidity with autism spectrum disorder and its association with diagnosis timing using a nationally representative cohort. Research in Autism Spectrum Disorders, 2023, 104, 102134.	1.5	1
1375	Discrimination of auditory verbal hallucination in schizophrenia based on EEG brain networks. Psychiatry Research - Neuroimaging, 2023, 331, 111632.	1.8	1
1376	Dopamine Receptor Supersensitivity and Schizophrenia. , 2022, , 2163-2176.		0
1378	Editorial: Mapping psychopathology with MRI and connectivity analysis. Frontiers in Human Neuroscience, 0, 17, .	2.0	0
1380	Higher stress response and altered quality of life in schizophrenia patients with low membrane levels of docosahexaenoic acid. Frontiers in Psychiatry, 0, 14, .	2.6	1
1382	Editorial: Cerebellum-related learning and psychiatric diseases. Frontiers in Cellular Neuroscience, 0, 17, .	3.7	0
1383	Computer-aided diagnosis of schizophrenia based on node2vec and Transformer. Journal of Neuroscience Methods, 2023, 389, 109824.	2.5	0
1384	Neutrophil gelatinase-associated lipocalin (NGAL) and tumor necrosis factor-Î± (TNF-Î±) levels in patients with schizophrenia. Psychopharmacology, 2023, 240, 1091-1101.	3.1	3
1385	Oxidative Stress Biomarkers among Schizophrenia Inpatients. Brain Sciences, 2023, 13, 490.	2.3	5
1387	Neurodevelopmental trajectories, polygenic risk, and lipometabolism in vulnerability and resilience to schizophrenia. BMC Psychiatry, 2023, 23, .	2.6	0
1388	Understanding incomprehensibility: Misgivings and potentials of the phenomenological psychopathology of schizophrenia. Frontiers in Psychology, 0, 14, .	2.1	0
1389	The Hypothalamic-Pituitary-Gonadal Axis in Men with Schizophrenia. International Journal of Molecular Sciences, 2023, 24, 6492.	4.1	3
1390	Basal glutamate in the hippocampus and the dorsolateral prefrontal cortex in schizophrenia: Relationships to cognitive proficiency investigated with structural equation modelling. World Journal of Biological Psychiatry, 2023, 24, 730-740.	2.6	0
1391	Maternal Immune Activation and Enriched Environments Impact B2 SINE Expression in Stress Sensitive Brain Regions of Rodent Offspring. Genes, 2023, 14, 858.	2.4	0

#	Article	IF	Citations
1392	Family Neglect and Perspectives on Patients Living with Mental Health Disorders on the Street. Community Mental Health Journal, 0, , .	2.0	0
1393	Mitochondrial, cell cycle control and neuritogenesis alterations in an iPSC-based neurodevelopmental model for schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2023, 273, 1649-1664.	3.2	3
1394	The Age-dependent Neurovascular Coupling Characteristics in Children and Adults during General Anesthesia. Biomedical Optics Express, 0, , .	2.9	0
1395	Pharmacogenetic application in a patient diagnosed with Schizophrenia and OCD: A case report. International Journal of Radiology and Radiation Oncology, 2023, 9, 008-012.	0.1	0
1397	Current and future directions of drug delivery for the treatment of mental illnesses. Advanced Drug Delivery Reviews, 2023, 197, 114824.	13.7	5
1398	A consideration of the increased risk of schizophrenia due to prenatal maternal stress, and the possible role of microglia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2023, 125, 110773.	4.8	1
1399	Impact of Cannabinoid Receptors in the Design of Therapeutic Agents against Human Ailments. Current Topics in Medicinal Chemistry, 2023, 23, .	2.1	0
1400	Multivariate patterns of disrupted sleep longitudinally predict affective vulnerability to psychosis in 22q11.2 Deletion Syndrome. Psychiatry Research, 2023, 325, 115230.	3.3	2
1401	Probiotics as functional foods: How probiotics can alleviate the symptoms of neurological disabilities. Biomedicine and Pharmacotherapy, 2023, 163, 114816.	5.6	6
1402	Longitudinal change in neurocognitive functioning in children and adolescents at clinical high risk for psychosis: a systematic review. European Child and Adolescent Psychiatry, 0, , .	4.7	0
1403	Dopaminergic signalling and behavioural alterations by Comtâ€“Dtnbp1 genetic interaction and their clinical relevance. British Journal of Pharmacology, 0, , .	5.4	0
1405	Sparsityâ€guided multiple functional connectivity patterns for classification of schizophrenia via convolutional network. Human Brain Mapping, 0, , .	3.6	0
1406	Widespread Intra- and Inter-Network Dysconnectivity among Large-Scale Resting State Networks in Schizophrenia. Journal of Clinical Medicine, 2023, 12, 3176.	2.4	1
1407	Development of network oscillations through adolescence in male and female rats. Frontiers in Cellular Neuroscience, 0, 17, .	3.7	1
1408	Patologia biochimicÄƒ a substanÅ£ei P Ã®n neuropsihiatrie. Psihiatru Ro, 2023, 72, 40.	0.0	0
1409	Linguistic anomalies observed in the Sentence Completion Test in patients with schizophrenia. Cognitive Neuropsychiatry, 2023, 28, 226-236.	1.3	0
1410	Genetic polymorphism of IL-17F rs763780 contributes to the susceptibility to bipolar disorder but not to schizophrenia in the Turkish population. Nucleosides, Nucleotides and Nucleic Acids, 0, , 1-15.	1.1	1
1411	YBX1â€Mediated DNA Methylationâ€Dependent SHANK3 Expression in PBMCs and Developing Cortical Interneurons in Schizophrenia. Advanced Science, 2023, 10, .	11.2	2

#	Article	IF	Citations
1412	A multivariate approach to investigate the associations of electrophysiological indices with schizophrenia clinical and functional outcome. European Psychiatry, 2023, 66, .	0.2	0
1413	The global burden of schizophrenia and the impact of urbanization during 1990â€“2019: An analysis of the global burden of disease study 2019. Environmental Research, 2023, 232, 116305.	7.5	4
1414	A tablet-based quantitative assessment of manual dexterity for detection of early psychosis. Frontiers in Psychiatry, 0, 14, .	2.6	1
1415	AAV11 enables efficient retrograde targeting of projection neurons and enhances astrocyte-directed transduction. Nature Communications, 2023, 14, .	12.8	1
1416	Addressing the Gap in Research Training in Child Psychiatry and Neurodevelopment. Journal of the American Academy of Child and Adolescent Psychiatry, 2024, 63, 105-108.	0.5	0
1417	Neurodevelopmental vulnerability to psychosis: developmentally-based methods enable detection of early life inhibitory control deficits that predict psychotic-like experiences at the transition to adolescence. Psychological Medicine, 0, , 1-10.	4.5	0
1418	Vascular Schizophrenia-like Psychosis in Older Adults. Journal of Clinical Medicine, 2023, 12, 4831.	2.4	1
1419	Prognostic and immunomodulatory roles of schizophrenia-associated genes HTR2A, COMT, and PRODH in pan-cancer analysis and glioma survival prediction model. Frontiers in Immunology, 0, 14, .	4.8	3
1420	Gross anatomical variations of the insular cortex in first-episode schizophrenia. Schizophrenia Research, 2023, 260, 23-29.	2.0	1
1421	Greenspace exposure is conducive to the resilience of public sentiment during the COVID-19 pandemic. Health and Place, 2023, 83, 103096.	3.3	1
1422	Measuring the Impact of Virtual Reality Environments in Building Empathy Towards People with Schizophrenia. , 2023, , .		0
1423	Disease-specific resting-state EEG network variations in schizophrenia revealed by the contrastive machine learning. Brain Research Bulletin, 2023, 202, 110744.	3.0	0
1424	Enhanced Beta2-band Oscillations Denote Auditory Hallucination in Schizophrenia Patients and a Monkey Model of Psychosis. Neuroscience Bulletin, 0, , .	2.9	0
1425	Six Decades of Dopamine Hypothesis: Is Aryl Hydrocarbon Receptor the New D2?. Reports, 2023, 6, 36.	0.5	1
1426	Schizophrenia in the genetic era: a review from development history, clinical features and genomic research approaches toÂinsights of susceptibility genes. Metabolic Brain Disease, 0, , .	2.9	0
1427	Diverging effects of mentalization based treatment for patients with borderline personality disorder and schizophrenia: an explorative comparison. Frontiers in Psychiatry, 0, 14, .	2.6	0
1428	A correlational and cross-sectional study on the relationship between internalized stigma and religious coping in patients with schizophrenia. Medicine (United States), 2023, 102, e34558.	1.0	1
1429	The Gutâ€“Organ Axis within the Human Body: Gut Dysbiosis and the Role of Prebiotics. Life, 2023, 13, 2023.	2.4	2

#	Article	IF	Citations
1430	Resolving the Delusion Paradox. Schizophrenia Bulletin, 2023, 49, 1425-1436.	4.3	4
1431	Basal-Forebrain Cholinergic Nuclei Alterations are Associated With Medication and Cognitive Deficits Across the Schizophrenia Spectrum. Schizophrenia Bulletin, 2023, 49, 1530-1541.	4.3	1
1432	Machine learning based techniques for the detection of schizophrenia - A survey report. AIP Conference Proceedings, 2023, , .	0.4	0
1433	Functional connectivity in people at clinical and familial high risk for schizophrenia. Psychiatry Research, 2023, 328, 115464.	3.3	0
1434	Neuropathological substrate of incident dementia in older patients with schizophrenia: A clinicopathological study. Psychiatry and Clinical Neurosciences, 2024, 78, 29-40.	1.8	1
1436	Robotically-induced auditory-verbal hallucinations: combining self-monitoring and strong perceptual priors. Psychological Medicine, 2024, 54, 569-581.	4.5	1
1438	Clustering Schizophrenia Genes by Their Temporal Expression Patterns Aids Functional Interpretation. Schizophrenia Bulletin, 2024, 50, 327-338.	4.3	1
1439	Adolescent neurostimulation of dopamine circuit reverses genetic deficits in frontal cortex function. ELife, 0, 12, .	6.0	0
1440	The Combination of a Graph Neural Network Technique and Brain Imaging to Diagnose Neurological Disorders: A Review and Outlook. Brain Sciences, 2023, 13, 1462.	2.3	1
1441	Sexual Dysfunction in Neurological Disorders with Special Emphasis on Parkinsonâ€™s Disease: Insights from Clinical Studies and Animal Models. , 0, , .		0
1442	Digital behavioural signatures reveal trans-diagnostic clusters of Schizophrenia and Alzheimer's disease patients. European Neuropsychopharmacology, 2024, 78, 3-12.	0.7	0
1443	Mental Health: Contemporary Approaches, Research, and Lingering Challenges. SSRN Electronic Journal, 0, , .	0.4	0
1444	Genomic Signatures of Positive Selection in Human Populations of the OXT, OXTR, AVP, AVPR1A and AVR1B Gene Variants Related to the Regulation of Psychoemotional Response. Genes, 2023, 14, 2053.	2.4	0
1445	Rethinking the First Episode of Schizophrenia: Identifying Convergent Mechanisms During Development and Moving Toward Prediction. American Journal of Psychiatry, 2023, 180, 792-804.	7.2	1
1446	Receptor-Independent Therapies for Forensic Detainees with Schizophreniaâ€“Dementia Comorbidity. International Journal of Molecular Sciences, 2023, 24, 15797.	4.1	0
1447	Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal. Expert Opinion on Investigational Drugs, 2023, 32, 1113-1121.	4.1	1
1448	The role of cell adhesion molecule IgSF9b at the inhibitory synapse and psychiatric disease. Neuroscience and Biobehavioral Reviews, 2024, 156, 105476.	6.1	1
1449	Brain Iron Homeostasis and Mental Disorders. Antioxidants, 2023, 12, 1997.	5.1	1

#	Article	IF	Citations
1450	Reshaping the diagnostic borders: Historical analysis of the diagnostic changes following the introduction of the schizophrenia concept. Schizophrenia Research, 2023, 262, 21-29.	2.0	0
1451	Sparse control-inspired features generation for Schizophrenia diagnosisâ‹†. IFAC-PapersOnLine, 2023, 56, 464-469.	0.9	0
1452	Research Progress on the Relationship between Zinc and Schizophrenia. Advances in Clinical Medicine, 2023, 13, 18189-18194.	0.0	0
1453	The Iron Triangle of Familiarity for Severe Mental Illness, Developmental Coordination Disorder and Risk of Psychosis: Recognize to Prevent. Current Developmental Disorders Reports, 0, , .	2.1	0
1454	Empowering precision medicine: AI-driven schizophrenia diagnosis via EEG signals: A comprehensive review from 2002â€“2023. Applied Intelligence, 2024, 54, 35-79.	5.3	2
1456	Differential regulation of innate immune system in frontal cortex and hippocampus in a â€œdouble-hitâ€• neurodevelopmental model in rats. Neurotherapeutics, 2024, 21, e00300.	4.4	0
1457	Diagnosis of schizophrenia based on transformation from EEG sub-bands to the image with deep learning architecture. Soft Computing, 0, , .	3.6	0
1458	Reduced anterior callosal white matter in risk for psychosis associated with processing speed as a fundamental cognitive impairment. Schizophrenia Research, 2024, 264, 211-219.	2.0	0
1459	Formulation and statistical optimization of clozapine solid self emulsification system for improving the dissolution properties. Journal of Dispersion Science and Technology, 0, , 1-13.	2.4	0
1460	Natural molecules in the treatment of schizophrenia. , 2024, , 259-280.		0
1461	Dyadic effects of stigma on quality of life in people with schizophrenia and their family caregivers: Mediating role of patients' perception of caregivers' expressed emotion. Family Process, 0, , .	2.6	0
1462	Comparing the Graphical Features of Simple Artificial Neural Networks and Cortical Development. , 2023, , .		0
1463	An exploratory study of psychosis risk factors in individuals who are referred but do not meet criteria for an early intervention in psychosis service. BJPsych Open, 2024, 10, .	0.7	0
1464	Effects of mind-body therapies on schizophrenia: A systematic review and network meta-analysis. Schizophrenia Research, 2024, 264, 236-247.	2.0	1
1466	Relationship between anemia and its correlates and cognitive function in Chinese patients with chronic schizophrenia: A large cross-sectional study. Schizophrenia Research: Cognition, 2024, 36, 100300.	1.3	0
1468	The network characteristics in schizophrenia with prominent negative symptoms: a multimodal fusion study. , 2024, 10, .		0
1469	Exploration of Positive and Negative Schizophrenia Symptom Heterogeneity and Establishment of Symptom-Related miRNA-mRNA Regulatory Network: Based on Transcriptome Sequencing Data. Molecular Neurobiology, 0, , .	4.0	0
1470	The spectrum of psychiatric manifestations in subacute sclerosing panencephalitis: A systematic review of published case reports and case series. CNS Spectrums, 2024, 29, 87-95.	1.2	0

#	Article	IF	Citations
1471	Cannabidiol, cognition and schizophrenia: a narrative review. Exploration of Medicine, 2024, 5, 48-58.	1.5	0
1472	Posterior Cerebellar Resting-State Functional Hypoconnectivity: A Neural Marker of Schizophrenia Across Different Stages of Treatment Response. Biological Psychiatry, 2024, , .	1.3	0
1473	We need to talk: a qualitative inquiry into pathways to care for young men at ultra-high risk for psychosis. Frontiers in Psychology, 0, 15, .	2.1	0
1474	Preliminary Study of Cerebral Myelin Content Alterations at Schizophrenia. Studies in Computational Intelligence, 2024, , 485-494.	0.9	0
1475	Analysing psycho-social conditions of people during the COVID-19 pandemic: A case of Kerala. International Journal of Disaster Risk Reduction, 2024, 103, 104327.	3.9	0
1476	Cognitive Function and Variability in Antipsychotic Drugâ€“Naive Patients With First-Episode Psychosis. JAMA Psychiatry, 2024, 81, 468.	11.0	0
1477	Anthropometry in antipsychotic-naÃ¯ve first-episode psychosis patients: An exploratory approach to the role of environmental early life events in two independent samples. Schizophrenia Research, 2024, 266, 216-226.	2.0	0
1478	How the forebrain transitions to adulthood: developmental plasticity markers in a long-lived rodent reveal region diversity and the uniqueness of adolescence. Frontiers in Neuroscience, 0, 18, .	2.8	0
1479	Using transcranial alternating current stimulation to enhance working memory skills in youths with 22q11.2 deletion syndrome: A randomized double-blind sham-controlled study. Psychiatry Research, 2024, 335, 115835.	3.3	0
1480	Phenotypes for general behavior, activity, and body temperature in 3q29 deletion model mice. Translational Psychiatry, 2024, 14, .	4.8	0
1481	Employing graph attention networks to decode psycho-metabolic interactions in Schizophrenia. Psychiatry Research, 2024, 335, 115841.	3.3	0
1482	Introducing neurofilament light chain measure in psychiatry: current evidence, opportunities, and pitfalls. Molecular Psychiatry, 0, , .	7.9	0